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List of abbreviations 
 
Aq aqueous 
Ac  Acetyl 
BOC t-Butyloxycarbonyl 
Bz Benzoyl 
Bn Benzyl 
c concentration 
Cbz Carbobenzyloxy 
Δ reflux 
DCM Dichloromethane 
de diastereomeric excess 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide 
dr diastereomeric ratio 
E Entgegen (opposite, trans) 
eq equivalent 
Et Ethyl 
g gram 
h hours 
iPr isopropyl 
LiHMDA Lithium Hexamethyldisilamide 
M molar mol/L 
Me Methyl 
min minutes 
mg milligram 
mL milliliter 
mp melting point 
Nu nucleophile 
Ph Phenyl 
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ppm parts per million 
Py Pyridine 
rt room temperature 
TBAF tetra-n-butylammonium fluoride 
TEA Triethylamine 
Tf Triflate 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TMS Trimethylsilyl 
Z Zusammen (together, cis) 
bs broad singlet (NMR) 
δ Chemical shift (NMR) 
13
C-NMR Carbon-13 Nuclear Magnetic Resonance 
COSY Correlation Spectroscopy (NMR) 
d doublet (NMR) 
dd doublet of a doublet (NMR) 
DEPT Distorsionless Enhancement by Polarisation Transfer (NMR) 
EI Electronic Impact (MS) 
ESI Electron Spray Ionisation 
FID Free Induction Decay (NMR) 
FT Fourier Tranform 
Hz Hertz 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate 
HETCOR Heteronuclear Correlation (NMR) 
HMQC Heteronuclear Multiple Quantum Coherence (NMR) 
HPLC High Performance Liquid Chromatography 
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General experimental procedure 
 All chemicals were purchased from commercial suppliers and were used without 
further purification. Anhydrous solvents were purchased in sure-seal bottles over 
molecular sieves and were used without further drying. Flash chromatography was 
performed on silica gel (230–400 mesh). Dowex 50WX2-200(H) ion-exchange 
resin was used for purification of free amino acids. NMR Spectra were recorded 
with Varian Gemini 200, Mercury Plus 400, or Unity Inova 600 MHz 
spectrometers. Chemical shifts ( ) are reported in ppm relative to the solvent peak 
of CDCl3 set at = 7.27 ppm (
1
H NMR) or =77.0 ppm (
13
C NMR), CD3OD set at 
= 3.31 ppm (
1
H NMR) or =49.0 ppm (
13
C NMR), or D2O set at = 4.79 ppm (
1
H 
NMR). Coupling constants (J) are given in Hz. LC–MS analyses were performed 
on an HP1100 liquid chromatograph coupled with an electrospray ionization mass 
spectrometer (LC-ESI-MS), using H2O/CH3CN as solvent at 258°C (positive scan 
100– 500 m/z, fragmentor 70 V). 
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Thesis outline 
 
In this thesis we investigated the versatility and the potential applications of 
different kinds of alkylidene malonates, acetoacetates, malonamides and 
acetoacetoamides. Our research group devoted great attention to this kind of 
compounds since alkylidenes can be considered important intermediates in the 
synthesis of several scaffolds, to be inserted into molecules of potential biological 
and pharmaceutical interest. The increasing use of alkylidenes is due to their ability 
to react as unsaturated electrophiles and to the possibility to exploit them as 
intermediates for the introduction of  different kind of functionalities, as will be 
discussed later on. 
The preparation of alkylidene malonates, acetoacetates, malonamides and 
acetoacetoamides is presented in chapter 1. 
This section deals with different preparation methods of alkylidenes that we 
developed during the last few years and to the technologies involved for each 
synthetic protocol. 
 
 
Fig.1. Knoevenagel reaction carried under microwave irradiation. 
 
The reactivity that allowed to use the alkylidenes as intermediates in the synthesis  
of scaffolds for biologically active compounds is shown in chapter 2. In particular, 
we will discuss the most important reactions used to obtain the desired molecules, 
and we will focus on the most interesting aspects of these latter ones. 
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Fig.2 Developed projects starting from alkylidenes. 
 
Finally, chapter 3 will illustrate the potential applications and the related syntheses 
of potential bioactive compounds. The synthesized molecules find application in 
several fields and for this reason we considered each class of compounds in its 
related branch of interest. 
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Chapter 1 
 
Preparation of Alkylidenes Malonates, Acetoacetates, 
Malonamides, Acetoacetoamides 
 
1.1 Introduction 
The , -unsaturated compounds have been considered since many decades the 
starting materials for the preparation of polyfunctionalized products through simple 
and economic transformations. The alkylidenes’ ability to be easily converted into 
a wide range of compounds with potential biological interest, position them – 
somehow –in a high position in the list of privileged structures. Indeed, starting 
from these kind of compounds, it is possible to obtain several scaffolds, which are 
part of some more complicated molecules and may be used in the biological or 
pharmaceutical field. 
Due to their high reactivity, alkylidenes take part to several reactions. However, we 
focused our attention on two of them: the conjugate Michael addition and the 
allylic substitution on the alcohol deriving from acetoacetic ketone reduction. 
To synthesize various alkylidenes (acetoacetates, malonates, acetoacetoamides and 
malonamides) we used the Knoevenagel reaction, a widely studied process that we 
have slightly modified by using a recently discovered and ever-increasing 
technology: the MAOS (Microwave-Assisted Organic Synthesis). 
In the Knoevenagel condensation, an aldehyde or a ketone react with an activated 
methylene compound to give a substituted olefin by using an amine base as 
catalyst. By deprotonation of the activated methylene the stabilized enolate is 
generated. The amine catalyst also reacts with the aldehyde or ketone to form an 
iminium ion, which then is attacked by the enolate. The obtained intermediate 
compound after base induced -elimination, yields the final olefin product.  
11 
 
Fig.3. Mechanism of Knoevenagel reaction. 
 
1.1.1 Microwaves in organic synthesis 
The ever-increasing demand of techniques to obtain a large number of compounds 
in relatively short time, allowed microwaves to gain importance among the 
technologies used in organic synthesis. In fact, with MAOS (Microwave-Assisted 
Organic Synthesis), it is possible to significantly reduce the reaction time because 
this kind of technique, raising the temperature very quickly, allows to fasten the 
reaction and may give access to different reaction routes, leading to unexpected 
yields, conversions and selectivities. 
In the initial experiments, organic chemists used MWs simply to obtain a rapid and 
constant heating, but very soon they realized that this technology was able to give 
additional benefits. Later on, in fact, the scientific community suggested that a 
chemical reaction could also be triggered by acting directly on bonds with an 
electromagnetic radiation exposure, and not merely by an increase of temperature 
as in the conventional heating. This microwave reaction is called “non-thermal 
effect”, and it is widely discussed in literature.1,2 
12 
 
 
Fig.4 Electromagnetic spectrum. 
 
Microwaves are electromagnetic radiations that range from 300 to 300 000 MHz on 
the electromagnetic spectrum. For this reason, they do not possess enough energy 
to break, rotate or to strongly vibrate chemical bonds, but they allow molecules to 
orientate their permanent dipolar moment parallel toward the applied electric field. 
In a simplified description, we can state that molecules with dipolar moment will 
try to realign themselves with the electric field they are continuously submitted to, 
that is oscillating. This generated motion turns into an increase of single molecules 
kinetic energy, which is transferred to the system as heat. Accordingly, we can state 
that microwaves induce heating that generates from “inside” the reaction mixture 
rather than from “outside”, as in a conventional heating. 
 
a)       b)  
Fig.5 a) Orientation of molecules with a dipolar moment subjected to an alternating 
electric field and b) difference between dipolar and conventional heating. 
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1.2 Preparation of Alkylidene Malonates and Acetoacetates 
As we said before, alkylidenes represent excellent substrates able to take part in 
reactions we are very interested in. They may be involved in different kind of 
reactions and, in particular, two of them are significant for us: the Michael addition 
of nucleophile and the allylic nucleophilic substitution (SN2’). 
First of all, we have developed a methodology based on the Knoevenagel reaction 
to obtain the desired alkylidenic compounds. This reaction has been widely studied 
under a variety of conditions, by changing solvent and introducing a base or a 
Lewis acid as catalyst. In addition, we combined the Knoevenagel reaction with a 
new and efficient technology as MAOS. 
 
 
Scheme 1. Synthetic route used to obtain alkylidene malonates and acetoacetates. 
 
Alkylidene malonates and acetoacetates are prepared by using an excess of the 
proper aldehyde in respect to methylene active compound (malonate or 
acetoacetate), in the presence of 15% of piperidine under microwave irradiation for 
7 minutes (Scheme 1). Mixtures of E and Z isomers (1/4) were obtained in good 
yields after work up performed by extraction with EtOAc and water. 
The mixture of isomers was easily separated through flash chromatography and the 
single isomers were stored in a freezer to prevent isomerization. 
Following this method, alkylidene malonates and acetoacetates showed in Fig. 6 
were synthesized and used for several purposes, which will be taken into 
consideration later in this thesis. The stereochemical assignment for compounds 
1a-l was realized on the basis of DPFGSE-NOE (Double Pulse Field Gradient Spin 
Echo NOE) experiments. We found that the major isomer (Z) exhibits a strong 
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NOE effect between the vinyl hydrogen and the ketone CH3 group, while the minor 
isomer (E) shows a strong NOE effect between the vinyl hydrogen and the ester 
chain. 
 
 
Fig. 6 Alkylidene malonates and acetoacetates synthesized through Knoevenagel 
reaction under microwave irradiation. 
 
1.3 Preparation of Alkylidene Malonamides and Acetoacetoamides. 
The alkylidene amides that result from the condensation among aldehyde, 
respective malonamides and acetoacetoamides are undoubtedly another important 
class of molecules that can be used as a potential starting material for synthetizing 
heterocyclic scaffolds. Regarding a synthesis of alkylidene malonamides, we 
started from methyl malonyl chloride, which, reacting with an amine, ethylamine in 
particular, afforded the corresponding amide through nucleophilic acylic 
substitution. The following Knoevenagel reaction with a proper aldehyde under 
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microwave assisted condition and in the presence of a catalytic amount of 
piperidine (15% mol), provided the corresponding alkylidene malonamides in 
satisfactory yields (Scheme 2). 
 
 
Scheme 2. Synthetic route to synthesize alkylidene malonamides. 
 
On the other hand, to obtain alkylidene acetoacetoamides we followed a different 
approach. Starting from 2,2,6-trimethyl-4H-1,3-dioxin-4-one, a masked 
acetoacetate, and  Leucine as amine, by means of Ytterbium triflate as catalyst and 
TEA, we obtained acetoacetoamides with good yield. The reaction was performed 
under microwave irradiation for 5 minutes. The presence of triethylamine is 
fundamental to relieve the Leucine from salt. The obtained acetoacetoamide was 
then once again irradiated for other 7 minutes after adding isobuthyraldehyde and 
piperidine in the same vessel in order to obtain the desired unsaturated compound 
in good yield (Scheme 3). 
 
 
Scheme 3. Synthetic route to synthesize alkylidene acetoacetoamides. 
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The raction time for the Knoevenagel condensation is very short, and that is also 
true for the same reaction carried out on the previously treated malonic esters and 
acetoacetate derivatives. This consideration let us state that the reported method is 
quite reproducible on different substrates.  
Concerning the one-pot-two-steps protocol for the preparation of alkylidene 
acetoacetamides, there are some dubts on the effective mechanism followed in 
particular in the first step, in the opening of the heterocycle. The mechanism 
hypothesized by us, envisage a direct attack of amine on carbonilic carbon 
activated by Lewis acid and subsequently rearrangement with loss of acetone 
(Scheme 4). 
 
 
Scheme 4. 
 
In literature a different mechanism is reported were the first loss of acetone 
obtained by heating, provides a very reactive ketene that undergoes a nucleophilic 
attack by amine to get the final amide (Scheme 5). 
 
Scheme 5 
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To better understand the real mechanism we tried to trap the ketene through a 2+2 
cycloaddition, using for instance benzylketimine, but we never found any trace of 
products deriving from reactions involving ketene. This attempt allows to suggest 
that the correct mechanism could be the one proposed by us. 
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1.4 Experimental section 
 
 
General procedure for the preparation of α,β-unsatured compounds 1a-o: 
Aldheyde (1,3eq), piperidine (0,15eq) and methylene active compound (1eq) were 
irradiated with microwaves for 7 minutes at 250 watt in neat conditions. The 
reaction mixture was then diluted with ethyl acetate and washed 3 times with water. 
The two phases were separated, the organic layer was dried over Na2SO4 and 
solvent was removed under reduced pressure. Compounds Z and E  were separated 
by flash chromatography on silica gel (c-Hex/EtOAc 95:5). The desired product 
was obtained in range yield of 60-90% with relative Z/E ratio depending from 
substrate. 
*For 1i and 1g the same procedure was performed at room temperature because the 
aldehyde is very volatile. 
1a: 
 1 
H-NMR (400 MHz, CDCl3) δ 6.85 (d, J= 10.8 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 
3H), 2.60-2.73 (m, 1H), 1.08 (d, J= 6.6 Hz, 6H). 
1b:
1 
H-NMR (400 MHz, CDCl3) Z isomer: δ 1.09 (d, 6H, J = 6.45 Hz), 1.55 (s, 
9H), 2.30 (s, 3H), 2.65 (m, 1H), 6.53 (d, 1H, J = 10.4 Hz); LC-MS rt 9.5 min, m/z : 
235; yield 80%. 
E isomer: δ 1.45 (d, 6H, J = 6.6 Hz), 1.51 (s, 9H), 2.34 (s, 3H), 2.60 (m, 1H), 6.58 
(d, 1H, J = 10.6 Hz); LC-MS rt 10.2 min, m/z 235; yield 20%. 
1c: : Z isomer: ; 
1
H NMR (200 MHz, CDCl3)  1.21-1.43 (m, 5H), 1.45 (s, 9H), 
1.60-1.77 (m, 5H), 2.31 (s, 3H), 2.37 (m, 1H), 6.63 (d, 1H, J = 9.8 Hz); GC-MS rt 
9.3 min, m/z: 252yellow oil; isolated yield 55% 
E isomer: 
1
H NMR (200 MHz, CDCl3)  1.14-1.26 (m, 5H) 1.45 (s, 9H), 1.66-1.77 
(m, 5H), 2.38 (s, 3H), 2.42 (m, 1H), 6.72 (d, 1H, J = 10.6 Hz). GC-MS rt 10.0 min, 
m/z: 252, yellow oil; isolated yield 23%. 
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1d: Z isomer:; 
1
H NMR (CDCl3, 200 MHz)  1.45 (s, 9H, OtBu)2.43 (s, 3H, 
COCH3), 7.28-7.48 (m, 5H, Ph), 7.58 (s, 1H, CH=). Yellow oil. Yield 72%. 
E isomer: 
1
H NMR (CDCl3, 200 MHz)  1.45 (m, 9H, OtBu), 2.36 (s, 3H, COCH3), 
7.34-7.39 (m, 5H, Ph), 7.68 (s, 1H, CH=). Yield 23%; 
1e: Z isomer: IR (film) /cm
-1
2980, 2936, 2841, 1726, 1655, 1601, 1513, 1452, 
1260, 1222, 1176, 1028.
 1
H NMR (300 MHz, CDCl3)  1.33 (t, 3H, J = 7.2 Hz), 
2.44 (s, 3H), 3.88 (s, 3H), 4.40 (q, 2H, J =7.2 Hz), 6.93 (d, 2H, J = 7.2 Hz), 7.46 (d, 
2H, J = 7.2 Hz), 7.50 (s, 1H); 
13
C NMR (50 MHz, CDCl3)  14.0, 26.2, 55.2, 61.4, 
114.2(2), 125.0, 131.6(2), 132.1, 140.9, 161.6, 168.1, 194.6. GC-MS rt 20.30 min, 
m/z: 248(100), 233(80), 217(21), 203(30), 189(8), 174(24), 161(55), 137(18), 
117(9), 89(12). Yellow oil; isolated yield 50%. 
E isomer: IR (film) /cm
-1
2979, 2935, 2841, 2739, 1700, 1601, 1577, 1512, 1315, 
1258, 1174, 1026.
 1
H NMR (300 MHz, CDCl3) 1.31 (t, 3H, J = 7.2 Hz), 2.39 (s, 
3H), 3.89 (s, 3H), 4.27 (q, 2H, J =7.2 Hz), 7.00 (d, 2H, J = 7.2 Hz), 7.61 (s, 1H), 
7.83 (d, 2H, J = 7.2 Hz); 
13
C NMR (50 MHz, CDCl3) 14.1, 26.5, 55.4, 61.6, 
114.4(2), 125.5, 131.7(2), 132.3, 140.3, 161.5, 168.3, 194.6; GC-MS rt 20.20 min, 
m/z: 248(100), 233(88), 217(26), 203(35), 189(12), 174(29), 161(76), 137(31), 
117(17), 103(10), 89(31). Yellow oil; isolated yield 21%. 
1f: Z isomer: ; 
1
H NMR (200 MHz, CDCl3)  1.21-1.43 (m, 5H), 1.60-1.77 (m, 
5H), 2.31 (s, 3H), 2.37 (m, 1H), 3.82 (s, 6H), 6.63 (d, 1H, J = 9.8 Hz); GC-MS rt 
9.3 min, m/z: 252yellow oil; isolated yield 63% 
E isomer: 
1
H NMR (200 MHz, CDCl3)  1.14-1.26 (m, 5H), 1.66-1.77 (m, 5H), 
2.38 (s, 3H), 2.42 (m, 1H),3.83 (s, 6H), 6.72 (d, 1H, J = 10.6 Hz). GC-MS rt 10.0 
min, m/z: 252, yellow oil; isolated yield 20%. 
1g:see chapter 3 because this product was obtained at room temperature to avoid 
side product. 
1h: Z isomer: ; 
1
H NMR (200 MHz, CDCl3)  1.45 (s, 9H), 2.30 (s, 3H), 7,2-7,6 
(m, 3H), 8.27 (s, 1H). 
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E isomer: ; 
1
H NMR (200 MHz, CDCl3)  1.45 (s, 9H), 2.32 (s, 3H), 7,2-7,6 (m, 
3H), 8.25 (s, 1H). 
1i: Z isomer: ; 
1
H NMR (200 MHz, CDCl3)  1.45 (s, 9H), 2.10 (d, J= 7.2 Hz, 3H), 
2.30 (s, 3H), 7,10 (q, J= 10.4 Hz, 1H). Yield 20%. 
E isomer: ; 
1
H NMR (200 MHz, CDCl3)  1.45 (s, 9H), 2.10 (d, J= 7.2 Hz, 3H), 
2.30 (s, 3H), 7,20 (q, J= 10.4 Hz, 1H). Yield 5%. 
1j: Z isomer: 
1
H NMR (CDCl3, 300 MHz)  0.75 (t, J = 6.9 Hz, 3H, CH3CH2CH), 
0.97 (d, J = 6.6 Hz, 3H, CHCH3), 1.22 (t, J = 7.2 Hz, 3H, CH3CH2O), 1.34 (m, 2H, 
CH3CH2CH), 2.21 (s, 3H, COCH3), 2.35 (m, 1H, CH3CH2CH), 4.20 (q, J = 7.2 Hz, 
2H, CH3CH2O), 6.50 (d, J = 10.8 Hz, 1H, CH=). 
13
C NMR (CDCl3, 75 MHz):  
11.5(CH3), 13.9(CH3), 19.3(CH), 26.5(CH2), 29.1(CH3), 36.3(CH3), 60.9(CH2), 
136.0(C), 152.8(CH), 166.4(C), 195.0(C). Colorless clear oil. Yield 66%. 
E isomer: 
1
H NMR (CDCl3, 300 MHz)  0.74 (t, J = 6.9 Hz, 3H, CH3CH2CH), 0.93 
(d, J = 6.9 Hz, 3H, CHCH3), 1.20 (t, J = 7.2 Hz, 3H, CH3CH2O), 1.34 (m, 2H, 
CH3CH2CH), 2.25 (s, 3H, COCH3), 2.35 (m, 1H, CH3CH2CH), 4.16 (q, J = 7.2 Hz, 
2H, CH3CH2O), 6.56 (d, J = 10.8 Hz, 1H, CH=). 
13
C NMR (CDCl3, 75 MHz):  
11.6(CH3), 13.9(CH3), 19.2(CH), 26.3(CH2), 29.0(CH3), 35.4(CH3), 61.0(CH2), 
134.5(C), 153.0(CH), 164.1(C), 201.2(C). Anal. Calcd. For C11H18O3: C, 66.64; H, 
9.15. Found: C, 66.72; H, 9.14. 
1k: : Z isomer:; 
1
H NMR (CDCl3, 200 MHz)  3.77 (s, 6H), 7.28-7.48 (m, 5H, Ph), 
7.58 (s, 1H, CH=). Yield 73%. 
E isomer: 
1
H NMR (CDCl3, 200 MHz)  3.77 (s, 6H), 7.34-7.39 (m, 5H, Ph), 7.68 
(s, 1H, CH=). Yield 15%. 
1l: Z isomer: IR (film) /cm
-1 
2967, 2936, 2872, 1731, 1698, 1670, 1467, 1321, 
1258, 1212, 1036.
 1
H NMR (200 MHz, CDCl3)  1.07 (d, 6H, J = 6.6 Hz), 1.31 (t, 
3H, J = 7.4 Hz), 2.30 (s, 3H), 2.65 (m, 1H), 4.29 (q, 2H, J =7.4 Hz), 6.60 (d, 1H, J 
= 10.6 Hz); 
13
C NMR (50 MHz, CDCl3)  14.1, 21.9 (2), 26.8, 29.6, 61.2, 134.9, 
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154.0, 166.6, 195.4; GC-MS rt 11.74 min, m/z: 184(2), 138(100), 123(60), 110(15), 
96(57), 81(24), 67(32), 55(26). Yellow oil; isolated yield 61%. 
E isomer: IR (film) /cm
-1 
2965, 2933, 2872, 1705, 1638, 1467, 1367, 1239, 1200, 
1051.
 1
H NMR (200 MHz, CDCl3)  1.02 (d, 6H, J = 6.6 Hz), 1.30 (t, 3H, J = 7.4 
Hz), 2.37 (s, 3H), 2.62 (m, 1H), 4.24 (q, 2H, J =7.4 Hz), 6.69 (d, 1H, J = 10.6 Hz); 
13
C NMR (50 MHz, CDCl3)  13.9, 21.6, 21.8, 26.5, 29.4, 61.1, 134.8, 154.0, 
166.5, 197.9; GC-MS rt 11.45 min, m/z: 184(2), 138(100), 123(55), 110(15), 
96(64), 81(26), 67(31), 55(19). Yellow oil; isolated yield 26%. 
1m: Z isomer: %; IR (film) /cm
-1
2981, 2928, 2852, 1731, 1698, 1673, 1635, 1448, 
1380, 1305, 1210, 1150, 1035.
 1
H NMR (200 MHz, CDCl3)  1.21-1.43 (m, 5H), 
1.34 (t, 3H, J = 7.0 Hz), 1.60-1.77 (m, 5H), 2.31 (s, 3H), 2.37 (m, 1H), 4.30 (q, 2H, 
J =7.0 Hz), 6.63 (d, 1H, J = 9.8 Hz); 
13
C NMR (50 MHz, CDCl3)  14.1, 25.1(2), 
25.3, 26.7, 31.7, 31.8, 39.1, 61.0, 135.2, 152.5, 166.6, 197.9. GC-MS rt 9.3 min, 
m/z: 225, yellow oil; isolated yield 55% 
E isomer: IR (film) /cm
-1 
2927, 2853, 2360, 2342, 1701, 1654, 1637, 1448, 1274, 
1253.
 1
H NMR (200 MHz, CDCl3)  1.14-1.26 (m, 5H), 1.27 (t, 3H, J = 7.0 Hz), 
1.66-1.77 (m, 5H), 2.38 (s, 3H), 2.42 (m, 1H), 4.26 (q, 2H, J =7.0 Hz), 6.72 (d, 1H, 
J = 10.6 Hz); 
13
C NMR (50 MHz, CDCl3)  14.1, 25.0 (2), 25.6, 31.3, 31.9 (2), 
38.3, 61.0, 133.9, 152.8, 164.7, 201.3. GC-MS rt 10.0 min, m/z: 225, yellow oil; 
isolated yield 23%; 
1n: Z isomer:; 
1
H NMR (CDCl3, 200 MHz)  1.28 (t, J = 7.2 Hz, 3H, CH3CH2O), 
2.43 (s, 3H, COCH3), 4.34 (q, J = 7.2 Hz, 2H, CH3CH2O), 7.28-7.48 (m, 5H, Ph), 
7.58 (s, 1H, CH=). 
13
C NMR (CDCl3, 75 MHz):  13.8(CH3), 26.5(CH3), 
61.7(CH2), 128.8 (CH), 129.5(CH), 130.7(CH), 132.9(C), 134.6(C), 141.2(CH), 
167.7(C), 194.6(C). Yellow oil. Yield 72%. 
E isomer: 
1
H NMR (CDCl3, 200 MHz)  1.34 (t, J = 7.2 Hz, 3H, CH3CH2O), 2.36 
(s, 3H, COCH3), 4.30 (q, J = 7.2 Hz, 2H, CH3CH2O), 7.34-7.39 (m, 5H, Ph), 7.68 
(s, 1H, CH=). 
13
C NMR (CDCl3, 75 MHz):  14.1(CH3), 31.1(CH3), 61.5(CH2), 
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128.8 (CH), 129.6(CH), 130.3(CH), 132.8(C), 134.0(C), 140.4, (CH), 164.3(C), 
203.3(C). Anal. Calcd. For C13H14O3: C, 71.54; H, 6.47. Found: C, 71.59; H, 6.48. 
isolated yield 23%; 
1o: Z isomer:; 
1
H NMR (CDCl3, 400 MHz)  1.20 (t, J = 7.2 Hz, 3H, CH3CH2O), 
2.38 (s, 3H, COCH3), 4.27 (q, J = 7.2 Hz, 2H, CH3CH2O), 7.50 (d, J= 8.4 Hz, 1H, 
Ph), 7.56 (d, J= 8.4 Hz, 1H,Ph), 7.62 (s, 1H, CH=), 8.16 (m, 2H). Yellow oil. Yield 
80%. 
 
 
 
Procedure for the preparation of 2: Under inert conditions, were added 
ethylamine (1.2eq), triethylamine (2eq) and THF (1M). The reaction mixture, 
maintained under stirring, was cooled to a temperature of 0°C, and then proceed 
with the gradual addition of methyl malonylchloride (1eq). The reaction was 
carried at room temperature maintaining the stirring for 24 h. His course was 
followed by TLC. The work-up was performed concentrating the THF and 
performing extractions with H2O/DCM. The recovered organic phase was dried 
with Na2SO4, concentrated and dried by vacuum pump. Yellow oil. Yield 79%. 
2:
 1
H-NMR (400 MHz, CDCl3): δ 1.18 (t, 3H, J=8 Hz), 3.35 (m, 4H), 3.78 (s, 3H), 
7.25 (bs, 1H); 
 
 
 
Procedure for the preparation of 3a-b: Methyl-3-(ethylamino)-3-ossopropanoato 
(1eq), proper aldehyde (6eq) and piperidine (15%) were added to perform a 
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reaction to microwave, setting the instrument to a power of 250W for 7 min. The 
work-up was performed by extraction with H2O/AcOEt. The recovered organic 
phase was dried with Na2SO4, concentrated and dried by vacuum pump. Yellow 
oil. The crude was subjected to purification by flash chromatography on silica gel 
with eluent 8:2 c-Hex/AcOEt in order to separate the two geometric isomers that 
are obtained. The isomer (E) appears as a yellow solid, while the isomer (Z) 
appears as a white solid. The total yield, calculated with respect to methyl 
malonylchloride not having performed in any previous step purification, amounts 
to 79%. 
3a:
 1
H-NMR (200 MHz, CDCl3): δ 1.2 (t, 3H, J=3.7 Hz), 1.75 (m, 11H), 3.4 (m, 
2H), 3.78 (s, 3H), 6.98 (d, 1H, J=5 Hz, isomero (E)); 
3b:
 1
H-NMR (400 MHz, CDCl3): δ 1.04 (d, 6H, J=6.8 Hz), 1.15 (t, 3H, J=7.6 Hz), 
3.00 (m, 1H), 3.33 (m, 2H), 3.81 (s, 3H), 6,93 (d, 1H, J=10,8 Hz, isomero (Z)), 
7.24 (d, 1H, J=5.2 Hz, isomero (E)), 7.73 (bs, 1H). 
 
 
 
Procedure for the preparation of 5: In a flask were added in order L-Leucine 
methyl ester (2,76 mmol, 1eq) or HN-Gly-OtBu (1eq), 10 ml of toluene, 10 ml of 
DMF, 1eq of 2,2,6-trimethyl-1,3-dixin-4-one, 1eq of TEA and 5% of Yb(OTf)3. 
The mixture was irradiated by microwave at 250 watt for 5 min with strirring bar. 
After cooling of the mixture were added 1.78ml (7eq) of isobutyraldehyde and 
submitted another time under microwave irradiation for 30 min at 150 watt. The 
work-up was performed by extraction with H2O/AcOEt. The recovered organic 
phase was dried with Na2SO4, concentrated and dried by vacuum pump. Brown oil. 
The crude was subjected to purification by flash chromatography on silica gel with 
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eluent 6:4 c-Hex/AcOEt in order to separate the two geometric isomers that are 
obtained.Yield 41% over two steps.Z/E ratio 9/1. E-isomer not isolated. 
Z-5:
 1
H NMR (CDCl3, 400 MHz) J z), 1.11 (d, 6H, J= 6.8), 1.65 
(m, 1H, J= 6.8 Hz), 1.73 (m, 1H, J= 6.8 Hz), 1.74 (m, 1H, J= 6.8), 2.37 (s, 3H), 
3.16 (m, 1H, J= 3.2), 3.75 (t, 3H, J= 2.4 Hz), 4.71 (m, 1H, J= 5.2Hz), 6.71 (d, 1H, 
J= 10Hz), 7.10 (br d, 1H, J= 7.6Hz).
 13
C NMR (CDCl3, 100 MHz):  198.1, 173.1, 
165.1, 158.3, 135.1, 52.2, 50.8, 41.2, 29.1, 26.9, 24.9, 22.8, 22.1, 21.8.HPLC-MS: 
rt 8.9 min, m/z 284 (M+H). 
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Chapter 2 
Reactivity of alkylidene derivatives 
 
2.1 Introduction 
In this second chapter, we will examine the most important reactions performed 
starting from alkylidene malonates, acetoacetates and malonamides, that afforded 
the polyfunctionalized molecules with potential bioactivity discussed in the next 
chapter. In this context, we have explored three main routes, leading to different 
scaffolds for bioactive derivatives. 
The ways that we have followed are: 
- the Michael conjugate addition with N,O-Bis(trimethylsilyl)hydroxylamine, used 
to obtain isoxazolinic and isoxazolidinonic compounds,  
- the same reaction with several indole derivatives to get a library of β-tryptophan-
like molecules,  
-the Luche reduction of alkylidene derivatives to allylic alcohols and the following 
nucleophilic allylic substitution as steps to achieve a cyclic β-dehydropyrrolic 
derivative. 
Later on, specific reactivity of alkylidene derivatives in the above mentioned  
reactions will be discussed individually. 
 
2.2 Michael conjugate addition 
From a biological and pharmaceutical point of view, the1,4-Michael addition is one 
of the most used reactions to obtain interesting compounds. In literature there are 
several synthetic procedures to carry out this kind of reaction. Over the last few 
years, in our research group, methods to synthesize isoxazolines
3
 and 
isoxazolidinones
4
 have been developed starting from alkylidene acetoacetates and 
malonamides respectively. 
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2.2.1 Michael conjugate addition on alkylidene malonamides 
Alkylidene malonamides are starting materials used in the synthesis of 
isoxazolidinones. In this reaction, the nucleophilic attack of TMSONHTMS to 
electrophilic position of the unsaturated alkene allowed to obtain 1,4-adducts that, 
after treatment with TBAF, gave the final isoxazolidinone through intramolecular 
acyl substitution. It is interesting to note that during the reaction work-up of the 
Michael reaction, the loss of trimethylsilyl group on nitrogen spontaneously 
occurred. 
 
 
Scheme 6. Synthetis of isoxazolidinones through Michael addition. 
 
Differently from the reaction already carried out on alkylidene acetoacetates, we 
observed that the conjugate addition on alkylidene malonamides proceeds also 
without catalyst. Preliminary tests have demonstrated that the presence of the 
catalyst does not afford benefit to the correct reaction course but, on the contrary, 
favors quick degradation of the products in the reaction vessel. 
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2.2.2 Michael conjugate addition on alkylidene acetoacetates 
The same procedure seen for alkylidenes malonamides, was applied to alkylidene 
acetoacetates in order to obtain isoxazolines. The reaction was performed this time 
in the presence of a catalyst. As our research group recently published, the Lewis 
acid (Yb(OTf)3) employed in the reaction allows to reduce the overnight reaction 
time by 1-2 hours depending on the substrate, and it directs the regioselectivity of 
the reaction.
5
 In fact, the initial alkylidene, depending on the reaction conditions, 
may be subjected either to 1,4- or 1,2-nucleophilic attack, thus providing 
respectively  the 1,4- addition product desired, the 5-hydroxyisoxazolidine-4-
carboxylate, or the oxime. 
For these reasons, reaction conditions were previously optimized in our research 
group to induce the regioselective formation of 1,4-addition products versus 
oximes deriving from the 1,2-addition process. On the basis of this study, we 
carried out the following syntheses using the catalyst in 5% molar amount to limit 
the oxime formation. The resulting adduct spontaneously rearranges to give the 
isoxazolidine 9, a scaffold that was used to obtain the integrin ligands discussed in 
chapter 3. 
 
 
Scheme 7. Synthetis of isoxazolines through Michael addition. 
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2.3 Synthesis of dehydro-pyrrole scaffold 
2.3.1 Luche reduction 
The Luche reduction is a highly regioselective 1,2-reduction of unsaturated 
ketones, aldehydes, or enones and it is very useful to selectively reduce the 
carbonyl moiety is the presence of a double bond. In fact, this reaction is able to 
transform α,β-unsatured compounds into allylic alcohols by using NaBH4/CeCl3 in 
alcoholic solvent. 
NaBH4 is the main reagent in the reaction, and it is responsible for adding a 
hydride to the carbonyl group. It is a soft nucleophile and the selective reduction of 
the carbonyl group requires a harder nucleophile to get a 1,2 addition. 
The role of lanthanoid chloride CeCl3 is to transform the reducing agent from a 
hydrogen-based reducing agent to a –OR group based compound. This hardens the 
reducing agent, making it more likely to add a hydride specifically to the carbonyl 
group. 
An alcohol solvent (methanol or ethanol) provides the hydrogen atom necessary to 
add onto the alkoxide group after that reducing agent has added hydride to the 
carbonyl group. The alcohol solvent is activated by the Ce
3+
 ion, making its proton 
very acidic, which then comes off and is added to the oxygen atom of the ketone. 
The effective reaction mechanism is still not very clear but Luche himself has 
suggested the following hints: in summary, Ce
3+
 catalyzes the transformation of the 
reducing borohydride by the alcohol solvent and also activate the latter, making it 
easier for the oxygen of the carbonyl group to pick up the hydrogen atom from 
alcohol. The novel reducing agent adds a hydride to the carbon atom of the 
carbonyl group, creating an alkoxide. The alkoxide then is protonated by the 
activated alcohol solvent, completing the reduction of the carbonyl to an alcohol. In 
such a way, we can justify the reduction selectivity with the HSAB theory. 
However, for further precautions, the reaction was carried out at low temperature to 
avoid side attacks on the present double bond. 
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Scheme 8. Luche reduction and relative mechanism. 
 
Therefore, from the alkylidene acetoacetates and acetoacetoamides we obtained the 
related racemic alcohols that we needed to transform to the corresponding 
enantiopure carbonates. To this purposes we performed an enzymatic resolution
 
followed by treatment with methyl chloroformiate, as we will explain in the next 
section. 
 
Scheme 9. Synthesis of carbonates enantiomerically pure starting from alcohol 
obtained by Luche reaction and solved by enzymatic resolution. 
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2.3.2 Kinetic enzymatic resolution 
Following the procedure previously optimized in our research group (after enzyme 
and conditions screening),
6
 the resolution of racemic mixtures of the allylic 
alcohols shown before have been performed using Pseudomonas Cepacia lipase 
(EC 3.1.1.3) as catalyst.
7
  
 
 
Scheme 10. Kinetic enzymatic resolution of racemic alcohols deriving from Luche 
reduction. 
 
The selected lipase proved to be very successful for the resolution of Z-alcohols, 
giving the acetylated compounds in good yields and high e.e., although in sluggish 
reaction times. Indeed, racemic alcohols were submitted to enzyme catalyzed 
acetylation employing vinyl acetate in diethyl ether at 30 °C for 30 hours. Under 
these conditions, both products were isolated in good yields and excellent 
enantiomeric excesses. The reaction can be monitored by 
1
H-NMR and GC-MS, 
which allow the determination of the conversion. The racemic alcohols were 
analytically resolved into their enantiomers by chiral HPLC and were compared 
with the alcohols that derived from enzymatic resolution. 
Acetates 12 (R) were hydrolyzed to corresponding alcohols with a K2CO3 in 
methanol treatment (Scheme 11). Enatiomeric excesses of resulted alcohols were 
determined via HPLC by comparison with corresponding racemates. As we 
mentioned in the previous paragraph, enantiopure alcohols were transformed into 
the corresponding carbonates by treatment with methyl chloroformate (Scheme 9). 
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Scheme 11. Hydrolysis of acetates obtained by enzymatic resolution. 
 
2.3.3 Nucleophilic allylic substitution (SN2’) 
As illustrated in Scheme 12, the allylic carbonate can be used as intermediate for a 
synthesis of interesting heterocyclic scaffolds and, in particular, it is possible to 
utilize it to obtain a dehydropyrrole ring. The retrosynthetic pathway shows that, if 
the desired heterocycle can be synthesized by ring closing methatesis, the substrate 
for this reaction has to be prepared through a SN2’ reaction on the allylic carbonate. 
On the basis of our research group’s experience, the racemic and enantiopure 
carbonates, that we have seen above, have been subjected to nucleophilic allylic 
substitution with allyl amine. The reaction was carried out in absence of catalyst or 
under Ir-catalyzed conditions.
8 
 
 
Scheme 12. Retrosynthetic route to synthesize optically active dehydropyrroles. 
 
Recently, we observed that Iridium precursor and phosphate or phosphoramidite 
ligands combination have been described as excellent catalytic system with a 
number of different nucleophiles for allylic substitution.
9
 Iridium complexes have 
been also successfully applied in the stereoselective formation of C-N bonds via 
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allylic amination,
10– mostly on monosubstituted alkenyl carbonates,11– but they 
have been never applied to allylic carbonates such as compound 11, which presents 
alkyl substituents on both terminals and a carboxylic group in the central position. 
In an initial screening we observed that the choice of solvent and of the 
phosphorous ligand strongly influence the regioseletivity and the stereoselectivity. 
Among the other, we tested also ethanol as solvent because it has been reported
12
 to 
favor the formation of the product deriving from SN2’ mechanism. Some selected 
results are shown in Table 2. 
 
 
Scheme 13. Nucleophilic allylic substitution on racemic and enantiopure 
carbonates. 
Reactions performed without any catalyst in refluxing acetonitrile (Table 2, entries 
1-7) afforded good yields but only after three days and by using a large excess of 
amine (9 equivalents). Deriving from SN2’ mechanism, the regioisomer 13 was 
exclusively obtained, as 4/1 Z/E isomers mixture, and no traces of the product 14 
could be detected. The enantiomeric excess of the initial carbonate was completely 
retained and enantiopure 13a-f was obtained starting from the corresponding chiral 
carbonates (entries 2-5). When using ethanol as solvent in presence of Ir-
phosphorous ligand as catalytic couple, we observed an increase of yield with 
regioselectivity retention. To confirm the good action of the combination between 
Ir and phosphourus ligand, we tried to perform the reaction only with ethanol and 
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then without phosphourus ligand. In both cases, the obtained results weren’t 
comparable to those provided with Ir-phosphorous catalytic couple. 
 
Entry  Carbonate Solvent Allylamine(eq) Catalyst Time Yielda
(%) 
13:14 
1 rac-Z-11a MeCN 9 / 72 86 >99:1
b 
2 (S)-Z-11a
c MeCN 9 / 72 85 >99:1b 
3 (R)-Z-11a
c MeCN 9 / 72 85 >99:1b 
4 (S)-Z-11b
c MeCN 9 / 72 65 >99:1b 
5 (R)-Z-11b
c MeCN 9 / 72 68 >99:1b 
6 rac-Z-11e MeCN 9 / 72 50 >99:1
b 
7 rac-Z-11f MeCN 9 / 72 85 >99:1
b 
8 rac-Z-11a THF 15 Pd2(dba)3CHCl3 72 35 >99:1 
9 rac-Z-11a EtOH 3 [Ir(COD)Cl]2(2%) 
P(OPh)3(8%) 
10 >99 >99:1 
10 rac-Z-11a EtOH 3 / 16 52 >99:1 
11 rac-Z-11a EtOH 3 [Ir(COD)Cl]2(2%) 16 60 >99:1 
12 rac-Z-11c EtOH 3 [Ir(COD)Cl]2(2%) 
P(OPh)3(8%) 
8 >99 >99:1d 
13 rac-Z-11d EtOH 3 [Ir(COD)Cl]2(2%) 
P(OPh)3(8%) 
10 95 >99:1e 
14 rac-Z-11e EtOH 3 [Ir(COD)Cl]2(2%) 
P(OPh)3(8%) 
10 >99 75:25 
15 rac-Z-11f EtOH 3 [Ir(COD)Cl]2(2%) 
P(OPh)3(8%) 
10 90 60:40 
Table 2.  
a
 Yields were calculated after purification of the products by flash chromatography on silica gel. 
The unreacted carbonate 11 was completely recovered after work-up as pure Z-isomer. 
b 
Compound 13 was always obtained as 4/1 mixture of Z/E isomers.
 
c 
Enantiomeric excess of substrates and products was determined by HPLC on chiral column 
(always >95% ee).
 
d 
In this case only the one product is formed for the symmetry of the molecule.
 
e 
Obtained as a 5/1 mixture of Z/E isomers, each as 1:1 diastereomeric mixture.
 
 
 
At this point it has been opportune to consider a possible screening of phosphorous 
ligands. The reaction was repeated on enantiopure (S)-11a. The “memory effect” of 
allylic substitution leading to conservation of the enantiomeric purity depends on 
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the rate of isomerization of Ir-allyl intermediates and the selection of the proper 
phosphorous ligand may influence the e.e. decrease.
13
 Therefore, the reaction was 
repeated in the presence of different catalysts and the enantiospecificity (e.s. = 
eeproduct / eesubstrate) was determined (Table 3). The selected phosphoramidite ligands 
are reported in Figure 7. 
As expected, all reactions are completely regioselective, affording exclusively 
compound 13a. The enantiomeric excess of the product was determined by HPLC 
on chiral column and the enantiospecificity was calculated. The result, obtained 
without phosphorous ligand (entry 1), was quite similar to those obtained with 
triphenylphosphite or phosphoramidite L2 (entries 2 and 4). The best result was 
observed for the reaction performed with ligand L1, that allowed to enhance the 
enantiospecificity up to 91%. 
 
 
Fig. 7. Phosphorous ligands used to optimized the SN2’. 
 
 
Entrya Carbonate Lignd (R)-Z-13a/(S)-E-13a 
1 (S)-Z-11a / 86/14 
2 (S)-Z-11a P(OPh)3 87/13 
3 (S)-Z-11a L1 95/5 
4 (S)-Z-11a L2 87/13 
Table 3. a Enantiomeric excess of substrates and products was determined by HPLC on chiral 
column. 
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2.3.4. Ring closing methatesis (RCM) 
As previously suggested, ring closing methatesis (RCM) is useful method to 
synthesize cyclic scaffolds for potential biological or pharmaceutical applications. 
This reaction allows to obtain from 5- to 30-membered cyclic alkenes and the E/Z 
selectivity depends on the ring strain. The reaction proceeds in presence of a 
catalyst and most widely employed of them are Ruthenium catalysts shown in.  
 
 
Scheme 14. Protecting group employed to perform RCM. 
 
Exploiting the ability of this reaction to easily provide an unsatured ring, we 
thought to utilize the diene amine synthesized through the  SN2’ reaction discussed 
above, to obtain 2,5-dihydropyrrole derivatives. Before performing RCM, we 
needed to protect the nitrogen, because it may poison the ruthenium catalyst by 
coordination of the nitrogen electron pair to the metal-alkylidene complex. 
Therefore, we decided to protect the nitrogen with three different N-protecting 
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groups in order to investigate the reactivity of these compounds and the large use 
that the RCM products could have. The employed protecting groups include an 
amide and two carbamates, as shown in scheme 14. 
Taking the synthesis of dihydropyrrole derivatives into consideration as final 
target, we selected more easily cleavable protecting groups as –BOC and –CBz. 
Among the inserted protecting group, there is the N-malonamide derivative in order 
to use it as a useful intermediate for the preparation of bioactive integrin ligands. 
This derivative was synthesize in good yield by treatment of starting amine with 
methylmalonyl chloride and TEA in DCM at rt for 3h. The N-BOC derivative was 
obtained after a treatment with BOC2O in ethanol at rt for 3h in excellent yield and 
finally the synthesis of N-CBz derivative was performed using the corresponding 
chloride in a solution of starting amine and K2CO3 in water/dioxane (1:1 ratio) at rt 
overnight. The reaction has led to 80% yield after isolation. 
 
 
Scheme 15. Ring closing methatesis on protected allylic amines. 
 
We then turned our attention to RCM. To determine the best catalyst for our 
transformation we screened different commercially available compounds (Figure 
8). A strong effect on catalyst efficacy is linked to steric hinderance of substrate 
and to the electronic nature of the olefins. When the steric bulk and the electron 
withdrawing character of the olefin substituents are combined in the same 
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substrate, the rate of RCM is strongly reduced and the metal-complex may 
decompose before reacting.
14
 
Fig. 8. Ruthenium catalysts employed. 
 
In a recent Kuhn’s work 15it is shown to what extent methyl tertbutyl ether (MTBE) 
is the ideal solvent for the synthesis of 2,5-dihydropyrroles via metathesis reaction. 
Afterwards, we chose it for our reactions in presence of 3% of catalyst. 
On both carbamates, catalyst A doesn’t provide the product allowing the recovery 
of starting materials without any trace of the heterocyclic compound, even after 
long reaction times. On these grounds, catalyst A was not tested on the amide 
derivative. However, performing the reactions on the carbamates with second-
generation Grubbs’ catalyst B,  cyclic products have been obtained quantitatively. 
The same reactivity is registered on the Z/E mixture of isomers and the complete 
transformation to the desired products was observed in 1,5-2h on the N-CBz and 
N-BOC compounds respectively. On N-CBz derivatives were also tested Hoveyda-
Grubbs’ second-generation catalysts C and D providing the dihydropyrrole 
compounds slightly faster. Comparing the results using catalyst B with the one 
obtained by employing the more expensive catalysts C and D, it is possible to see 
how there is a lack of significant improvement but for a few time. In a similar way, 
the reaction on malonamide was carried out with catalysts B,C and D. With the use 
of Hoveyda-Grubbs’ second-generation catalysts C and D, quantitative yields of 
product have been obtained over a lapse of 12h of reaction whereas, by employing 
catalyst B, after 16h we recovered dihydropyrrole derivative only  in 54% yield. 
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Entry Starting Material Catalyst Time (h) Yield 
1 15a A 16 / 
2 15a B 2 >98 
3 15b A 16 / 
4 15b B 1.5 >98 
5 15b C 1 >98 
6 15b D 1 >98 
7 15c B 16 54 
8 15c C 12 >98 
9 15c D 12 >98 
10 15d C 12 >98 
Table 4. Ring closing methatesis on protected diene amines. 
 
 
2.4 Multicomponent reactions 
Nowadays, Multicomponent Reactions (MCRs) represent a novel and challenging 
frontier in synthetic organic chemistry. In this kind of processes three or more 
components react in the same vessel leading to the final product without the need 
of isolating any intermediate. Since the very beginning of their validation and 
application, MCRs proved to be a very useful tool for the synthesis of structurally 
complex molecules (in particular natural products) and in the field of drug 
discovery. 
 
2.4.1 Yonemitsu-type trimolecular condensation 
One kind of MCRs is the Yonemitsu Reaction by which differently substituted 
indoles, aldehydes and dicarbonylic compounds react to give tryptophan 
derivatives.
16
 In the late seventies, Yonemitsu and coworkers reported a new 
trimolecular condensation among the Meldrum’s acid, an indole and an aldehyde, 
which provided 3-substituted indols. During the following years and up to the 
present day, this reaction has been reinvestigated in order to overcome its 
limitations. In fact, replacing Meldrum’s acid with another active methylene 
compound, which possess a different pKa value, poor results could be obtained 
under standard conditions.  As explained by the reaction sequence reported below, 
the Yonemitsu reaction consists in two different steps: first the formation of the 
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alkylidene derivative occurs through a Knoevenagel reaction and than it is followed 
by indole addition to the double bond by Michael conjugate addition. Each single 
step has been optimized by changing L.A., method, solvent, temperature and time. 
In literature several examples are reported about this process but they present some 
negative aspects such as a stoichiometric amount of catalyst
 17
(using TiCl4) or long 
reaction times and low yields. From these groundwork and our research group’s 
past experience on microwave assisted reactions we have developed an improved 
protocol to obtain greater efficiency for the Yonemitsu-type trimolecular 
condensation. 
Figure 9. Knoevenagel reaction represented by steps. 
 
The MCR was performed following a sequential protocol, by synthesizing the 
intermediates 1a-b in few minutes using microwaves under solvent free conditions 
and adding in the same reaction vessel L.A., solvent and indole to obtain 17a-b. 
For the reaction performed using acetoacetate derivative as starting material, we 
also tried to improve diasteroselectivity finding the best conditions. 
To optimize conditions, we choose as stardard reaction the condensation of 
dimethyl malonate with isobutylaldehyde and indole (Scheme 16). Initially, we 
tried to perform a domino MCR by adding all reagents simultaneously in the 
microwave reactor and irradiating at 250W for 20 minutes without solvent. Under 
these conditions very dirty reaction crudes were always observed since a number of 
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condensations among reagents could occur, and for this reason we decided to 
optimize the reaction by searching the best conditions for each step. 
The best conditions for the first step had been already discussed in a previous part 
of this thesis, and by following them, equimolar amounts of dimethyl malonate or 
acetoacetate were reacted with isobutyraldehyde, using 15% of piperidine as 
catalyst under microwave irradiation at 250W for 7 minutes. Alkylidene malonate 
1a or alkylidene acetacetate 1b were obtained in 90% yield after isolation by flash 
chromatography.  
 
 
Scheme 16. One pot-two steps Yonemitsu-type condensation. 
 
We then focused our attention on the second step, that was initially performed on 
purified 1a. Some selected results are reported in Table 1.  
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On the basis of previously reported methods, we choose to begin our screening by 
using Yb(OTf)3 as catalyst in different solvents (entries 1-3). By using toluene or 
acetonitrile to dissolve reagents, side product 18 was mainly obtained. On the other 
hand, using DMF as solvent better results were obtained, achieving adduct 17a in 
41% yield. The formation of bis-indolic derivative 18 could be easily explained in 
the one pot reaction, where a double addition of indole to the aldehyde may be 
supposed, but is quite unexpected starting from alkylidene malonate. As already 
suggested by Gao and Wu,
18
 the adduct 17 is probably converted into a reactive 
indolenine derivative
19
 by the loss of the active methylene fragment, which reacts 
with another molecule of indole (Figure 10).  
 
 
Fig. 10. Hypothetical formation mechanism of bis-indole compound starting from 
intermediate 2. 
 
To select the optimal catalyst several L.A. have been screened. In the presence of 
Cu(OTf)2, compound 17a could be isolated in 51% yield, but evolution into 
compound 18 (21%) and decarboxylation to 19a (5%) was always observed (entry 
5). On the contrary, Zn(OTf)2 was not an efficient catalyst affording a very low 
yield under the same conditions (entry 6). The reaction performed in the presence 
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of Sc(OTf)3 afforded a satisfactory amount of product (entry 7), without presence 
of undesired bis-indolic derivative 18. No advantages have been registered 
attempting to enhance the yield by changing microwave power (entries 8 and 9) or 
reaction times (entries 10-12), since an increase of side-products was always 
observed. 
 
 
 
Entry Reagent Power 
(W) 
Time 
(min) 
Solvent Lewis Acid Yield 
17(%)a 
Yield 
18(%)a 
Yield 
19(%)a 
1 1a 250 20 Toluene Yb(OTf)3 28 36 / 
2 1a 250 20 DMF Yb(OTf)3 41 21 15 
3 1a 250 20 CH3CN Yb(OTf)3 6 29 / 
4 1a 250 20 CH3CN Sc(OTf)3 6 42 / 
5 1a 250 20 DMF Cu(OTf)2 51 21 7 
6 1a 250 20 DMF Zn(OTf)2 18 / 5 
7 1a 250 20 DMF Sc(OTf)3 57 / 16 
8 1a 150 20 DMF Sc(OTf)3 20 6 5 
9 1a 300 20 DMF Sc(OTf)3 45 9 20 
10 1a 250 20 DMF Sc(OTf)3 45 v 12 
11 1a 250 20 DMF Sc(OTf)3 31 16 35 
12 1b 250 20 DMF Yb(OTf)3 19 9 55 
13 1b 250 20 DMF Cu(OTf)2 / 12 75 
14 1b 250 20 DMF Zn(OTf)2 / 9 38 
15 1b 250 20 DMF Sc(OTf)3 41 7 44 
16b 1b 250 20 DMF Sc(OTf)3 30 5 16 
17 1b 250 20 DMF / / 18 / 
Table 5.Screening of Lewis acid in the second step in the Yonemitsu-type condensation. 
 
With the same step by step approach, the reaction that use acetoacetate 1b as 
starting material has been studied and it must be specified that this reaction has 
been less investigated than the corresponding on alkylidene malonate. This is 
probably due to the fact that, with acetoacetate, the newly formed adduct has two 
stereocenters and, unfortunately, maintainance of diastereocontrol is quite difficult 
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due to the strong acidity of the acetoacetic proton. Equilibration to a 60/40 
diastereomeric mixture indeed often occurs by storing compounds at room 
temperature. For these reasons the conjugate addition of indole to alkylidene 
acetoacetate 1b required milder conditions. 
Skipping the first step discussed before
20
 we focused our attention on the conjugate 
addition. Microwave irradiation at 250W for 20 minutes in the presence of Yb, Cu 
or Zn triflates always afforded complete conversion of the starting material mainly 
to bis-indole derivative 18 or decarboxylated adduct 19b (entries 12-14). Only 
Sc(OTf)3 allowed to isolate 17b in 41% yield, together with an equal amount of 
19b (entry 15). Increasing the dilution from 1M to 0.1 M we registered similar 
results but a lower conversion of the starting material that was recovered in 50% 
amount (entry 16). When the reaction was performed without Lewis acid, the 
presence of 84% of starting material was observed in the crude mixture together 
with 16% of bis-indole compound 18, but no traces of the adduct 17b could be 
detected (entry 17). These results showed that isolation of satisfactory amount of 
17b is quite difficult, since evolution to 18 or 19b always occurs before complete 
transformation of the starting material. On these basis, we thought that microwave 
activation should be avoided in the second step for alkylidene acetoacetate 1b. 
Basing on registered information from the two distinct step, we performed the one-
pot two steps reaction. In this protocol, reagents are added in a sequential way 
without isolating the unsaturated intermediate. Some selected results are reported in 
Table 2. The reactions were performed by adding the reagents for the second step 
directly into the vessel, without performing any work-up to the first step crude. We 
started to studied conditions for dimethyl malonate reaction. Initially it has been 
verified that simple introduction of pure indole, without adding solvent or catalyst, 
is not sufficient to induce product formation but only the bis-indole derivative was 
observed in small amount (entry 1). Considering the unreacted starting materials in 
the first step that could be still present in the vessel, we checked for products 
deriving from the condensation of aldehyde, indole and piperidine,
21
 but no traces 
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of these derivatives were ever observed. The reaction has been performed under the 
same conditions (250W, 10 min, neat) in the presence of Yb(OTf)3, but the 
complete recover of the alkylidene intermediate 1a (entry 2) suggesting us that 
second step requires a solvent.  
 
Entry Reagent 1st step 2nd step Solvent Lewis 
Acid 
Yield 
17(%)a 
Yield 
18(%)a 
Yield 
1(%)a 
1 A 250W-
7min 
250W-
10min 
/ / / 11 42 
2 A 250W-
7min 
250W-
10min 
/ Yb(OTf)3 / / 90 
3 A 250W-
7min 
250W-
20min 
DMF Sc(OTf)3 33 16 16 
4 A 250W-
7min 
250W-
20min 
DMF Yb(OTf)3 45 25 8 
5 A 250W-
7min 
r.t.-4h DMF Yb(OTf)3 / / 90 
6 A 250W-
7min 
r.t.-4h CH3CN Yb(OTf)3 30 3 9 
7b B 250W-
7min 
250W-
20min 
DMF Sc(OTf)3 / 5 12 
8 B 250W-
7min 
r.t.-4h DMF Yb(OTf)3 / 6 77 
9 B 250W-
7min 
r.t.-4h DMF Sc(OTf)3 / 6 85 
10 B 250W-
7min 
r.t.-4h CH3CN Yb(OTf)3 67(51/49) / 5 
11 B 250W-
7min 
r.t.-4h CH3CN Sc(OTf)3 75(63/37) 7 16 
12 B 250W-
7min 
r.t.-4h CH3CN Cu(OTf)2 47(50/50) 16 12 
13 B 250W-
7min 
r.t.-4h CH3CN Zn(OTf)2 23(61/49) 8 43 
14 B 250W-
7min 
0°C-17h CH3CN Sc(OTf)3 71(70/30) 7 16 
15 B 250W-
7min 
0°C-17h CH3CN Yb(OTf)3 66(60/40) 8 12 
16 B 250W-
7min 
-20°C-4h CH3CN Yb(OTf)3 29(75/25) 2 34 
Table 6.One pot-two steps optimization in the Yonemitsu-type condensation. 
 
The experiments carried out under MW irradiation in DMF afforded yields in the 
range between 33% and 45% and, as expected, a large amount of compound 18 was 
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also obtained both with scandium or ytterbium triflates (entries 3-4). On the basis 
of these results, we performed the second step at room temperature (entries 5-6) 
using acetonitrile as solvent, since it is resulted to be the more suitable to our 
purposes under these conditions, even if the yield was comparable to those 
obtained under microwave conditions. 
At this point, the one-pot two step reaction starting from ethyl acetoacetate has 
been studied following the same approach. Performing both steps under microwave 
catalyzed conditions, the reaction didn’t afford satisfactory results (entry 7), 
because decarboxylation of 17b cannot be avoided, as previously observed when 
the second step was performed on isolated 1b. By conducting the second step at 
room temperature in DMF we could observe the presence of the unsaturated 
intermediate 1b as major product, thus confirming that under these conditions 
DMF is not the solvent of choice (entries 8-9). The reaction carried out in CH3CN 
provided the desired product 2b in satisfactory yield. By changing the Lewis acid 
(entries 10-13) we could verify that Yb(OTf)3 or Sc(OTf)3 are the best catalysts, 
since from the reaction with copper or zinc, bis-indole 18 and alkylidene 
intermediate 1b were isolated in considerable amount. The diastereomeric ratio has 
been improved lowering the reaction temperature in the second step. In fact, we 
obtained an improvement from 51/49 at room temperature up to 75/25 at -20°C 
(entry 14-16). The (2S*,3S*) stereochemistry of the preferred stereoisomer was 
attributed by comparison with the literature.
22 
Anyway, the diastereomeric excess 
of the mixture is unstable due to the acidity of the α-proton, and fast equilibration 
to 60/40 mixture occurs under mild basic conditions.  
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Scheme 17. MCR via one-pot two steps method with substituted indoles on 
aliphatic and aromatic aldehydes. 
 
Applying the optimized conditions to the condensation of ethyl acetoacetate with 
aromatic aldehydes and substituted indoles, we developed a small library of 
compounds (Scheme 17). In the reactions performed with benzaldehyde (entries 1-
4), we obtained modest yields till maximum 39% when 5-F-indole was employed 
(entries 2). The reaction of indole with 4-NO2-benzaldehyde afforded a better result 
(55% yield, entry 5). 
On the contrary, from the condensation with isobutyraldehyde and 5-substituted 
indoles, quite satisfactory yields have been observed. The reactions with this 
aldehyde led to a reduced amount of side products (entries 6-8). In particular, the 
reaction with 5-F-indole gave an excellent result, because the product 17h was 
obtained in 55% yield and no traces of bis-indolic derivative could be detected in 
the crude by 
1
H NMR nor it could be isolated after flash chromatography. The 
reaction performed with 1-Me-indole and isobutyraldehyde afforded 17l in 61% 
yield (entry 8), a result similar to that obtained with unsubstituted indole, while a 
very unsatisfactory yield was observed when the same reaction was performed with 
benzaldehyde (entry 4). 
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Entry R1 R2 R3 
Product 
 
Yield 
17(%)a 
Yield 
bisindole(%)a 
1 Ph H H 17c 
 
36 27 
2 Ph F H 17d 
 
39 30 
3 Ph Me H 17e 
 
32 29 
4 Ph H Me 17f 
 
23 33 
5 4-NO2- Ph H H 17g 
 
55 22 
6 iPr F H 17h 
 
55 < 5 
7 iPr Me H 17i 
 
50 18 
8 iPr H Me 17l 
 
61 18 
Table 7. Small library produced by Yonemitsu-type condensation protocol. 
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2.5 Experimental section 
 
Addition on malonamides: 
General procedure for the 1,4 addition of N,O 
bis(trimethylsilyl)hydroxylamine to compound 3a-b (compounds 6a-b). 
Lewis acid (0.25 mmol) was added to a stirred solution of alkylidene malonamide 1 
(5mmol, 1.3 g) in dry DCM (25 mL) at -40°C. After ten minutes, N,O-
bis(trimethylsilyl)hydroxylamine (2.2 equiv., 11 mmol, 2.35 mL) was added 
dropwise and the solution was monitored by TLC and quenched with water (20 
mL) at appearance of degradation products. After washing twice with water (20 
mL), the organic layer was dried with Na2SO4 and solvent was removed under 
reduced pressure. Compounds 6a-b were obtained as yellow oil with 83-76% of 
yield respectively. 
6a:
 1
H-NMR (200 MHz, CDCl3): δ 0.1 (s, 9H), 1.18 (m, 3H), 1.7 (m, 11H), 3.4 (m, 
4H), 3.78 (s, 3H); 
6b:
 1
H-NMR (400 MHz, CDCl3): δ 0.1 (s, 9H), 0.94 (t, 6H, J=6.7 Hz), 1.18 (m, 
3H), 1.87 (m, 1H), 3.28 (m, 3H), 3.74 (d, 1H, J=3 Hz), 3.78 (s, 3H). 
 
General procedure to obtain isoxazolidinones 7a-b. 
Tetrabutylammonium fluoride (2 equiv., 1.5 g) was added to a solution of 6 (3 
mmol, 0.92 g) in THF at room temperature. The solution was stirred overnight and 
then the solvent was removed under reduced pressure. The residue was diluted with 
diethyl ether (10 mL) and washed twice with water (10 ml). The organic layers 
were dried with Na2SO4 and solvent was removed under reduced pressure. 
Isoxazolidinones 7a-b were obtained in 43-26% yield respectively after purification 
by flash chromatography on silica gel (cyclohexane/EtOAc, 8:2). 
7a: 
1
H-NMR (200 MHz, CDCl3): δ 1.21 (t, 3H, J=4 Hz), 1.77 (m, 11H), 3.38 (m, 
3H), 4.01 (m, 1H), 6.3 (bs, 1H). 
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7b:
 1
H-NMR (200 MHz, CDCl3): δ 0.96 (d, 6H, J=3.4 Hz), 1.19 (t, 3H, J=3.9 Hz), 
1.6 (bs, 1H), 1.89 (m, 1H), 3.32 (m, 3H), 3.99 (m, 1H), 6.26 (bs, 1H). 
 
Addition on alkylidene acetoacetates: 
General procedure for the 1,4 addition of N,O 
bis(trimethylsilyl)hydroxylamine to compound 1(various) (compounds 9) 
To a stirred solution of 1 (0.5 mmol) in dry DCM (2.5 mL) at 0 °C under nitrogen, 
N,O-bis(trimethylsilyl)hydroxylamine (2 equiv., 1 mmol) was added in one 
portion. The reaction was monitored by TLC and quenched after 16 h with H2O. 
The residue was then diluted with DCM (10 mL) and washed with H2O (2X10 
mL). The organic layer was dried with Na2SO4, and the solvent was removed under 
reduced pressure. Compounds 8 were purified by flash chromatography with silica 
gel (cyclohexane/EtOAc, 9:1). 
9a-methyl ester: Yield >95%, colorless clear oil; Major anomer 
1
H NMR (CDCl3, 
300 MHz): δ 0.88 (d, J = 6.6 Hz, 3H), 0.97 (d, 3H, J = 6.6 Hz), 1.67 (s, 3H), 1.69 
(m, 1H), 2.96 (d, J = 5.4 Hz, 1H), 3.56 (dd, J = 5.4, 7.5 Hz, 1H), 3.76 (s, 3H). 
13
C 
NMR (CDCl3, 75 MHz): δ 18.7(CH3), 19.2(CH3), 23.8(CH), 32.5(CH3), 52.4(CH), 
60.2(CH3), 67.9(CH), 106.5(C), 171.0(C). Minor anomer 
1
H NMR (CDCl3, 300 
MHz): δ 0.92 (d, J = 6.9 Hz 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.50 (s, 3H), 1.70 (m, 
1H), 2.95 (d, J = 7.6 Hz 1H), 3.58 (m, 1H), 3.74 (s, 3H). 
13
C NMR (CDCl3, 75 
MHz):  19.6(CH3), 20.3(CH3), 22.2(CH), 30.1(CH3), 52.2(CH), 62.0(CH3), 
71.3(CH), 108.4(C), 172.0(C). Anal. Calcd. For C9H17NO4: C, 53.19; H, 8.43; N, 
6.89. Found: C, 53.14; H, 8.45; N, 6.92. 
9a-ethyl ester: Yield 95%, yellow oil; Major anomer 
1
H NMR (C6D6, 600 MHz): δ 
0.82 (d, J = 6.6 Hz, 3H), 0.93 (t, 3H, J = 7.2 Hz), 0.97 (d, 3H, J = 6.6 Hz), 1.51 (s, 
3H), 1.64 (m, 1H), 2.83 (d, J = 5.4 Hz, 1H), 3.58 (dd, J = 5.4, 7.2 Hz, 1H), 3.93 (m, 
1H), 3.98 (m, 1H). 
13
C NMR (CDCl3, 75 MHz): δ 14.1(CH3), 18.7(CH3), 
19.4(CH3), 23.8(CH), 32.6(CH3), 60.1(CH2), 61.3(CH), 67.9(CH), 106.5(C), 
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170.7(C). Minor anomer 
1
H NMR (C6D6, 600 MHz): δ 0.86 (d, J = 7.2 Hz 3H), 
0.88 (d, J = 6.6 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H), 1.45 (s, 3H), 1.50 (m, 1H), 3.03 
(d, J = 7.8 Hz 1H), 3.88 (dd, J = 7.8, 7.2 Hz, 1H), 3.92 (m, 2H). 
13
C NMR (CDCl3, 
75 MHz):  14.2(CH3), 19.6(CH3), 20.4(CH), 22.2(CH3), 30.1(CH3), 61.1(CH2), 
62.0(CH), 71.9(CH), 108.4(C), 171.5(C). Anal. Calcd. For C10H19NO4: C, 55.28; 
H, 8.81; N, 6.45. Found: C, 55.31; H, 8.79; N, 6.43. 
9b: Yield 90%, pale yellow oil; Major anomer 
1
H NMR (CDCl3, 300 MHz): δ 
0.80-1.06(m, 8H) 1.30 (t, 3H, J = 7.2 Hz), 1.58 (m, 1H), 1.67 (s, 3H), 2.96 (d, J = 
6.0 Hz, 1H), 3.67 (t, J = 6.0 Hz, 1H), 4.23 (m, 2H). 
13
C NMR (CDCl3, 75 MHz): δ 
11.2(CH3), 14.1(CH3), 15.2(CH3), 23.8(CH), 26.2(CH2), 39.0(CH3), 59.8(CH), 
61.3(CH2), 66.6(CH), 106.1(C), 170.7(C). Minor anomer 
1
H NMR (CDCl3, 300 
MHz): δ 0.80-1.06(m, 8H) 1.29 (t, 3H, J = 7.2 Hz), 1.53 (s, 3H), 1.58 (m, 1H), 2.95 
(m, 1H), 3.68 (m, 1H), 4.25 (m, 2H).
13
C NMR (CDCl3, 75 MHz):  11.8(CH3), 
13.6(CH3), 18.2(CH3), 23.1(CH), 26.6(CH2), 40.1(CH3), 60.3(CH), 61.9(CH2), 
70.1(CH), 105.0(C), 167.2(C). Anal. Calcd. For C11H21NO4: C, 57.12; H, 9.15; N, 
6.06. Found: C, 57.11; H, 9.19; N, 6.08. 
9c: Yield 95%, yellow oil; Major anomer 
1
H NMR (CDCl3, 300 MHz) 0.92-1.40 
(m, 6H), 1.29 (t, J= 7.2 Hz, 3H), 1.52-1.78 (m, 4H), 1.67 (s, 3H), 2.00 (m, 1H), 
3.00 (d, J= 5.7 Hz, 1H), 3.56 (dd, J= 5.7, 8.1 Hz, 1H), 4.24 (m, 2H); 
13
C NMR 
(CDCl3, 75 MHz) δ 14.1 (CH3), 23.9(CH), 25.8 (CH2), 26.0 (CH2), 26.3 (CH2), 
29.4(CH2), 29.9 (CH2), 42.3 (CH3), 60.1(CH), 61.4 (CH2), 67.2 (CH), 106.3 (C), 
170.8 (C). Minor anomer 
1
H NMR (CDCl3, 300 MHz) 0.92-1.40 (m, 6H), 1.33 (t, 
J= 7.2 Hz, 3H), 1.52-1.78 (m, 4H), 1.64 (s, 3H), 1.85 (m, 1H), 2.96 (d, J= 7.5 Hz, 
1H), 3.56 (t, J= 7.5 Hz, 1H), 4.30(m, 2H); 
13
C NMR (CDCl3, 75 MHz) δ 14.1 
(CH3), 22.0(CH), 25.1 (CH2), 25.6(CH2), 26.9 (CH2), 30.9(CH2), 31.0 (CH2), 40.0 
(CH3), 61.0(CH), 62.1 (CH2), 70.2(CH), 108.2 (C), 171.4 (C). Anal. Calcd. For 
C13H23NO4: C, 60.68; H, 9.01; N, 5.44. Found: C, 60.75; H, 9.00; N, 5.41. 
9h: Yield 80%, yellow oil; Major anomer 
1
H NMR (CDCl3, 300 MHz) δ 1.31 (t, J= 
7.2 Hz, 3H), 1.74 (s, 3H), 3.24 (d, J= 5.4 Hz, 1H), 4.27 (q, J= 7.2 Hz, 2H), 5.09 (d, 
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J= 5.4 Hz, 1H),7.28-7.57 (m, 5H); 
13
C NMR (CDCl3, 75 MHz) δ 14.4 (CH3), 24.4 
(CH3), 61.9 (CH2), 65.0 (CH), 70.2(CH), 107.0 (C), 126.3 (2CH), 127.3 (2CH), 
128.7 (CH), 134.1 (C), 178.0 (C). Minor anomer 
1
H NMR (CDCl3, 300 MHz) δ 
1.27 (t, J= 7.2 Hz, 3H), 1.64 (s, 3H), 3.41 (d, J= 7.2 Hz, 1H), 4.15 (q, J= 7.2 Hz, 
2H), 4.94 (d, J= 7.2 Hz, 1H), 7.28-7.60 (m, 5H); 
13
C NMR (CDCl3, 75 MHz) δ 
14.1 (CH3), 25.1 (CH3), 60.9 (CH2), 64.2 (CH), 69.3(CH), 105.8 (C), 126.5 (2CH), 
127.1 (2CH), 128.9 (CH), 136.1 (C), 169.4 (C). Anal. Calcd. For C13H17NO4: C, 
62.14; H, 6.82; N, 5.57. Found: C, 62.19; H, 6.80; N, 5.53. 
 
Luche reduction: 
General procedure for Luche reduction to compounds 10. 
To a stirred solution of compound  Z-1 and E-1 (5 mmol) in THF/MeOH 9:1 (10 
mL) at room temperature, CeCl3
.
7H2O (1 equiv., 5 mmol, 1,86 g) was added. After 
30 min the solution was carried at -30°C and NaBH4 (1.1 equiv., 5.5 mmol, 0.2 g) 
was added in one portion. The solution was monitored by TLC and quenched after 
disappearence of the starting ketone by addition of water (5 mL). After removal of 
THF and MeOH under reduced pressure, the residue was diluted with ethyl acetate 
(10 ml) and washed twice with water (5 ml). The two phases were separated, the 
organic layer was dried over Na2SO4 and solvent was removed under reduced 
pressure. Racemic alcohols Z-10-rac or E-10-rac were isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 80/20 as eluant). 
Z-10a. Yellow oil; IR (film) ν/cm-1 3437, 2964, 2933, 2870, 1717, 1467, 1372, 
1228, 1178, 1159. 
1
H NMR (200 MHz, CDCl3)  1.00 (d, 6H, J = 6.6 Hz), 1.24 (m, 
6H), 3.10 (m, 1H), 4.23 (q, 2H, J = 6.6 Hz), 4.42 (q, 1H, J = 6.2 Hz) 5.87 (d, 1H, J 
= 10.0 Hz); 
13
C NMR (50 MHz, CDCl3)  14.1, 22.4, 22.5, 28.2, 60.3, 69.2, 133.1, 
146.9, 167.7. GC–MS rt 11.62 min, m/z: 186(2), 171(36), 144(21), 125(100), 
115(20), 97(61), 79(35), 67(25), 55(24). (3S)-Z-10a: HPLC on Chiralcel OF 
(97.5/2.5 n-hexane/ 2-propanol, flow 1.0 mL/min): rt 14.5 min, [α]= -11,0 (c 1.0, 
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CHCl3).(3R)-Z-10a: HPLC on Chiralcel OF (97.5/2.5 n-hexane/2-propanol, flow 
1.0 mL/min): rt 16.4 min, [α]= +12,4 (c 1.0, CHCl3). 
E-10a. Yellow oil; IR (film) m/cm
-1
 3452, 2963, 2871, 1693, 1641, 1466, 1368, 
1261, 1176, 1190. 
1
H NMR (200 MHz, CDCl3)  1.03 (d, 3H, J = 6.6 Hz), 1.06 (d, 
3H, J = 6.6 Hz), 1.24 (t, 3H, J = 7.2 Hz), 1.42 (d, 3H, J = 6.6 Hz), 2.77 (m, 1H), 
4.22 (q, 2H, J = 7.2 Hz), 4.72 (m, 1H), 6.52 (d, 1H, J = 10.2 Hz); 
13
C NMR (50 
MHz, CDCl3)  14.1, 22.2(2), 23.8, 27.1, 60.4, 65.0, 131.7, 149.2, 167.5. GC–MS 
rt 11.80 min, m/z: 186(2), 171(64), 143(27), 125(100), 115(11), 97(46), 79(20), 
67(18), 55(15). 
Z-10b. Yellow oil; IR (film) ν/cm-1 3438, 2926, 2851, 1714, 1448, 1373, 1303, 
1263, 1208, 1178, 1153. 
1
H NMR (200 MHz, CDCl3)  1.01–1.36 (m, 5H), 1.25 (t, 
3H, J = 7.0 Hz), 1.25 (d, 3H, J = 6.6 Hz), 1.60–1.73 (m, 5H), 2.30 (br s, 1H), 2.75 
(m, 1H), 4.24 (q, 2H, J = 7.0 Hz), 4.41 (q, 1H, J = 6.6 Hz), 5.88 (d, 1H, J = 10.0 
Hz); 
13
C NMR (50 MHz, CDCl3) d 14.0, 22.5, 25.4, 25.7, 25.9, 32.4, 32.5, 37.9, 
60.2, 69.2, 133.4, 145.6, 167.7. GC–MS rt 16.40 min, m/z: 226(2), 208(38), 
179(33), 162(100), 147(28), 133(51), 119(37), 107(20), 99(29), 91(36), 81(87), 
67(38), 55(34). (3S)-Z-1b: HPLC on Chiralcel OF (97.5/2.5 n-hexane/ 2-propanol, 
flow 1.0 mL/min): rt 17.7 min, α= -8,7 (c 1.0, CHCl3). (3R)-Z-10b: HPLC on 
Chiralcel OF (97.5/2.5 n-hexane/ 2-propanol, flow 1.0 mL/min): rt 19.3 min, 
α=+9,4 (c 1.0, CHCl3). 
E-10b: Yellow oil; IR (film) ν/cm-1 3423, 2926, 2852, 1691, 1448, 1368, 1263. 1H 
NMR (200 MHz, CDCl3)  1.11–1.25 (m, 5H), 1.29 (t, 3H, J = 7.4 Hz), 1.39 (d, 
3H, J = 6.6 Hz), 1.44–1.73 (m, 5H), 2.34 (m, 1H), 4.19 (q, 2H, J = 7.4 Hz), 4.70 (q, 
1H, J = 6.6 Hz) 6.50 (d, 1H, J = 9.8 Hz); 
13
C NMR (50 MHz, CDCl3)  14.1, 23.9, 
25.4 (2), 25.7, 32.1(2), 37.0, 60.6, 65.1, 132.1, 147.8, 167.7. GC–MS rt 16.81 min, 
m/z: 226(2), 211(100), 179(18), 165(68), 143(55), 129(38), 119(35), 105(19), 
91(32), 81(70), 67(45), 55(43). 
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10c: Yellow oil, 
1
H NMR (400 MHz, CDCl3)  0.94 (d, J= 6.8 Hz, 6H), 0.95 (d, J= 
6.4 Hz, 6H), 1.46 (d, J= 6.8, 3H, major isomer), 1.48 (d, J= 6.8 Hz, 3H, minor 
isomer), 1.50-190 (m, 3H), 2.00 (m, 1H), 3.74 (s, 3H), 3.79 (s, 3H), 4.41 (m, 1H), 
5.26 (m, 1H). LC-MS-ESI rt 9.0 min, m/z 344 (M+1). 
 
Synthesis of racemic and enantiomerically pure acetates: 
General procedure for the synthesis of racemic acetates 12. 
To a solution of compound  Z-10 (1 mmol) in dry THF (5 mL), under inert 
atmosphere at 0°C, LiHMDS (1.5 equiv., 1.5 mL 1M solution in THF) was added 
dropwise. The solution was stirred for 30 minutes and then acetyl chloride (1.5 
equiv., 1.5 mmol, 0.1 mL) was added in one portion and ice bath was removed. 
After one hour, the mixture was quenched with water (5 mL) and THF removed 
under reduced pressure. The residue was diluted with ethyl acetate (10 ml) and 
washed twice with water (5 ml). The two phases were separated, the organic layer 
was dried over Na2SO4 and solvent was removed under reduced pressure. Racemic 
and enantiomerically pure acetates Z-12 were isolated by flash chromatography on 
silica gel (cyclohexane/ethyl acetate 90/10 as eluant). 
12a: (3R)-Z-12a: Yellow oil; IR (film) ν/cm-1 2963, 1644, 1466, 1241, 1178, 1097. 
1
H NMR (300 MHz, CDCl3)  1.05 (d, 6H, J = 6.6 Hz), 1.34 (m, 6H), 2.08 (s, 3H), 
3.15 (m, 1H), 4.26 (q, 2H, J = 7.2 Hz), 5.65 (q, 1H, J = 6.6 Hz) 5.91 (d, 1H, J = 9.9 
Hz); 
13
C NMR (75 MHz, CDCl3)  14.1, 19.8, 21.2, 22.4, 22.5, 28.2, 60.4, 69.9, 
130.5, 147.9, 169.9,170.5. GC–MS rt 12.89 min, m/z: 213(2), 185(24), 168(35), 
143(100), 123(57), 95(83), 79(54), 67(35), 55(28). α=+36:5 (c 1.0, CHCl3). 
12b: (3R)-Z-12b. Yellow oil; IR (film) ν/cm-1 2926, 2852, 1690, 1448, 1368, 1303, 
1263, 1222, 1155, 1064. 
1
H NMR (200 MHz, CDCl3)  0.89–1.25 (m, 5H), 1.26 (t, 
3H, J = 7.0 Hz), 1.33 (d, 3H, J = 6.6 Hz), 1.55–1.77 (m, 5H), 2.02 (s, 3H), 2.80 (m, 
1H), 4.19 (q, 2H, J = 7.0 Hz), 5.60 (q, 1H, J = 6.6 Hz), 5.88 (d, 1H, J = 10.0 Hz); 
13
C NMR (75 MHz, CDCl3)  14.1, 19.9, 21.2(2), 25.5(2), 26.0, 32.4, 32.6, 37.8, 
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60.2, 69.9, 130.8, 146.7, 166.4, 170.1. GC– MS rt 17.40 min, m/z: 268(2), 225(18), 
208(55), 179(63), 162(100), 151(10), 143(95), 133(57), 119(35), 105(33), 91(41), 
81(84), 67(38), 55(31). α=+27:2 (c 1.0, CHCl3). 
 
Enzymatic resolution: 
General procedure for Enzymatic resolution 
To a solution of racemic alcohol 10-rac (5 mmol) in diethyl ether (25 mL) at 40 
°C, vinylacetate (4 equiv., 4 mmol, 0.37 mL) and Lipase from Pseudomonas 
Cepacia (46 U/mg, 0.2 mass equiv.) were added. The progress of the reaction was 
assessed every 12 h by GC-MS. The reaction was stopped by filtration of the 
enzyme and elimination of solvent and byproducts under reduced pressure. 
Enantiomerically pure alcohols (3S)-Z-10 and acetates  (3R)-Z-12 were separated 
by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10 then 80/20 
as eluant). For NMR spectra of alcohol see before (Luche reduction). 
 
Hydrolysis of enantiomerically pure acetates 12 to enantiomerically pure 
alcohols 10. 
Acetate (3R)-Z-12 (0.5 mmol) was stirred in MeOH (5 mL) in the presence of 
K2CO3 (1 equiv., 0.5 mmol, 70 mg) for 30 min. at room temperature. The reaction 
was quenched by addition of 0.1 M HCl (5 mL). After removal of MeOH under 
reduced pressure, the residue was diluted with ethyl acetate (10 mL) and washed 
twice with water. The two phases were separated, the organic layer was dried over 
Na2SO4 and solvent was removed under reduced pressure. Enantiomerically pure 
alcohols (3R)-Z-10 were purified by flash chromatography on silica gel 
(cyclohexane/ethyl acetate 80/20 as eluant). For NMR spectra see before )Luche 
reduction). 
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General procedure for the synthesis of racemic and enantiopure carbonate 11. 
To a solution of LiHMDS (1.5 equiv., 1.5 mL 1M solution in THF) in dry THF (5 
mL), compound Z-10 (1 mmol) under inert atmosphere at -78°C, was added 
dropwise and stirred for 30 min. Then methyl chloroformiate (2 equiv.) was added 
in one portion and the reaction mixture was stirred at -78°C for . After one hour, 
the mixture was quenched with water (5 mL). The mixture was diluted with ethyl 
acetate (10 ml) and washed twice with water (5 ml). The two phases were 
separated, the organic layer was dried over Na2SO4 and solvent was removed under 
reduced pressure. Racemic and enantiomerically pure acetates Z-12 were isolated 
by flash chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as 
eluant).Yield 65-70%. 
11a: 
1
H NMR (200 MHz, CDCl3)  1.01 (d, J= 6.6 Hz, 6H), 1.42 (d, J= 6.6 Hz, 
3H), 1.50 (s, 9H), 3.02-3.17 (m, 1H), 3.77 (s, 3H), 5.46 (q, J= 6.6 Hz, 1H), 5.84 (d, 
J= 9.6 Hz, 1H). 
13
C NMR (50 MHz, CDCl3) 19.8, 22.5, 26.2, 28.1, 54.5, 74.0, 
81.2, 131.3, 146.7, 155.0, 165.6 
11b: 
1
H NMR (200 MHz, CDCl3)  1.02-1.14 (m, 5H), 1.50 (s, 9H), 1.60-1.82 (m, 
6H). 3.77 (s, 3H), 5.46 (q, J= 6.6 Hz, 1H), 5.84 (d, J= 9.6 Hz, 1H). 
11c: 
1
H NMR (400 MHz, CDCl3)  0.92-0.99 (m, 12H), 1.44 (d, J= 6.0 Hz, 3H, 
major isomer), 1.45 (d, J= 6.8 Hz, 3H, minor isomer), 1.59 (m, 1H), 1.83 (m, 1H), 
2.01 (m, 1H), 2.49 (m, 1H), 3.70 (s, 3H, major isomer), 3.72 (s, 3H, minor isomer), 
3.75 (s, 3H, minor isomer), 3.76 (s, 3H, major isomer), 3.77 (s, 3H, minor isomer), 
5.04 (dd, J= 9.6 Hz, 5.2 Hz, 1H), 5.41-5.50 (m, 2H). 
13
C NMR (100 MHz, CDCl3) 
 171.1, 171.0, 169.4, 167.7, 153.9 major isomer, 153.2 minor isomer, 137.1 major 
isomer, 134.6 minor isomer, 57.3, 54.6 minor isomer, 54.1 major isomer, 54.0 
major isomer, 53.6 minor isomer, 52.4 major isomer, 52.3 minor isomer, 38.7 
minor isomer, 38.6 major isomer, 38.4 major isomer, 38.2 minor isomer, 29.7, 
28.6, 25.1, 23.1, 22.3 minor isomer, 22.2 major isomer, 21.8 minor isomer, 21.7 
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major isomer, 19.5 major isomer, 19.3 minor isomer. LC-MS-ESI rt 10.5 min, m/z 
424 (M+Na). 
 
Nucleophilic allylic substitution: 
General procedure for allylic amination in the presence of Iridium catalyst 
To a stirred solution of [Ir(COD)(Cl)]2 (0.02 mmol) and phosphorous ligand (0.08 
mmol) in EtOH (5 mL) under nitrogen atmosphere, carbonate 11 (1 mmol) and 
allylamine (3 mmol, 3 equiv.) were added in one portion at room temperature. The 
solution was stirred under refluxing conditions and monitored by TLC. After 
removal of the solvent and the excess of allylamine under reduced pressure, the 
residue was diluted with ethyl acetate (10 mL). The organic solution was extracted 
three times with 0.1 M HCl (10 mL), then was dried over Na2SO4 and solvent was 
removed under reduced pressure to recover unreacted starting carbonate. 1 M 
NaOH was added dropwise to the acid aqueous layer until basic pH was achieved 
and then the solution was extracted three times with DCM (10 mL). The organic 
layers were dried over Na2SO4 and solvent was removed under reduced pressure to 
afford allylamino derivative 13 in quantitative yield as a yellow oil. Compound 13 
was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 
70:30 as eluant). 
Z-13a: Yellow oil; 
1
H NMR (200 MHz, CDCl3)  0.68 (d, J = 6.6 Hz, 3H), 1.02 (d, 
J = 6.6 Hz, 3H), 1.41 (s, 9H), 1.69 (d, J = 7.4 Hz, 3H), 1.97 (m, 1H), 2.91 (dd, J = 
14.0, 6.2 Hz, 1H), 3.05 (d, J = 9.2 Hz, 1H), 3.16 (dd, J = 14.0, 5.4 Hz, 1H), 5.03–
5.18 (m, 2H), 5.89 (m, 1H), 6.91 (q, J = 7.2 Hz, 1H); 
13
C NMR (75 MHz, CDCl3)  
13.9, 20.0, 21.0, 28.1, 32.0, 49.7, 61.4, 80.4, 115.0, 133.3, 134.3, 138.4, 166.7. LC–
MS–ESI rt 14.97 min, 254 (M+1). (S)-Z-13a [a]D =+19.5 (c 1 in CHCl3); (R)-Z-
13a [a]
D
 = -20.6 (c 1 in CHCl3); Anal. cald. for C15H27NO2 (253.20): C 71.10, H 
10.74, N 5.53; found C 70.84, H 10.65, N 5.57. 
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E-13a: Yellow oil; 
1
H NMR (200 MHz, CDCl3)  0.77 (d, J = 6.6 Hz, 3H), 0.89 (d, 
J = 6.6 Hz, 3H), 1.40 (s, 9H), 1.84 (d, J = 7.0 Hz, 3H), 1.97 (m, 1H), 2.72 (d, J = 
8.2 Hz, 1H), 2.91 (dd, J = 14.0, 6.2 Hz, 1H), 3.16 (dd, J = 14.0, 5.4 Hz, 1H), 5.03-
5.18 (m, 2H), 5.68 (q, J = 7.0 Hz, 1H); 5.89 (m, 1H); 
13
C NMR (75 MHz, CDCl3) 
14.8, 20.0, 21.0, 28.0, 32.1, 49.8, 61.4, 80.0, 115.0, 133.3, 134.8, 137.8, 167.8. 
LC–MS–ESI rt 15.84 min, 254 (M+1). Anal. cald. for C15H27NO2 (253.20): C 
71.10, H 10.74, N 5.53; found C 71.22, H 10.68, N 5.50. 
Z-13b: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  0.78 (m, 1H), 0.92 (m, 1H), 
1.11–1.25 (m, 4H), 1.42 (s, 9H), 1.49 (m, 4H), 1.76 (d, J = 6.8 Hz, 3H), 2.28 (m, 
1H), 2.96 (dd, J = 17.6, 6.6 Hz, 1H), 3.20 (d, J = 9.2 Hz, 1H), 3.22 (dd, J = 17.6, 
5.6 Hz, 1H), 5.04 (dd, J = 1.4, 10.0 Hz, 1H), 5.13 (dd, J = 1.4, 17.2 Hz, 1H), 5.88 
(m, 1H), 6.89 (q, J = 7.2 Hz, 1H); 
13
C NMR (75 MHz, CDCl3)  14.0, 26.3, 26.7, 
28.2, 30.7, 31.7, 41.6, 60.1, 80.2, 115.2, 134.0, 137.9, 138.6, 166.9. LC–MS–ESI rt 
16.21 min, 294 (M+1). (S)-Z-13b [a]
D
 = + 14.3 (c 1 in CHCl3); (R)-Z-13b [a]
D
 = -
16.6 (c 1 in CHCl3). Anal. cald. for C18H31NO2 (293.24): C 73.67, H 10.65, N 4.77; 
found C 73.91, H 10.61, N 4.78. 
E-13b: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  0.78 (m, 1H), 0.92 (m, 1H), 
1.11–1.25 (m, 4H), 1.42 (s, 9H), 1.49 (m, 4H), 1.90 (d, J = 6.8 Hz, 3H), 2.28 (m, 
1H), 2.82 (d, J = 8.6 Hz, 1H), 2.96 (dd, J = 17.6, 6.6 Hz, 1H), 3.20 (d, J = 9.2 Hz, 
1H), 3.22 (dd, J = 17.6, 5.6 Hz, 1H), 5.04 (dd, J = 1.4, 10.0 Hz, 1H), 5.13 (dd, J = 
1.4, 17.2 Hz, 1H), 5.78(q, J = 7.2 Hz, 1H); 5.89 (m, 1H); 
13
C NMR (75 MHz, 
CDCl3)  15.0, 26.4, 26.7, 28.2, 30.6, 31.7, 41.8, 68.1, 80.6, 115.2, 133.6, 137.8, 
138.6, 166.9. LC–MS–ESI rt 16.95 min, 294 (M+1). Anal. cald. for C18H31NO2 
(293.24): C 73.67, H 10.65, N 4.77; found C 73.39, H 10.60, N 4.75. 
Z-13c::Yellow oil; 
1
H NMR (400 MHz, CDCl3) 1.33 (d, J = 7.2 Hz, 3H), 1.50 (s, 
9H), 1.79 (d, J = 7.2 Hz, 3H), 3.07 (dd, J = 14.0, 6.0 Hz, 1H), 3.18 (dd, J = 14.0, 
6.0 Hz, 1H), 3.75 (q, J = 7.2 Hz, 1H), 5.06–5.17 (m, 2H), 5.92 (m, 1H), 6.81 (q, J = 
7.2 Hz, 1H); 
13
C NMR (75 MHz, CDCl3)  13.8, 20.5, 28.3, 50.1, 59.8, 81.4, 117.4, 
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132.3, 135.8, 137.6, 166.5. LC–MS–ESI rt 10.32 min, 226 (M+1). Anal. cald. For 
C13H23NO2 (225.17): C 69.29, H 10.29, N 6.22; found C 69.03, H 10.10.27, N 6.22. 
E-13c: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.44 (d, J = 6.8 Hz, 3H), 1.53 (s, 
9H), 1.91 (d, J = 6.8 Hz, 3H), 3.11 (dd, J = 13.8, 6.0 Hz, 1H), 3.24 (dd, J = 13.8, 
6.0 Hz, 1H), 3.36 (q, J = 6.8 Hz, 1H), 5.06-5.17 (m, 2H), 5.86-5.96 (m, 2H); 
13
C 
NMR (75 MHz, CDCl3)  14.1, 20.2, 28.3, 51.1, 60.0, 81.2, 116.9, 132.2, 135.6, 
137.8, 167.4. LC–MS–ESI rt 11.44 min, 226 (M+1). Anal. cald. for C13H23NO2 
(225.17): C 69.29, H 10.29, N 6.22; found C 69.58, H 10.24, N 6.25. 
Z-13d: Yellow oil; 
1
H NMR (200 MHz, CDCl3) 0.70 d, J = 7.2 Hz, 3H), 1.05 (d, 
J = 7.2 Hz, 3H), 1.00–1.82 (m, 3H), 1.46 (s, 9H), 1.74 (d, J = 7.2 Hz, 3H), 2.82–
3.28 (m, 3H), 4.99–5.16 (m, 2H), 5.82 (m, 1H), 6.87 (q, J = 7.2 Hz, 1H); 13C NMR 
(75 MHz, CDCl3)  11.6, 13.9,16.2, 26.5, 28.4, 38.7, 50.4, 59.6, 80.8, 115.8, 132.6, 
134.9, 137.8, 164.1. LC–MS–ESI rt 16.11 min, 268 (M+1). Anal. cald. for 
C16H29NO2 (267.22): C 71.86, H 10.93, N 5.24; found C 71.64, H 10.95, N 5.25. 
E-13d: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  0.77 (d, J = 7.0 Hz, 3H), 0.84 (d, 
J = 6.8 Hz, 3H), 1.00–1.82 (m, 3H), 1.48 (s, 9H), 1.90 (d, J = 7.2 Hz, 3H), 2.82–
3.28 (m, 3H), 4.99–5.16 (m, 2H), 5.71–5.96 (m, 2H); 13C NMR (75 MHz, CDCl3)  
12.2, 13.3,18.2, 26.1, 28.3, 36.2, 50.0, 60.1, 81.6, 118.0, 132.1, 133.7, 138.1, 167.3. 
LC–MS–ESI rt 13.34 min, 268 (M?1). Anal. cald. for C16H29NO2 (267.22): C 
71.86, H 10.93, N 5.24; found C 72.00, H 
10.88, N 5.21. 
Z-13e: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.31 (s, 9H), 1.93 (d, J = 7.6 Hz, 
3H), 3.21 (dd, J = 14.0, 6.0 Hz, 1H), 3.32 (dd, J = 14.0, 5.6 Hz, 1H), 4.83 (s, 1H), 
5.11 (dd, J = 1.6, 10.4 Hz, 1H), 5.22 (dd, J = 1.6,16.8 Hz, 1H), 5.99 (m, 1H), 7.01 
(q, J = 7.6 Hz, 1H), 7.18-7.43 (m, 5H); 
13
C NMR (75 MHz, CDCl3)  14.5, 28.8, 
49.8, 60.6, 81.6, 116.8, 127.4, 127.9, 128.5, 132.1, 133.9, 136.0, 139.2, 166.4. LC–
MS–ESI rt 20.22 min, 288 (M?1). Anal. cald. for C18H25NO2 (287.19): C 75.22, H 
8.77, N 4.87; found C 75.40, H 8.72, N 4.84. 
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E-13e: Yellow oil; 
1
H NMR (400 MHz, CDCl3) 1.30 (s, 9H), 1.94 (d, J = 7.2 Hz, 
3H), 3.12 (dd, J = 14.0, 6.4 Hz, 1H), 3.20 (dd, J = 14.0, 6.0 Hz, 1H), 4.45 (s, 1H), 
5.05 (dd, J = 1.6, 10.4 Hz, 1H), 5.15 (dd, J = 1.6,17.2 Hz, 1H), 5.88 (m, 1H), 6.09 
(q, J = 7.2 Hz, 1H), 7.18–7.43 (m, 5H); 13C NMR(75 MHz, CDCl3)  16.1, 28.7, 
50.1, 60.2, 83.4, 117.9, 127.5, 127.8, 128.2, 132.6, 134.6, 137.2, 138.9, 167.9. LC–
MS–ESI rt 21.56 min, 288 (M+1). Anal. cald. For C18H25NO2 (287.19): C 75.22, H 
8.77, N 4.87; found C 75.01, H 8.75, N 4.86. 
Z-13f: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.42 (s, 9H), 1.97 (d, J = 7.2 Hz, 
3H), 3.26 (dd, J = 14.0, 5.6 Hz, 1H), 3.38 (dd, J = 14.0, 5.6 Hz, 1H), 4.89 (s, 1H), 
5.16–5.31 (m, 2H), 6.03 (m, 1H), 7.09 (q, J = 7.2 Hz, 1H), 7.10 (m, 1H), 7.24–7.35 
(m, 2H); 
13
C NMR (75 MHz, CDCl3)  13.9, 28.4, 49.9, 57.6, 81.3, 115.9, 120.3, 
125.4, 128.1, 132.4, 134.4, 136.5, 139.0, 168.0. LC–MS–ESI rt 19.02 min, 294 
(M+1). Anal. cald. for C16H23NO2S (293.14): C 65.49, H 7.90, N 4.77, S 10.93; 
found C 65.64, H 7.91, N 4.76, S 10.98. 
E-13f: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.44 (s, 9H), 2.05(d, J = 7.2 Hz, 
3H), 3.22–3.34 (m, 2H), 4.57 (s, 1H), 5.16–5.31 (m, 2H), 5.98–6.15 (m, 2H), 7.12 
(m, 1H), 7.24–7.35 (m, 2H); 13C NMR (75 MHz, CDCl3)  14.6, 28.3, 49.7, 57.0, 
80.9, 117.1, 122.2, 125.6, 128.0, 132.1, 135.0, 136.9, 140.2, 166.5. LC–MS–ESI rt 
16.43 min, 294 (M+1). Anal. cald. for C16H23NO2S (293.14): C 65.49, H 7.90, N 
4.77, S 10.93; found C 65.77, H 7.88, N 4.74, S 10. 94. 
E-14e: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.38 (d, J = 6.8 Hz, 3H), 1.49 (s, 
9H), 2.83 (dd, J = 14.0, 6.4 Hz, 1H), 3.03 (dd, J = 14.0, 7.6 Hz, 1H), 3.84 (q, J = 
6.8 Hz, 1H), 4.83–4.90 (m, 2H), 5.71 (m, 1H), 7.18-7.31 (m, 5H), 7.61 (s, 1H); 13C 
NMR (75 MHz, CDCl3)  21.2, 28.4, 51.3, 58.2, 80.9, 117.4, 127.5, 127.7, 128.0, 
129.1, 134.9, 136.7, 138.0, 165.9. LC–MS–ESI rt 18.44 min, 288 (M+1). Anal. 
cald. for C18H25NO2 (287.19): C 75.22, H 8.77, N 4.87; found C 75.33, H 8.77, N 
4.85. 
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Z-14e: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.43 (s, 9H), 1.45 (d, J = 6.8 Hz, 
3H), 2.84 (dd, J = 14.0, 6.4 Hz, 1H), 3.02 (dd, J = 14.0, 7.6 Hz, 1H), 4.59 (q, J = 
6.8 Hz, 1H), 4.83–4.90 (m, 2H), 5.78 (m, 1H), 6.82 (s, 1H), 7.15–7.40 (m, 5H); 13C 
NMR (75 MHz, CDCl3)  19.2, 28.3, 51.3, 58.6, 81.2, 116.9, 127.5, 127.6, 128.1, 
129.1, 134.6, 135.9, 138.6, 167.0. LC–MS–ESI rt 17.10 min, 288 (M?1). Anal. 
cald. for C18H25NO2 (287.19): C 75.22, H 8.77, N 4.87; found C 75.11, H 8.81, N 
4.87. 
 
Synthesis of N-BOC derivative 15a: 
Boc2O (1 mmol, 1 eq.) was added to a solution of 13a in EtOH (5 mL) at room 
temperature and the reaction mixture was left stirring for 3 h. Then, the solvent was 
removed under reduced pressure and the residue was diluted with EtOAc (10 mL). 
After washing three times with water (5 mL), the organic layer was dried over 
Na2SO4 and solvent was removed under reduced pressure. Compound 15a was 
purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 70:30 as 
eluant). 
Z-15a: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  0.79 (d, J = 6.4 Hz, 3H), 0.90 (d, 
J = 6.4 Hz, 3H), 1.48 (s, 9H), 1.53 (s, 9H), 1.92 (d, J = 7.4 Hz, 3H), 2.62 (m, 1H), 
3.82-4.01 (m, 2H), 4.81(d, J = 11.2 Hz, 1H), 4.94-5.04 (m, 2H), 5.74 (m, 1H), 6.83 
(q, J = 7.2 Hz, 1H); 
13
C NMR (75 MHz, CDCl3)  14.2, 19.7, 27.7, 27.9, 28.1, 45.6, 
58.4, 78.8, 79.9, 114.4, 133.9, 136.1, 142.4, 155.8, 166.7. LC–MS–ESI rt 16.6 min 
354 (M+1), 729 (2M+23). Anal. cald. for C20H35NO4 (353.26): C 67.95, H 9.98, N 
3.96; found C 67.77, H 10.00, N 3.94. 
E-15a: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  0.92(d, J = 6.8 Hz, 6H), 1.48 (s, 
9H), 1.53 (s, 9H), 1.92 (d, J = 7.4 Hz, 3H), 2.62 (m, 1H), 3.82–4.01 (m, 2H), 
4.62(d, J = 10.8 Hz, 1H), 4.94-5.04 (m, 2H), 5.48 (q, J = 7.2 Hz, 1H), 5.76 (m, 1H); 
13
C NMR (75 MHz, CDCl3) 14.2, 20.1, 27.7, 27.9, 29.4, 45.3, 59.6, 78.8, 79.4, 
114.4, 133.9, 135.5, 141.6, 155.4, 166.7 LC– MS–ESI rt 14.9 min 354 (M+1), 729 
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(2M+23). Anal. cald. for C20H35NO4 (353.26): C 67.95, H 9.98, N 3.96; found C 
68.26, H 9.95, N 3.96. 
 
Synthesis of N-CBz derivative 15b: 
Benzyloxycarbonyl chloride (1.5 mmol, 1.5 equiv.) and K2CO3 (2 mmol, 2 equiv) 
were added to a solution of 13a (1 mmol) in dioxane/ water (1:1 solution, 5 mL). 
The reaction mixture was stirred at room temperature overnight. The solution was 
diluted ethyl acetate (10 mL) and washed three times with water (10 mL). The 
organic layer was dried over Na2SO4 and solvent was removed under reduced 
pressure. Compound 15b was purified by flash chromatography on silica gel 
(eluant cyclohexane/EtOAc 97:3). 
Z-15b: : Yellow oil; 
1
H NMR (400 MHz, CDCl3) : 0.79 (d, J = 6.8 Hz, 3H), 0.92 
(d, J = 6.8 Hz, 3H), 1.46 (s, 9H), 1.90 (d, J = 7.2 Hz, 3H), 2.68 (m, 1H), 3.94-4.06 
(m, 2H), 4.83 (d, J = 9.8 Hz, 1H), 4.90–5.18 (m, 4H), 5.67 (m, 1H), 6.85 (q, J = 7.2 
Hz, 1H) 7.20–7.40 (m, 5H); 13C NMR (75 MHz, CDCl3)  14.5, 19.8, 20.0, 27.8, 
28.0, 45.7, 59.7, 67.0, 80.3, 115.0, 127.6, 128.2, 128.5, 133.6, 135.8, 137.0, 143.0, 
156.8, 166.8. LC–MS–ESI rt 14.7 min 388 (M+1), 410 (M+23). Anal. cald. for 
C23H33NO4 (387.24): C 71.29, H 8.58, N 3.61; found C 71.43, H 8.56, N 3.96. 
E-15b: Yellow oil; 
1
H NMR (400 MHz, CDCl3) : 0.91 (d, J = 6.8 Hz, 6H), 1.44 
(s, 9H), 1.90 (d, J = 7.2 Hz, 3H), 2.68 (m, 1H), 3.94–4.06 (m, 2H), 4.62 (d, J = 9.2 
Hz, 1H), 4.90–5.18 (m, 4H), 5.68 (m, 1H), 6.01 (q, J = 7.2 Hz, 1H), 7.20–7.40 (m, 
5H); 
13
C NMR (75 MHz, CDCl3)  14.1, 19.9, 20.3, 27.8, 29.7, 46.2, 59.9, 67.3, 
80.4, 115.3, 127.6, 128.2, 128.5, 133.5, 135.2, 136.6, 142.0, 156.0, 166.8. LC–MS–
ESI rt 13.5 min 388 (M+1), 410 (M+23). Anal. cald. for C23H33NO4 (387.24): C 
71.29, H 8.58, N 3.61; found C 71.07, H 8.62, N 3.95. 
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Synthesis of N-malonamido derivative 15c-d:  
To a stirred solution of 13a (1 mmol) in dry DCM (5 mL), methyl malonyl chloride 
(1.5 mmol, 1.5 equiv.) and triethylamine (1.5 mmol, 1.5 equiv.) were added at 
room temperature. After stirring for 3 h, the reaction mixture diluted with DCM (10 
mL) and washed twice with water (10 mL). The organic layer was dried over 
Na2SO4 and solvent was removed under reduced pressure. Purification of the crude 
residue by flash chromatography on silica gel (eluant cyclohexane/EtOAc 9:1) 
afforded compound 15c-d. The desired product was obtained in yields up to 95% as 
an yellow oil. 
Z-15c: Yellow oil; 
1
H NMR (400 MHz, CDCl3) : 0.81(d, J = 6.6 Hz, 3H), 0.92 (d, 
J = 6.6 Hz, 3H), 1.45 (s, 9H), 1.95 (d, J = 7.4 Hz, 3H), 2.67 (m, 1H), 3.38 (d, J = 
15.4 Hz, 1H), 3.53 (d, J = 15.4 Hz, 1H), 3.74 (s, 3H), 3.94 (dd, J = 18.2 Hz, 5.2 Hz, 
1H), 4.44 (dd, J = 18.2 Hz, 2.4 Hz, 1H), 5.04 (d, J = 17.2 Hz, 1H), 5.13 (d, J = 10.4 
Hz, 1H), 5.33 (d, J = 11.6 Hz, 1H), 5.70 (m, 1H), 6.91 (q, J = 7.2 Hz, 1H); 
13
C 
NMR (75 MHz, CDCl3,)  14.6, 19.7, 27.8, 28.0, 41.2, 46.8, 52.1, 57.0, 80.4, 
115.7, 132.9, 135.0, 143.9, 166.6, 167.0, 168.4. LC–MS–ESI rt 10.7 min 376 
(M+23), 729 (2M+23). Chiral HPLC analysis (Chiralpak IC, eluted with n-
hexane/2-propanol, typical program: from 96/4 to 90/10 in 30 min, flux 0.6 
mL/min) rt 33.24 min for (R)-Z-15c and 36.62 min for (S)-Z-15c; (R)-Z-15c [a]
D
 
= +26.7 (c 1 in CHCl3). (S)-Z-15c [a]
D
 = -30.8 (c 1 in CHCl3); Anal. cald. for 
C19H31NO5 (353.22): C 64.56, H 8.84, N 3.96; found C 64.89, H 8.90, N 3.95. 
E-15c: Yellow oil; 
1
H NMR (400 MHz, CDCl3)  0.94 (d, J = 6.6 Hz, 3H), 0.96 (d, 
J = 6.6 Hz, 3H), 1.43 (s, 9H), 1.92 (d, J = 7.4 Hz, 3H), 2.67 (m, 1H), 3.44 (d, J = 
15.4 Hz, 1H), 3.54 (d, J = 15.4 Hz, 1H), 3.76 (s, 3H), 4.02 (dd, J = 18.2, 5.0 Hz, 
1H), 4.23 (dd, J = 18.2, 2.0 Hz, 1H), 5.04 (d, J = 17.2 Hz, 1H), 5.13 (d, J = 10.4 Hz, 
1H), 5.15 (d, J = 10.0 Hz, 1H), 5.70 (m, 1H), 6.18 (q, J = 7.2 Hz, 1H); 
13
C NMR 
(CDCl3, 100 MHz)  14.3, 19.8, 27.8, 29.2, 41.0, 46.9, 52.1, 57.3, 80.2, 115.0, 
133.1, 135.0, 142.7, 166.6, 167.1, 168.4. LC–MS–ESI rt 10.1 min 376 (M+23), 729 
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(2M+23). Chiral HPLC analysis (Chiralpak IC, eluted with n-hexane/2-propanol, 
typical program: from 96/4 to 90/10 in 30 min, flux 0.6 mL/min) rt 48.40 min for 
(R)-E-15c and 59.28 min for (S)-E-15c. Anal. cald. for C19H31NO5 (353.22): C 
64.56, H 8.84, N 3.96; found C 64.58, H 8.82, N 3.98. 
15d: : Yellow oil; 
1
H NMR (400 MHz, CDCl3)  1.02-1.21 (m, 5H), 1.45 (s, 9H), 
1.50-165 (m, 6H), 1.92 (d, J = 7.4 Hz, 3H), 3.35 (d, J= 15.2 Hz, 1H), 3.48 (d, 
J=15.2 Hz, 1H), 3.94 (m, 1H), 4.39 (m, 1H), 4.85-5.10 (m, 2H), 5.38 (d, J= 11.2 
Hz, 1H), 5.66 (m, 1H), 6.85 (q, J= 6.8 Hz, 1H).
 13
C NMR (CDCl3, 100 MHz)  
14.7, 25.8, 26.3, 28.0, 29.8, 30.2, 36.9, 41.1, 46.9, 52.1, 53.4, 55.7, 80.4, 115.8, 
132.6, 135.0, 144.0, 166.7, 167.0, 168.4. LC-MS-ESI rt 10.3 min 394 (M+1). 
 
Ring closing metathesis: 
General procedure for the ring closing metathesis (RCM) with ruthenium 
catalyst:  
Catalyst A–D (0.03 mmol) was added to a solution of 15a-d (1 mmol) in MTBE 
and the reaction mixture was stirred at reflux for 3 h. Then the reaction cooled to 
room temperature and was quenched by addition of ethyl vinyl ether (0.1 mL). The 
solvent was removed under reduced pressure and the crude residue was purified 
through by chromatography on silica gel (cyclohexane/ EtOAc 95:5). 
16a: Yellow oil (1:1 trans/cis conformers mixture); 
1
H NMR (400 MHz, CDCl3)  
Trans conformer: 0.82(d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H), 1.46 (s, 18H), 
2.21 (m, 1H), 3.98 (bd, J = 18.6 Hz, 1H), 4.31 (bd, J = 18.6 Hz, 1H), 4.91 (bm, 
1H), 6.76 (bm, 1H); Cis conformer: 0.84 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 7.0 Hz, 
3H), 1.43 (s, 9H), 2.21 (m, 1H), 4.08 (bd, J = 18.0 Hz, 1H), 4.42 (bd, J = 18.0 Hz, 
1H), 4.78 (bm, 1H), 6.63 (bm, 1H); 
13
C NMR (CDCl3, 100 MHz)  Trans 
conformer: 17.0, 19.1, 25.0, 27.4, 31.7, 53.5, 65.3, 78.6, 80.2, 135.3, 136.0, 153.7, 
161.9. Cis conformer: 16.6, 19.2, 27.2, 27.9, 32.1, 53.5, 67.2, 79.1, 82.4, 135.7, 
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136.1, 154.0, 161.1. LC–MS–ESI rt 12.6 min, 334 (M+23). Anal. cald. for 
C17H29NO4 (311.21): C 65.57, H 9.39, N 4.50; found C 65.80, H 9.35, N 4.47. 
16b: Yellow oil (1.1 trans/cis conformers mixture); 
1
H NMR (400 MHz, CDCl3)  
Trans conformer: 0.83 (d, J = 7.2 Hz, 3H), 0.96 (d, J = 7.2 Hz, 3H), 1.49 (s, 9H), 
2.53 (m, 1H), 4.10 (bd, J = 18.0 Hz, 1H), 4.39 (bd, J = 18.0 Hz, 1H), 4.91 (bm, 
1H), 6.64 (bm, 1H), 7.28–7.41 (m, 5H); Cis conformer: 0.88 (d, J = 6.6 Hz, 3H), 
0.89 (d, J = 6.6 Hz, 3H), 1.43 (s, 9H), 2.21 (m, 1H), 4.10 (bd, J = 18.0 Hz, 1H), 
4.48 (bd, J = 18.0 Hz, 1H), 4.84 (bm, 1H), 6.71 (bm, 1H), 7.28-7.41 (m, 5H); 
13
C 
NMR (CDCl3, 100 MHz)  Trans conformer: 17.6, 19.0, 28.0, 32.3, 54.6, 66.8, 
67.9, 81.2, 127.9, 128.0, 128.1, 128.5, 135.7, 136.8, 154.9, 162.6. Cis conformer: 
17.4, 19.2, 29.6, 32.7, 54.0, 67.1, 68.5, 81.2, 127.9, 128.0, 128.1, 128.5, 136.1, 
136.6, 155.3, 162.6. LC–MS–ESI rt 12.2 min, 368 (M+23). Anal. cald. For 
C20H27NO4 (345.19):C69.54,H7.88,N4.05; found C 69.33, H 7.92, N 4.06. tert-16c: 
Yellow oil (70:30 trans/cis conformers mixture); 
1
H NMR (400 MHz, CDCl3)  
Trans conformer: 0.91(d, J = 7.0 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 1.50 (s, 9H), 
2.41 (m, 1H), 3.41 (s, 2H), 3.75 (s, 3H), 4.27 (ddd, J = 16.6, 2.0, 4.4 Hz, 1H), 4.35 
(dd, J = 16.6, 2.4 Hz, 1H), 5.12 (bt, J = 3.2 Hz, 1H), 6.64 (bm, 1H); Cis conformer: 
0.92 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H), 1.51 (s, 9H), 1.96 (m, 1H), 3.45 
(d, J = 15.0 Hz, 1H), 3.51 (d, J = 15.0 Hz, 1H), 3.76 (s, 3H), 4.08 (ddd, J = 18.8, 
1.6, 3.0 Hz, 1H), 4.35 (dd, J = 18.8, 2.8 Hz, 1H), 4.77 (bt, J = 3.2 Hz, 1H), 6.76 
(bm, 1H); 
13
C NMR (CDCl3, 100 MHz)  Trans conformer:18.3, 18.4, 28.0, 31.8, 
42.2, 52.5, 54.6, 68.0, 81.6, 134.1, 136.7, 162.5, 164.3, 167.7. Cis conformer:17.5, 
18.7, 28.0, 34.5, 40.8, 52.5, 53.8, 68.4, 81.5, 134.9, 137.3, 162.5, 164.8, 167.5. LC–
MS–ESI rt 8.25 min, 312 (M+1), 334 (M+23), 645 (2M+23). (S)-16c [a]D = + 34.9 
(c 1 in CHCl3); (R)-16c [a]
D
 = -28.7 (c 1 in CHCl3). Anal. cald. for C16H25NO5 
(311.17): C 61.72, H 8.09, N 4.50; found C 61.98, H 8.11, N 4.52. 
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Yonemitsu: 
Representative procedure for one-pot two steps trimolecular condensation  
(second step with microwaves) 
Dimethyl malonate or ethyl acetoacetate (1 mmol), aldehyde (1 equiv, 1 mmol) and 
piperidine (0.15 equiv, 0.15 mmol, 15 L) were mixed in the microwave reactor 
and submitted to irradiation at 250 W for 7 minutes. The mixture was allowed to 
reach room temperature and diluted with DMF (1 mL). Indole (1 equiv) and Lewis 
acid (0.1 equiv) were then added and the solution was submitted to microwave 
irradiation at 250W for 20 minutes.  After cooling to room temperature, the 
reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). 
The extract was washed with water and brine then dried (Na2SO4). Evaporation of 
solvent left the crude products, which were purified by column chromatography 
over silica (cyclohexane/ ethyl acetate 90:10).  
Representative procedure for one-pot two steps trimolecular condensation  
(second step at r.t.) 
Dimethyl malonate or ethyl acetoacetate (1 mmol), aldehyde (1 equiv, 1 mmol) and 
piperidine (0.15 equiv, 0.15 mmol, 15 L) were mixed in the microwave reactor 
and submitted to irradiation at 250 W for 7 minutes. The mixture was allowed to 
reach room temperature and diluted with DMF (1 mL). Indole (1 equiv) and Lewis 
acid (0.1 equiv) were then added and the solution was left stirring at room 
temperature  for 4 h. The reaction was monitored by TLC and stopped at 
disappearance of the starting material. The reaction mixture was diluted with water 
and then extracted with EtOAc (3 × 10 mL). The extract was washed with water 
and brine then dried (Na2SO4). Evaporation of solvent left the crude products, 
which were purified by column chromatography over silica (cyclohexane/ ethyl 
acetate 90:10). 
17a:
1
H NMR (400 MHz, Chloroform-d) δ 8.08 (s, 1H), 7.68 (dd, J = 7.8, 1.5, Hz, 
1H), 7.38 – 7.29 (m, 1H), 7.14 (m, 2H), 7.04 (d, J = 2.5 Hz, 1H), 4.00 (d, J = 11.0 
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Hz, 1H), 3.83 (dd, J = 11.0, 4.9 Hz, 1H), 3.75 (s, 3H), 3.36 (s, 3H), 2.17 – 1.97 (m, 
1H), 0.88 (d, J = 6.7 Hz, 6H).
 13
C NMR (100 MHz, Chloroform-d) δ 169.3, 168.7, 
135.6, 128.4, 122.6, 121.8, 119.6, 119.3, 113.0, 110.8, 56.3, 52.6, 52.2, 42.1, 30.6, 
21.9, 17.9. LC-ESI-MS rt 10.41 min, m/z 304 (M+1), 326 (M+Na), 629 (2M+Na).  
Anal. calcd. for C17H21NO4 (303.1): C 67.31, H 6.98, N 4.62; found C 67.50, H 
6.99, N 4.62. 
17b:
1
H NMR (400 MHz, Chloroform-d) mixture of isomers δ 8.19 (s, 0.4H, 
minor), 8.14 (s, 0.6H, major), 7.75 – 7.56 (m, 1H), 7.33 (dd, J = 8.0, 3.8, Hz, 1H), 
7.21 – 7.04 (m, 2H), 6.99 (d, J = 2.5 Hz, 0.6H), 6.89 (d, J = 2.0 Hz, 0.4H), 4.02 (d, 
J = 11.5 Hz, 0.6H), 3.95 (d, J = 12.1 Hz, 0.4H), 3.86 (dd, J = 11.5, 4.1 Hz, 0.6H), 
3.86 (dd, J = 12.1, 4.1 Hz, 0.4H), 2.32 (s, 3H), 2.10 (m, 0.6H), 2.02 – 1.95 (m, 
0.4H), 1.90 (s, 3H), 1.50 (s, 9H), 0.99 – 0.75 (m, 6H). 13C NMR (100 MHz, 
Chloroform-d) mixture of isomers δ 203.9, 203.2, 168.5, 167.5, 135.5, 135.4, 
128.9, 128.4, 123.3, 122.9, 121.9, 121.7, 119.9, 119.6, 119.3, 119.2, 113.3, 112.4, 
111.0, 110.7, 82.0, 81.3, 66.3, 66.0, 41.9, 41.4, 30.6, 30.4, 29.0, 27.9, 27.4, 27.1, 
22.2, 22.1, 17.5, 17.2. LC-ESI-MS rt 10.54 min (major), 11.05 min (minor), m/z 
352 (M+Na). Anal. calcd. for C18H23NO3 (329.2): C 72.92, H 8.26, N 4.25; found 
C 72.43, H 8.24, N 4.24. 
18: 
1
H NMR (400 MHz, Chloroform-d) δ 7.77 (s, 2H), 7.67 (d, J = 8.2 Hz, 2H), 
7.25 (dd, J = 8.0, 1.0 Hz, 2H), 7.21 – 7.03 (m, 4H), 6.99 (d, J = 2.4 Hz, 2H), 4.27 
(d, J = 8.4 Hz, 1H), 2.76 – 2.54 (m, 1H), 1.03 (d, J = 6.6 Hz, 6H). 13C NMR (100 
MHz, Chloroform-d) mixture of isomers δ 137.0, 136.1, 123.6, 121.5, 119.2, 118.7, 
110.9, 110.8, 58.9, 41.0, 21.8. LC-ESI-MS rt 10.91 min, m/z 289 (M+1), 
311(M+Na).  Anal. calcd. for C20H20N2 (288.2): C 83.30, H 6.99, N 9.71; found C 
83.23, H 6.97, N 9.73. 
19a:
1
H NMR (400 MHz, Chloroform-d) δ 8.00 (s, 1H), 7.65 (dd, J = 8.0, 1.3 Hz, 
1H), 7.35 (dd, J = 8.2, 1.0 Hz, 1H), 7.14-7.20 (m, 2H), 6.99 (d, J = 2.4 Hz, 1H), 
3.53 (s, 3H), 3.42 – 3.29 (m, 1H), 2.83 (dd, J = 15.0, 5.7 Hz, 1H), 2.71 (dd, J = 
15.0, 9.6 Hz, 1H), 2.20 – 1.97 (m, 1H), 0.92 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.7 
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Hz, 3H). 
13
C NMR (100 MHz, Chloroform-d) 170.6, 136.1, 127.5, 121.7, 120.9, 
119.2, 119.0, 117.9, 110.9, 49.6, 40.1, 32.6, 30.3, 20.5, 20.1 LC-ESI-MS rt 9.36 
min, m/z 246 (M+1), 268 (M+Na). Anal. calcd. for C15H19NO2 (245.1): C 73.44, H 
7.81, N 5.71; found C 73.61, H 7.82, N 5.70. 
19b:
1
H NMR (400 MHz, Chloroform-d) δ 8.01 (s, 1H), 7.66 (dd, J = 8.1, 1.3 Hz, 
1H), 7.44 – 7.29 (d, 2H, J = 7.2 Hz), 7.24 – 7.03 (m, 1H), 6.95 (d, J = 2.4 Hz, 1H), 
3.35 (dt, J = 8.0, 6.6 Hz, 1H), 2.95 (dd, J = 15.0, 8.0 Hz, 1H), 2.77 (dd, J = 15.0, 
6.6 Hz, 1H), 2.18 – 2.02 (m, 1H), 1.99 (s, 3H), 0.94 (d, J = 6.7 Hz, 3H), 0.89 (d, J 
= 6.7 Hz, 3H). 
13
C NMR (100 MHz, Chloroform-d) 209.4, 136.3, 127.2, 121.9, 
121.7, 119.3, 119.0, 117.3, 111.2, 47.0, 39.3, 32.7, 30.1, 20.5, 20.3.LC-ESI-MS rt 
8.71 min, m/z 230 (M+1), 252 (M+Na), 268 (M+K). Anal. calcd. for C15H19NO 
(229.1): C 78.56, H 8.35, N 6.11; found C 78.36, H 8.34, N 6.13. 
17c: Major isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 8.03 (bs,NH); 7.55 (d, 
1H, J= 5.0 Hz); 7.35-7.02 (m, 9H); 5.06 (d, 1H, J= 8.0 Hz); 4.39 (d, 1H, J= 8.0 
Hz); 3.96 (q, 2H, J= 7.2 Hz); 2.16 (s, 3H); 1.01 (t, 3H J= 7.2 Hz) ). 
13
C NMR (100 
MHz, Chloroform-d) δ: 203.1, 168.1, 141.3, 136.2, 128.3, 128.0, 126.7, 126.4, 
122.4, 121.4, 119.4, 111.2, 66.6, 61.4, 43.0, 30.3, 13.7 LC-ESI-MS rt 9.8 min; 
m/z= 358 (M+23); 693 (2M+23). Minor isomer: isomer
 1
H NMR (400 MHz, 
Chloroform-d) δ: 8.00 (bs,NH); 7.55 (d, 1H, J=5.0 Hz); 7.35-7.02 (m, 9H); 5.09 (d, 
1H, J= 8.0 Hz); 4.51 (d, 1H, J= 8.0 Hz); 3.98 (q, 2H, J= 7.2 Hz); 2.03 (s, 3H); 0.99 
(t, 3H J= 7.2 Hz) ). 
13
C NMR (100 MHz, Chloroform-d) δ: 202.2, 168.0, 141.3, 
136.1, 128.6, 128.1, 126.7, 126.6, 122.2, 120.7, 119.6, 117.2, 111.0, 65.8, 61.6, 
42.6, 30.9, 13.6. LC-ESI-MS rt 9.6 min; m/z= 358 (M+23); 693 (2M+23). Anal. 
calcd. for C21H21NO3 (335.1): C 75.20, H 6.31, N 4.18; found C 75.15, H 6.29, N 
4.20. 
17d: Major isomer
 1
H NMR (400 MHz, Chloroform-d)  
1
H NMR (400 MHz, 
Chloroform-d) δ: 8.00 (bs, NH); 7.39-7.11 (m, 7H); 6.99 (d, 1H, J=2.0 Hz), 6.85 
(m, 1H); 6.68 (s, 1H), 4.96 (d, 1H, J= 12.0 Hz); 4.37 (d, 1H, J= 12.0 Hz); 3.95 (q, 
2H, J= 7.2 Hz); 2.20 (s, 3H); 0.98 (t, 3H, J=7.2 Hz). 
13
C NMR (100 MHz, 
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Chloroform-d) δ: 202.1, 167.9, 157.8 (d, JC-F = 214 Hz), 140.9, 132.7, 128.4(d, JC-F 
= 10 Hz), 128.0, 127.3, 126.9, 123.0, 119.3, 111.7, 110.4 (d, JC-F =9 Hz), 104.6 (d, 
JC-F = 23 Hz), 66.3, 61.5, 29.6, 28.4, 13.9. LC-ESI-MS rt 9.7 min; m/z= 376 
(M+23); 729 (2M+23). Minor isomer: 
1
H NMR (400 MHz, Chloroform-d) δ: 7.97 
(bs, NH); 7.39-7.11 (m, 7H); 6.98 (d, 1H, J=2.0 Hz), 6.68 (s, 1H), 6.85 (m, 1H); 
5.00 (d, 1H, J= 11.6 Hz); 4.48 (d, 1H, J=11.6 Hz); 3.97 (q, 2H, J=7.2 Hz); 2.20 (s, 
3H); 0.98 (t, 3H, J=7.2 Hz)
 13
C NMR (100 MHz, Chloroform-d) δ:  202.9, 168.0, 
157.5 (d, JC-F = 214 Hz), 143.3, 133.2, 128.5(d, JC-F = 10 Hz), 127.9, 127.2, 126.4, 
122.5, 119.3, 111.6, 110.1 (d, JC-F =8 Hz), 104.8 (d, JC-F = 23 Hz), 65.6, 61.5, 30.4, 
28.4, 13.7. LC-ESI-MS rt 9.9 min; m/z= 376 (M+23); 729 (2M+23).  isomer
 
Anal. 
calcd. for C21H20FNO3 (353.1): C 71.37, H 5.70, N 3.96; found C 71.22, H 5.71, N 
3.97. 
17e: Major isomer: 
1
H NMR (400 MHz, Chloroform-d) δ: 7.95 (bs, NH); 7.37-6.95 
(m, 9H); 5.04 (d, 1H, J= 12.0 Hz); 4.36 (d, 1H, J=12.0 Hz); 3.96-4.00 (m, 2H); 2.40 
(s, 3H), 2.05 (s, 3H); 0.98 (t, 3H, J=7.2 Hz)
 13
C NMR (100 MHz, Chloroform-d) δ: 
202.3, 168.2, 141.4, 134.5, 128.7, 128.2, 127.9, 127.8, 126.6, 124.0, 121.4, 118.7, 
115.7, 110.6, 66.0, 61.4, 30.3, 28.0, 21.6, 13.6. LC-ESI-MS rt 10.4 min; m/z= 372 
(M+23); 721 (2M+23). 
 
Minor isomer 
1
H NMR (400 MHz, Chloroform-d) δ: 8.00 
(bs, NH); 7.37-6.95 (m, 9H); 5.07 (d, 1H, J= 11.8 Hz); 4.49 (d, 1H, J=11.8 Hz); 
3.96-4.00 (m, 2H); 2.40 (s, 3H), 2.05 (s, 3H); 1.01 (t, 3H, J=7.2 Hz)
 13
C NMR (100 
MHz, Chloroform-d) δ:  203.1, 168.0, 141.4, 134.5, 128.9, 128.5, 127.9, 127.8, 
126.8. 124.1, 121.5, 118.9, 116.7, 110.7, 66.8, 61.2, 30.4, 28.2, 21.4,  13.8. LC-
ESI-MS rt 10.2 min; m/z= 372 (M+23); 721 (2M+23). Anal. calcd. for C22H23NO3 
(349.4): C, 75.62; H, 6.63; N, 4.01; found C 75.64, H 6.60, N 4.02.  
17f: Major isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 7.69-7.11 (m, H); 7.00 
(m, 1H), 6.94 (s, 1H); 5.07 (d, 1H, J= 11.0 Hz); 4.39 (d, 1H, J=11.0 Hz); 3.98 (m, 
2H); 3.70 (s, 3H), 2.06 (s, 3H); 0.98 (t, 3H, J=7.2 Hz) 
13
C NMR (100 MHz, 
Chloroform-d) δ: 202.0, 167.9, 141.2, 136.9, 130.6, 128.0, 127.7, 126.6, 125.5, 
121.7, 119.1, 118.9, 115.6, 109.0, 65.9, 61.3, 42.6, 30.1, 13.8. Minor isomer: 
1
H 
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NMR (400 MHz, Chloroform-d) δ: 7.69-7.11 (m, 8H); 7.00 (m, 1H), 6.94 (s, 1H); 
5.10 (d, 1H, J= 11.2 Hz); 4.50 (d, 1H, J=11.2 Hz); 3.98 (m, 2H); 3.70 (s, 3H), 2.18 
(s, 3H); 1.00 (t, 3H, J=7.2 Hz)
 13
C NMR (100 MHz, Chloroform-d) δ: 202.9, 168.0, 
141.6, 136.9, 129.5, 128.2, 127.9, 126.8, 126.0, 121.9, 119.3, 118.9, 114.7, 109.1, 
66.6, 61.3, 43.0, 30.8, 13.7. LC-ESI-MS rt 10.7 min; m/z= 372 (M+23).  LC-ESI-
MS rt 11.2 min; m/z= 372 (M+23). Anal. calcd. for C22H23NO3 (349.2): C 75.62, H 
6.63, N 4.01; found C 75.49, H 6.62, N 4.03. 
17g: Major isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 8.47 (bs, NH); 8.05 (m, 
2H), 7.45-7.00 (m, 8H); 5.20 (d, 1H, J=12.0 Hz), 4.45 (d, 1H, J=12.0 Hz); 4.03 (m, 
2H); 2.18 (s, 3H); 1.07 (t, 3H, J=7.2 Hz)
 13
C NMR (100 MHz, Chloroform-d) δ:  
201.7, 167.6, 149.3, 146.5, 136.2, 126.2, 123.7, 122.7, 121.8, 119.9, 118.5, 114.6, 
111.3, 65.3, 61.8, 42.2, 30.9, 13.8. LC-ESI-MS rt 9.7 min; m/z= 398 (M+18), 403 
(M+23). Minor isomer: isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 8.42 (bs, 
NH); 8.05 (m, 2H), 7.45-7.00 (m, 8H); 5.23 (d, 1H, J=12.0 Hz), 4.55 (d, 1H, 
J=12.0 Hz); 4.05 (m, 2H); 2.16 (s, 3H); 0.99 (t, 3H, J=7.2 Hz)
 13
C NMR (100 MHz, 
Chloroform-d) δ:  201.0, 167.4, 149.5, 146.6, 136.3, 129.0, 125.9, 123.6, 122.5, 
121.2, 119.7, 118.7, 115.4, 111.5, 65.4, 61.7, 41.8, 30.2, 13.6. LC-ESI-MS rt 9.6 
min; m/z= 398 (M+18), 403 (M+23). Anal. calcd. for C21H20N2O5 (380.1): C 
66.31, H 5.30, N 7.36; found C 66.10, H 5.29, N 7.37. 
17h: Major isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 8.32 (bs, NH); 7.29 (dd, 
1H, JH-H = 1 Hz, JH-F = 9.6 Hz), 7.21 (dd, 1H, JH-H = 9.2 Hz, JH-F = 4.4 Hz), 6.89 (d, 
1H, J = 2.4 Hz), 6.87 (dd, 1H, JH-H = 9.2 Hz, JH-F = 2.4 Hz), 4.22 (m, 2H), 4.02 (d, 
1H, J=12.0 Hz), 3.77 (m, 1H), 2.03 (m, 1H), 1.94 (s, 3H), 1.31 (t, 3H, J=7.2 Hz), 
0.85 (d, 6H, J =6.6. Hz). 
 13
C NMR (100 MHz, Chloroform-d) δ:  203.3, 169.1, 
157.9 (d, JC-F = 233 Hz), 132.1, 129.0 (d, JC-F = 10 Hz), 125.1, 113.4, 111.6, 110.6 
(d, JC-F =12 Hz), 104.5 (d, JC-F = 18 Hz), 64.7, 61.5, 42.0, 30.6, 27.2, 21.9, 17.7, 
14.0. LC-ESI-MS rt 10.1 min; m/z= 342 (M+23), 661 (2M + 23). Minor isomer: 
isomer
 1
H NMR (400 MHz, Chloroform-d) δ 8.20 (1H, bs), 7.29 (dd, 1H, JH-H = 1 
Hz, JH-F = 9.6 Hz), 7.21 (dd, 1H, JH-H = 9.2 Hz, JH-F = 4.4 Hz), 7.02 (d, 1H, J = 2.8 
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Hz), 6.87 (dd, 1H, JH-H = 9.2 Hz, JH-F = 2.4 Hz), 4.22 (m, 2H), 4.10 (d, 1H, J=10.8 
Hz), 3.77 (m, 1H); 2.31 (s, 3H), 1.98 (m, 1H), 0.83 (d, 6H, J =6.6. Hz). 0.77 (t, 3H, 
J=7.2 Hz). 
13
C NMR (100 MHz, Chloroform-d) δ:  202.8, 168.5, 158.0 (d, JC-F = 
233 Hz), 132.0, 128.7 (d, JC-F = 10 Hz), 124.6, 113.3, 112.4, 110.1 (d, JC-F =12 Hz), 
103.4 (d, JC-F = 18 Hz), 64.8, 61.0, 41.7, 30.9, 29.1, 22.0, 17.2, 13.4. LC-ESI-MS rt 
9.8 min; m/z= 342 (M+23), 661(2M + 23). Anal. calcd. for C18H22FNO3 (319.1): C 
67.69, H 6.94, N 4.39; found C 67.71, H 6.90, N 4.38.  
17i: Major isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 7.97 (bs, NH); 7.45 (s, 
1H); 7.23-6.86 (m, 3H); 4.25 (q, 2H, J=7.2); 4.10 (d, 1H, J= 11.0 Hz); 3.83 (dd, 
1H, J= 2.8 Hz, 11.0 Hz); 2.47 (s, 3H); 2.31 (s, 3H); 2.04 (m, 1H); 1.31 (t, 3H, J= 
7.2 Hz), 0.88 (d, 6H, J= 6.6 Hz); 
 13
C NMR (100 MHz, Chloroform-d) δ:  :  203.6, 
169.4, 134.6, 128.8, 128.3, 123.6, 121.9, 119.2, 112.5, 110.6, 65.0, 61.0, 41.6, 31.0, 
29.2, 21.9,  17.8, 17.3, 13.5. LC-ESI-MS rt 10.5 min; m/z= 338 (M+23); Minor 
isomer: isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 8.02 (bs, NH); 7.45 (s, 1H); 
7.23-6.86 (m, 3H); 4.02 (d, 1H, J=12.0 Hz); 3.86 (dd, 1H, J=4.0 Hz, 12.0 Hz); 3.80 
(q, 2H, J= 7.6 Hz);  2.43 (s, 3H); 1.98 (m, 1H); 1.92 (s, 3H); 1.02 (d, 3H, J= 6.6 
Hz); 0.88 (d, 6H, 6.6 Hz); 0.81 (t, 3H, J=7.6 Hz); 
13
C NMR (100 MHz, 
Chloroform-d) δ:  203.3, 168.6, 134.0, 128.7, 128.1, 123.3, 121.8, 119.0, 111.5, 
110.4,  64.9, 61.4, 41.8, 30.8, 29.0, 21.5, 17.6, 17.1, 14.1. LC-ESI-MS rt 10.8 min; 
m/z= 338 (M+23). Anal. calcd. for C19H25NO3 (315.2): C 72.35, H 7.99, N 4.44; 
found C 72.42, H 7.96, N 4.45. 
17l: Major isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 7.65 (d, 1H, J= 8.0 Hz); 
7.25-7.08 (m, 3H); 6.74 (s, 1H); 4.23 (q, 2H, J=7.2 Hz); 4.09 (d, 1H, J= 10.8 Hz); 
3.81 (dd, 1H, J= 4.4 Hz, 10.8 Hz); 3.70 (s, 3H); 1.91 (s, 3H); 1.96 (m, 1H); 1.28 (t, 
3H, J=7.2 Hz); 0.84 (d, 3H, J=6.6 Hz); 0.83 (d, 3H, J= 6.6 Hz); 
13
C NMR (100 
MHz, Chloroform-d) δ:  203.3, 1695, 128.7, 127.5, 121.5, 119.7, 119.0, 110.4, 
109.1, 64.8, 61.4, 41.7, 32.8, 30.6, 29.0, 22.1, 17.7, 14.1 LC-ESI-MS rt 10.8 min; 
m/z= 338 (M+23). Minor isomer: isomer
 1
H NMR (400 MHz, Chloroform-d) δ: 
7.65 (d, 1H, J= 8.0 Hz); 7.25-7.08 (m, 3H); 6.88 (s, 1H); 4.20 (q, 2H, J=7.2 Hz); 
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4.01 (d, 1H, J= 12.0 Hz); 3.86 (dd, 1H, J= 4.0 Hz, 12.0 Hz); 3.71 (s, 3H); 2.28 (s, 
3H); 2.02 (m, 1H); 0.84 (d, 3H, J= 6.6 Hz); 0.83 (d, 3H, J= 6.6 Hz);0.73 (t, 3H, 
J=7.2 Hz).
13
C NMR (100 MHz, Chloroform-d) δ:  203.2, 168.5, 136.4, 129.0, 
121.2, 119.3, 118.8, 111.4, 108.8, 65.0, 60.8, 42.0, 32.7, 30.4, 27.6, 22.0, 17.2, 
13.4. LC-ESI-MS rt 10.5 min; m/z= 338 (M+23). Anal. calcd. for C19H25NO3 
(315.2): C 72.35, H 7.99, N 4.44; found C 72.60, H 7.98, N 4.43. 
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Chapter 3 
 
Applications of synthesized molecules as scaffolds for 
bioactive compounds generation 
 
In this part of the thesis we will discuss about applications of synthesized 
compounds during the last three years. Classes of compound will be divided into 
topics and discussed within their relative field of interest. 
We will begin by talking about αVβ3 and α5β1 integrin ligands, whose potential 
applications are as anticancer compounds and we will consider their biological 
evaluations. For this class of compounds, we report also the syntheses conjugated 
molecules with a fluorescent fragment to obtain a diagnostic tool. The second topic 
taken into account deals with α4β1 integrin ligands, which differ from those 
mentioned above for the insertion of a further pharmacophoric moiety to fit in the 
different binding site. Also for this class, related biological tests and syntheses are 
reported. Potential Linezolid-like antibiotics have been finally developed and the 
corresponding syntheses and biological evaluations will be discussed in the third 
part of this chapter. 
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3.1 αVβ3 and α5β1 Integrin Ligands 
 
3.1.1 Introduction to integrins αVβ3 and α5β1 
Integrins are a large family of heterodimeric transmembrane glycoproteins and they 
are involved in several cellular activities  as adhesion, differentiation, proliferation 
and cellular migration.
23
 Alterations or aberrations in integrin-mediated cell 
adhesion have been connected with the pathogenesis of several diseases such as 
atherosclerosis, osteoporosis, cancer and a variety of inflammatory disorders and 
for these reasons integrins are an attractive target for the development of 
therapeutic agents.
24
 In general, every development of an antagonist compound 
with a potential biological effect is based on the identification of key-recognition 
motifs between the target molecule and the natural ligand. Actually, the above-
mentioned motifs have been identified for only few subtypes of integrins. Among 
different classes of these proteins, the αVβ3 has been deeply investigated as it is 
involved in tumor proliferation and metastasis through the formation of new blood 
vessels. It is known that αVβ3 integrin interacts with extracellular matrix (ECM) 
through a specific recognition motif: the RGD tripeptide sequence (Arg-Gly-Asp). 
Using this recognition triad, the protein is able to bind a wide number of 
extracellular matrix components like fibronectin, fibrinogen, vitronectin and 
osteopontin.
25
 
 
         
Fig. 11. Integrin αVβ3 into membrane (left) and isolated representation (right). 
74 
 
Another integrin family, recognized as proangiogenic receptor
26
, use the same 
recognition sequence to bind fibronectin: the α5β1.
27
 During their migration in vitro 
or angiogenesis in vivo, this integrin may regulate the function of integrin αVβ3 on 
endothelial cells. Activation of α5β1 potentiates αVβ3-mediated migration, whereas 
α5β1 integrin antagonists inhibit αVβ3-mediated cell spreading. On this base, it is 
possible to realize that a single antagonist that mime a RGD sequence, could 
mediate the activity of both types of integrine and then block the same pathway of 
angiogenesis.
27
  
In literature several classes of integrin ligands that contain the RGD sequence have 
been reported and the X-ray analysis
28
 of the complex between one of them 
(RGDfV) and αVβ3 integrin, shows that the ligand interacts manly through 
electrostatic forces. To bind the protein, the ligand uses a charged clamp that is 
attracted by regions with an opposite charge in the binding site: Asp interact with a 
metal cation in the β subunit and Arg with two Asp in the α subunit. 
Integrin ligands containing the RGD sequence have important problems that - only 
recently – the scientific community had to face and overcome. The major problem 
is their oral bioavailability and this makes the good activity registered by linear and 
cyclic antagonist less interesting. This is mainly due to the degradation of peptide 
ligand by peptidase enzyme that occurs under physiological conditions. Research 
groups that work on this field are motivated to invest their force in finding a good 
compound able to retain high activity versus integrins and, at the same time, to 
provide a good bioavailability by possessing a low molecular weight and a non-
peptidic backbone that mimicks the RGD sequence. A large part of developed 
ligands is based on a central rigid scaffold, to which it is possible to insert 
appendages that are able to mimic Arg and Asp side chains.
29
 
As reported in the literature, the arginine-mimiking group and the carboxylic 
aspartate-mimiking group are essential to bind the active site on protein.
30
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Fig.12. v 3/ 5 1 integrin ligands containing an unsaturated - or -amino acid 
fragment (A, B) and novel linear dehydro- -amino acid structures (C). 
 
Some years ago, in our group, a series of αVβ3 integrin ligands based on 5,6-
dihydropyridin-2-one were identified as scaffold and they showed promising 
interactions with integrin receptors.
31
 The introduction of a β-amino acid into 
RGD-containing cyclic peptides has been already reported with the aim to stabilize 
distinct conformations, having a γ-turn with centrally positioned glycine. On the 
other hand, the incorporation of a linear or constrained amino acid into an RGD 
sequence may give access to simple mimetics with an increased bioactivity and 
stability. From that experience we tried to develop new classes of integrin ligands 
by changing the central heterocyclic core and by inserting β-aminoacids also in the 
structure of linear antagonist. 
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3.1.2 Synthesis of heterocyclic αVβ3 and α5β1 integrin ligands 
Novel synthetic pathways for the preparation of bioactive small molecules are 
based on heterocyclic scaffolds
32
 and for this reason their syntheses receive ever-
increasing interest. The central rigid core, represented by the heterocycle, is often 
the initial point from which more complex molecules with specific activity begin to 
be prepared. Moreover, inserting a lateral appendage on hetereocycle allows easy 
construction of small libraries, differing for the substitution pattern. Recently, the 
term “privileged structure” has been frequently reported to define recurring 
structural elements that are likely to facilitate bindings with biological target, 
inducing ordered spatial disposition of side chains
33
. In this context, the proline 
represents a good starting point to synthesize potential molecules with biological 
activity. In fact, the cyclic structure of this amino acid gives to the residue a 
particular conformational rigidity due to the reduced allowed rotations
34
 and it is 
possible to use it where a turned peptide backbone is required. Several 
modifications have been performed on the proline scaffolds and, among these, β-
proline has received great attention since the substitution of an α-amino acid with 
the corresponding β-analog in key position of a bioactive sequence still affords 
conformational restrictions. These modifications represent a winning approach to 
develop mimetics, overcoming the low bioavailability limitations of natural 
peptides.
35
 Our research group showed that the peptides containing the β-analog of 
proline recorded a good receptor affinity together with enhanced stability towards 
enzymatic hydrolysis.
36
 On the other hand, unsaturated α-amino acids have been 
also explored and 3,4-dehydroproline (Dhp), the analog of proline having a double 
bond between Cβ and Cγ, showed to induce changes in the structure and biological 
properties of collagen, proteins and peptides.
37
 On this base, we tried to combine 
the notions mentioned above by synthesizing a dehydro-β-proline employable as 
scaffold for our researches. 
To synthesize dehydro-β-pirrole ligands we started from intermediates 16c-d 
discussed in section 2.6 that, through a deprotection of t-Butyl ester carried out 
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with TFA in dichloromethane in 24h, provided corresponding acids 20c-d (Scheme 
18). Crude reaction mixtures could be directly used for the subsequent reaction. 
The following step is the coupling with 4-aminobenzylamine. Even if in theory 
both the amine functions could give this reaction, the primary amine’s reaction rate 
was remarkably faster, and only products 21c-d were observed in good yields. This 
synthetic pathway allowed us to obtain the final products in yields included 
between 50-80%, after methyl ester hydrolysis by treatment with K2CO3 in 
THF/H2O (1:4 ratio). Compounds 22c-d were purified by DOWEX ion exchange 
resin. 
 
Scheme 18. Synthesis of β-dehydropyrrolic ligands. 
 
Another class of integrin ligands developed by us, contains the isoxazoline 
scaffold. 
Willing to test a different scaffold for integrin ligands, our choice has fallen on 
isoxazoline because its isoxazolidine precursor may be consider as a masked amino 
acid, as a 1,3 amino alcohol equivalent, or as a furanose ring mimetic in the 
preparation of bioactive compounds. Indeed, several transcriptional activators 
contain the isoxazolinic nucleus as conformational constrain element. In the 
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literature compounds containing isoxazoline and isoxazolidine ring are reported  as 
antimitotic combrestatin analogues. Aware of that, we developed a small library of 
integrin ligands that present isoxazoline core as scaffold and the same lateral 
appendages inserted in a dehydro-β-pyrrolic ligands discussed before, to retain the 
pharmacophoric entity  
 
Scheme 19. Synthesis of isoxazolinic compounds. 
 
The synthesis of these class of compounds began from intermediates 9 met in 
section 2.2.2. The nitrogen on the ring has been protected with benzyl malonic 
derivative that will correspond to the acidic part of the final RGD mimetic (Scheme 
19) to get 23. After the treatment of this compound with mesyl chloride and TEA 
in excess, the corresponding dehydrate isoxazoline 24 has been obtained. The 
relative acids 25 were obtained by the hydrolysis of the terbutylester with 
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trifluoroacetic acid. Compounds 25 were coupled with 4-amino-benzylamine to 
afford amides, finally by simple hydrogenation of 26 final products 27 were 
obtained.  
The third class of heterocyclic compound developed is relative to pyrimidindione 
derivatives. After the deprotection of t-Bu ester on carbonate 11a-c with TFA in 
DCM, we coupled the resulted acid with Gly-OtBu using HBTU and TEA in DCM 
to obtain compound 29a-c (Yield 60-65%). 
 
Scheme 20.Synthesis of pyrimidindione and linear derivatives. 
 
This was protected on nitrogen with Boc using Boc2O, DMAP and TEA in DCM to 
provide 30a-c. Performing the SN2’ with p-aminobenzylamine on these 
compounds, we have seen a different behavior, in comparison with the one 
observed for similar reactions on different substrates. After prolonged reaction 
times (4 days), spontaneous intramolecular cyclization to compound 31a occurred 
(60% yield). On the contrary, starting from 30c, compound 34c was isolated in 
70% yield, and no traces of the cyclic derivative could be detected even after 
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longer refluxing times. Simultaneous removal of the ester and carbamate 
protections by treatment of 34a e c in a phosphoric acid/dichloromethane biphasic 
mixture, allowed to obtain 35a e c in 95 e 80% yield. 
The different behaviors of 30a and 30c in the intramolecular cyclization can be 
ascribed to the different conformational arrangement induced by the steric 
hindrance of methyl and isopropyl chains. The rotation of the C2eC3 bond in 7 that 
may occur to minimize steric hindrance, displays for 30a the amine nitrogen in the 
proper position to act as nucleophile on the carbamate carboxylic group (Fig. 13).  
 
Fig. 13. Proposed conformational arrangements of major isomers Z-30a and Z-30c, 
explaining the alternative behaviors in intramolecular cyclization. 
 
Since this reaction affords dihydropyrimidindiones, that have been successfully 
introduced as rigid scaffolds in bioactive molecules of considerable interest for the 
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pharmaceutical industry, this process deserves further investigation. The effect of 
the carbamate leaving group, amine nucleophile, C3 stereochemistry and amino 
acid chain will be evaluated by computational studies and reported in due course. 
To explore whether the cyclic structure could be suitable for the interaction with 
the receptor, dihydropyrimidindione 31a was further decorated with a second 
glycine residue. Compound 32a was isolated in 90% yield, following the usual 
coupling protocol and then deprotected to afford the free amino acid 33a (80% 
yield). 
 
3.1.3 Synthesis of linear αVβ3 and α5β1 integrin ligands 
In previous papers, we have identified a series of v 3/ 5 1 integrin dual ligands, 
sharing as a common feature the presence of an unsaturated - or -amino acid 
fragment, inserted into a cyclic backbone (Fig. 12, compounds A and B).
38
 The 
introduction of a amino acid into RGD-containing cyclic peptide has been 
already reported in the literature with the aim to stabilize distinct conformations, 
having a -turn with centrally positioned glycine. In this part, we will describe a 
novel class of linear integrin antagonists derived from dehydro-β-amino acids, as 
esemplified in Figure 12, where the heterocycle in A is substituted by the dehydro-
β-amino acid linked to a carboxylic acid and a basic function to mimic aspartic and 
guanidinic appendages. Dehydro- -amino acid containing molecules, with different 
variations at the nature and length of the side chains were synthesized through SN2’ 
substitution of chiral carbonate-esters or amides and analyzed as integrin 
antagonists. At first, the small library of N-p-aminobenzyl-dehydro- -amino acids 
37a-c and 37f was prepared through an easy two step procedure starting form 
carbonates 11a-f (Scheme 21). The regio- and stereoselective synthesis of amino 
esters 36a-f was based on our previously reported results and has been described in 
due papers, where each compound has been accurately analyzed.
39
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Scheme 21. Synthesis of linear compounds. 
 
Removal of the ester protection to obtain free amino acids 37a-f was performed by 
treatment with an excess of trifluoroacetic acid in DCM at room temperature (77 e 
95% yield). Although the compounds 37a-f have a shorter length than that 
generally required for RGD mimetic ligands, their low molecular weight and the 
respect of the commonly accepted rules for bioavailability 
40
, suggested that they 
could represent valuable lead compounds. On the other hand, the shorter length 
may lead to a partial ligand/receptor interaction and to an uncommon effect on 
adhesion and intracellular signaling. 
The spontaneous cyclization occurring during the substitution reaction on N-Boc 
amide 30c described before, suggested that inversion of the steps in the synthetic 
protocol could allow the easier isolation of the linear compound. Thus, compound 
38a was isolated in 84% yield by treatment of 36a with Fmoc-Gly-Cl in the 
presence of triethylamine. After removal of the tert-butyl ester, coupling with Gly-
OtBu under the usual peptide synthesis conditions, allowed to obtain 39a in 55% 
overall yield. Selective removal of Fmoc and t-butyl protection afforded 40a in 
60% yield (Scheme 22). 
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Scheme 22. Synthesis of modified linear compounds 
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3.1.4 Biological evaluations 
Inhibition of v 3 and 5 1 integrin-mediated cell adhesion (Isoxazoline 
derivatives) 
The ability of racemic compounds shown in table 8 to inhibit the adhesion of K562 
cells (human erythroleukemia expressing 5 1 integrin) or SK-MEL-24 cells 
(human malignant melanoma expressing v 3 integrin) to immobilized fibronectin 
was evaluated. These models are widely used to investigate potential antagonists of 
v 3 integrin-mediated SK-MEL-24 cell adhesion and 5 1 integrin-mediated 
K562cell adhesion.
41
 
As reported in this table, only the final products have been tested, which possess 
the functional groups and spacing required for receptor affinity. In these 
experiments, cells were seeded onto plates coated with different substrata and 
allowed to adhere before quantitation of the number of adherent cells in the 
presence of increasing concentrations of test compounds. Under these conditions, 
no significant cell adhesion was observed for bovine serum albumin (BSA)-coated 
plates (negative control) or nonspecific substrate- coated plates (i.e., collagen I for 
SK-MEL-24 expressing v 3 integrin and poly-l-lysine for K562 expressing 5 1 
integrin; data not shown). The registered inhibition of the adhesion of SK-MEL-24 
and K562 cells to fibronectin or vitronectin was compared with that of the standard 
compounds, Ac-Asp-Arg-Leu-Asp-Ser-OH and H-Gly-Arg-Gly-Asp-Asn-Pro-OH, 
known to be potent inhibitors of cell adhesion mediated by v 3 integrin (entry 6-
7).
42
 
Among the five new RGD mimetics tested, the compound 27b in entry 2 exhibited 
the highest potency as an inhibitor of cell adhesion mediated by v 3 and 5 1 
integrins because its IC50 values are in the nanomolar range. 
The compound 27a (entry 1), which has a smaller methyl substituent on the 
isoxazoline ring, maintained notable efficacy, showing IC50 values only tenfold less 
potent than the isopropyl substituted analogue (IC50 = 32 nm versus v 3 integrin 
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and 12 nm versus 5 1 integrin). The sec-butyl-substituted derivative 27h (entry 3) 
showed decreased inhibitory activity, but an increase in selectivity toward v 3 
integrin. A strong preference of compound 27c (entry 4) for v 3 integrin was 
observed, as it has an IC50 value of 20 nm as an v 3 integrin antagonist, whereas 
its IC50 value toward 5 1 is 1 m. Finally, the compound in reported entry 5, which 
was designed to verify the effect of elongation and a terminal aliphatic amine on 
adhesion inhibition, exhibited poor IC50 values, in the millimolar to sub-millimolar 
range. 
Entry Compound IC50[nM] 
αvβ3
 
IC50[nM] 
α5β1 
 
1 
a)  
 
32±3 
 
12±4 
 
2 
27b  
 
8.8±0.6 
 
1.05±0.3 
 
3 
27h  
 
360±70 
 
1320±80 
 
4 
27c  
 
20±6 
 
1030±50 
 
5 
a)  
 
15500±900 
 
>100000 
6 Ac-Asp-Arg-Leu-Asp-Ser-OH 25±3 >100000 
7 H-Gly-Arg-Gly-Asp-Asn-Pro-OH 234±32 >100000 
Table 8. a) Synthesized in the past in our laboratory. 
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The results listed in Table 8 show that the isoxazoline ring is an effective scaffold 
for inducing the proper orientation of the Asp and Arg-mimicking chain, as smaller 
members of the library displayed excellent inhibitory activities toward adhesion 
mediated by both receptors, and can thus be regarded as dual inhibitors. 
Interestingly, compounds 6a and 6b are more potent than the reference compounds 
Ac-Asp-Arg-Leu-Asp-Ser-OH and H-Gly-Arg-Gly-Asp-Asn-Pro-OH, as they 
inhibit cell adhesion mediated by v 3 and 5 1 integrin with IC50 values lower 
than those of the reference compounds. Moreover, as 27b exhibited the highest 
potency as an inhibitor of cell adhesion to fibronectin, we tested its ability to block 
the adhesion of SK-MEL-24 cells to vitronectin relative to the standard peptide Ac-
Asp-Arg-Leu-Asp-Ser-OH. The compound showed an IC50 value of 3.14 nm, while 
the reference peptide showed an IC50 value in the sub-micromolar range (IC50= 
0.33 m) versus vitronectin mediated cell adhesion. 
 
Effect of an integrin antagonist on fibronectin-induced ERK phosphorylation 
(Isoxazoline derivatives) 
Connection of the extracellular matrix components with integrins generates an 
intracellular signaling that involves increased phosphorylation of cytoplasmic 
second messengers. In this contest, the phosphorylation of ERK plays a central role 
in fibronectin-mediated survival signaling through integrins: in fact, cell adhesion 
activates ERK by binding of 5 1 integrins at the cell surface to ECM proteins such 
as fibronectin.
43
 Therefore, we investigated the effect of our most effective 
compound 27b on fibronectin-induced phosphorylation of ERK in K562 cells, 
which express 5 1 integrin. 
K562 cells were serum-starved in RPMI-1640 containing 1% fetal bovine serum 
(FBS) for 16 h; thereafter, they were pre-incubated with our compound for 30 min 
in suspension and plated for 30 min on fibronectin or poly-l-lysine (used as non-
specific substrate). 
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In agreement with other studies, the ERK pathway is activated in K562 cells 
exposed to phorbol-12-myristate- 13-acetate (PMA, 65 nm; Figure 2). In cells 
exposed to fibronectin, a significant increase in phosphorylated ERK is observed 
after 60 min, whereas no change is detected for shorter exposure times, as 
previously described. This late ERK phosphorylation induced by fibronectin has 
been previously reported.
43 
 
 
Fig. 14. 
 
Compound 27b prevents fibronectin-induced phosphorylation of ERK. K562 cells 
were serum-starved in RPMI-1640 containing 1% FBS for 16 h; cells were then 
pre-incubated with our compound for 30 min in suspension. The cells were kept in 
suspension (Ctrl) or plated on fibronectin (FN) or on poly-l-lysine (poly-l-Lys). 
After 30 min, cells were lysed, and lysates were analyzed by Western blot using an 
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antibody directed against phosphorylated ERK (pERK) or total ERK (tERK). The 
information reported in figure 14 may be resumed as reported below: 
a) Western blot shows that control cells exposed to PMA (65 nm) or plated on FN 
had a much stronger signal for phosphorylated ERK than those plated on poly-l-
lysine (used as nonspecific substrate). Pre-incubation with our compound before 
plating on fibronectin caused a significant decrease in the amount of 
phosphorylated ERK in K562 cells.  
b) The densitometric analysis of the bands (mean ±SEM; n=6): p42 (white color), 
p44 (grey color) is also reported; the amount of phosphorylated ERK is normalized 
to the total amount of ERK. Densitometric quantification confirmed that our 
compound specifically decreases fibronectin-induced phosphorylation of ERK. In 
control cells, as expected, PMA induced a significant increase in ERK 
phosphorylation; *p<0.01 versus Ctrl, **p<0.001 versus FN60’ (Newman–Keuls 
test after ANOVA). 
 
Inhibition of v 3 and 5 1 integrin-mediated cell adhesion (β-dehydro-pyrrole 
derivatives) 
Relatively to the results reported in Table 9 the β-dehydro-pyrrole derivatives have 
been submitted to the same kind of biological assays already presented for 
definition of  activity against αvβ3 and α5β1 integrins., Derivatives with c-Hex side 
chain afforded no activity (entry 4-5) while derivatives bearing iPr side chain 
possess a good activity (entry 1-3)  
In particular, the racemic mixture (entry 1) showed two IC50 values comparable to 
the  isoxazolinic compounds seen before, while the isolated enantiomers have a 
different behavior. The R-enantiomer presents a selective inhibition versus αvβ3 
than α5β1 (entry 2) and the S-enantiomer is not active to αvβ3 and showed a 
moderate inhibition value versus α5β1. From these results we can suppose a 
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possible synergic action between enantiomers difficult to understand only on the 
data that we have to date. 
 
Entry Compound IC50[ M] 
αvβ3
 
IC50[ M] 
α5β1 
 
1 
22c-rac  
 
0.01142 
 
0.0036 
 
2 
22c-R  
 
0.0376 
 
90.5 
 
3 
22c-S  
 
Not active 
 
0.531 
 
4 
22d-S  
 
Not active 
 
Not active 
 
5 
22d-R  
 
Not active 
 
Not active 
Table 9. v 3 integrin and 5 1 integrin-mediated cell adhesion to fibronectin in the 
presence of dehydro- -amino acid containing RGD mimetics (dehydro-pyrrole 
derivatives). 
 
 
Inhibition of v 3 and 5 1 integrin-mediated cell adhesion (linear and uridinic 
derivatives) 
In table 10 the activities of linear dehydro- -amino acids and of six membered ring 
derivative 33a are presented. The shorter molecules reported in entries 1-4 showed 
unexpected activity and selectivity depending on the substituent in position 3. 
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Treatment with methyl derivative (entry 1) did not affect v 3 integrin-mediated 
cell adhesion, but excellent affinity toward 5 1 integrin was observed. On the 
other hand, the introduction of the isopropylic group, gave better results since 
comparable affinity could be observed toward both integrins (entry 2). Increased 
activity toward 5 1 integrin was observed for thiophenyl derivative (entry 3), 
while for c-Hex derivative a preferential affinity toward v 3 receptor could be 
observed (entry 4). Anyway, the difference in the affinity among the members of 
this class of compounds is not sufficient to deduce strong structure-activity 
relationship effects. 
Moreover, these molecules are quite smaller than the usual RGD mimetics as 
cilengitide, and for this reason difference in the steric hindrance of the side chain 
may not be crucial for receptor affinity. Bringing the molecules to a more 
appropriate length, it has been possible to observe an increase in the anti-adhesion 
activity (entries 5-6). In particular the iPr-derivate (entry 6) showed an increased 
5 1 integrin-mediated inhibitory activity respect to the corresponding shorter 
analog (entry 2). On the contrary, 35c displayed good activity and a strong 
preference toward v 3 integrin, behaving as a selective not dual inhibitor. 
Introduction of a second further glycine unit allowed elongation of the molecule. 
Moreover in this ligand the interaction with the  chain of the receptor should no 
longer occur through the aniline group but with the glycine amino moiety. These 
modification allowed to obtain the most potent dual antagonist (entry 7). Finally, 
the last tested molecule 33a does not have significant activity to the studied 
integrins, because a dramatic decrease in affinity toward both integrins occurred for 
this compound (entry 8), thus suggesting that the conformational constraint 
introduced by the cyclic scaffold doesn’t allow pharmacophore’s proper 
orientation. 
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Entry Compound IC50[nM]
a 
αvβ3
 
IC50[nM]
a 
α5β1 
 
1 37c  
 
>100 
 
0.019±0.003 
 
2 37a  
 
1.49±0.05 
 
9.8±0.6 
 
3 
37f  
 
3.3±0.3 
 
4.7±0.2 
 
4 
37b  
 
0.83±0.08 
 
2.1±0.8 
 
5 35c  
 
0.12±0.03 
 
9.8±0.3 
 
6 35a  
 
2.0±0.1 
 
0.22±0.05 
 
7 
40a  
 
0.27±0.06 
 
0.17±0.03 
 
8 
33a  
 
>100 
 
>100 
9 Gly-Arg-Gly-Asp-Thr-Pro
b 
0.00062±0.00003 0.93±0.08 
10 H-Gly-Arg-Gly-Asp-Asn-Pro-OH
b 
0.23±0.03 >100 
Table 10. v 3 integrin and 5 1 integrin-mediated cell adhesion to fibronectin in 
the presence of dehydro- -amino acid containing RGD mimetics (linear and 
pyrimidinone derivatives). 
a
 Values are means of three experiments. 
b
 Reference compounds. 
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Effect of dehydro-β-amino acid containing RGD mimetics on fibronectin-
induced ERK phosphorylation in DAOY or K562 cells (linear derivatives) 
To investigate the effect of the most effective compounds (entry 5 and 7 in table 
10) on intracellular integrin-mediated signaling activation we employed DAOY 
medulloblastoma cells, which express v 3 integrin (Fig. 15) .
44
 The tested 
compounds showed a similar potency as cell adhesion inhibitors in DAOY cells 
(data not shown). 
DAOY cells were serum-starved in DMEM for 16 h; thereafter, they were detached 
and pre-incubated with the two our integrin antagonists for 30 min and plated for 
90 min on fibronectin. As shown in Fig. 15, in cells exposed to fibronectin, a 
significant increase in phosphorylated ERK1/2 is observed after 90 min, while after 
120 min ERK1/2 activation is completely abolished (ERK1/2 phosphorylation was 
not detected in DAOY cells exposed for 30 or 60 min to fibronectin; data not 
shown). Pre-incubation with both compounds caused a significant decrease in the 
amount of fibronectin-induced ERK phosphorylation in DAOY cells. 
 
Fig. 15. 
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To investigate the effect of the most effective compounds 37c and 40a on 
intracellular 5 1 integrin-mediated signaling activation we employed K562 cells. 
As previously described, K562 cells were serum-starved in RPMI-1640 containing 
1% fetal bovine serum (FBS) for 16 h; thereafter, they were pre-incubated with 
compound 37c or 40a (10 M) for 60 min in suspension and plated for 60 min on 
fibronectin. In agreement with other studies,
45
 the ERK signaling is activated in 
K562 cells exposed to phorbol-12-myristate-13- acetate positive control (PMA, 65 
nm; Fig. 15). Cells exposed to PMA or fibronectin showed a significant increase in 
phosphorylated ERK after 60 min whereas compound 40a was able to revert 
fibronectin-induced ERK1/2 phosphorylation increment (Fig. 16). On the contrary, 
compound 37c was not able to block ERK pathway activation. The behavior of 
compound 37c, that is ineffective toward v 3 integrin-mediated cell adhesion and 
shows high affinity for 5 1 integrin but is not able to block signaling, suggest that 
probably, it could act through a different mechanism of action that deserves more 
investigation in future studies. Integrins and their endogenous ligands are large and 
complex molecules and so there is the potential for a competitive antagonists to 
interact with more than one site on the integrin to block ligand binding and to 
prevent the downstream sequela of integrin activation.
46
 It is conceivable that small 
molecules, like 37c described in this study, can prevent fibronectin-mediated cell 
adhesion in cells expressing 5 1 integrin, whereas they are not capable to block 
fibronectin-induced cell signaling. Integrin-mediated adhesion often occurs under 
tensile forces such as fluid flow or myosin-mediated contractions that cells exert to 
sample the rigidity of their surroundings. Thus, to enable mechanosensing, 
integrins could not be constitutively active.
47
 These events are mediated by 
fibronectin and seem to be antagonized by the compound 40a. On the contrary, 
compound 37c may not prevent fibronectin-initiated cell signaling which requires 
more complex integrin conformational modifications. 
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In the literature, examples of small molecule ligands that may only partially 
interact with the binding site and for this reason show an uncommon effect when 
compared with classical RGD ligands, have been reported.
48
 Moreover, several 
studies have also described compounds that could be classified as allosteric 
antagonist or allosteric effector: these molecules could not directly compete with 
the binding of integrin specific ligands.
49
 
 
Fig. 16. 
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3.1.5 Synthesis of fluorescent compounds 
In order to develop a new drug delivery system, we searched a molecule able to 
achieve this new challenge. If among the different classes of V 3 and 5 1 the 
choice fells easily on the most active isoxazolinic compounds, suitably modified, 
for the fluorescent compound to link to the latter, a class of compound developed in 
the Professor Luc Brunsveld’s laboratory in Eindhoven (NL) was chosen. These 
kind of compounds present different points of interest (Figure 17). 
Fig. 17. Fluorescent molecules synthesized and relative nanoparticles formation. 
 
How is possible to see in Figure 17, these molecules consist of a bicyclic aromatic 
central core on which are linked two fluorenyl entity which in turn are linked to 
two different gallic acid derivatives. In fact, the chains linked to the gallic acid 
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portions, have different nature: one is hydrophobic, since formed by a lipophilic 
satured chain, and the other is hydrophilic, because formed by a polyethylene 
glycol chain. The specific affinity towards different kind of solvents of these two 
portions allows us to obtain amphiphilic nanoparticles.
50
The presence of the 
fluorenyl moieties and the bicyclic aromatic central core provide a very good 
detection system under UV irradiation and, in addition, by changing the byciclic 
aromatic central core, it is possible to obtain a different color under UV lamp. It is 
also interesting to note that a terminal azide is present on the hydrophilic chain, 
which allows us the easy connection with an integrin ligand presenting an alkyne 
side chian, via a simple click reaction. During the PhD period spent abroad, the two 
fluorescent molecules described before have been synthesized.  
Scheme 23. 
 
First, we synthesized the lipophilic chain to insert on fluorenyl group. Starting from 
alcohol 43, by reduction of the double bond with H2/Pd/C 44 has been obtained in 
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99% yield, which, after treatment by N-bromosuccinimide and tryphenylphosphine, 
provided bromide 45. This bromo derivative has been inserted on fluorenyl group 
46 using TBAB (Tetra-n-butylammonium bromide) and 50 w% of NaOH in 
toluene,  giving 47 in good yield. By nitration with SiO2/H2SO4/HNO3 of the latter 
compound, it has been possible to obtain 48 that later provided the amine 49 in 
93% yield, by reduction of nitro group with SnCl2 in EtOH/EtOAc after three days 
of reflux. This amino-bromide has been used to obtain the boronic ester 50 in good 
yield by treatment with Bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2 in dioxane 
after 16 hours of reflux (Scheme 23). 
 
Scheme 24. 
At this point,  the two different bicyclic aromatic core able to give a different color 
under UV irradiation  have been inserted through a Suzuki coupling, using a 
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mixture of dioxane/H2O as solvent, Na2CO3, Pd[PPh3]4 and employing the 
corresponding bicyclic-dibromide 51 and 53. After 16h of reflux, 54% of 52 and 
81% of 54 have been recovered respectively (Scheme 24). Treating the gallic acid 
derivative 55 with Ghosez’s reagent, we obtained the chloride 56 that presents the 
hydrophobic chains. This chloride has been immediately added to 52 or 54 by 
syringe pump over 16 hours to obtain the mono-acylation of amine and to provide 
57 and 58 selectively (Scheme 25). 
Scheme 25. 
 
Finally, chloride 60 has been prepared following the same approach with Ghosez’s 
reagent on the gallic acid derivative possessing the hydrophilic moiety and then 
added to 57 and 58 to get 42 and 41 respectively (Scheme 25). 
For the experimental section see J. Am. Chem. Soc. 2011, 133, 17063–17071 and 
Chem. Commun., 2009, 1697–1699. 
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3.1.6 Conjugation of integrin ligands with fluorescent molecules 
As previously said, the class of V 3 and 5 1 integrin ligand chosen has been the 
class of isoxazolines and, in particular, the candidate molecule to link the 
fluorescent compound presents in its structure an alkyne able to react with an azide 
by click reaction. To synthesize this kind of isoxazolinic ligand, we prepared the 
aldehyde 62 by Swern oxidation using oxalyl chloride (99% yield) and then 
subjected it to Knoevenagel reaction with t-Butyl acetoacetate in presence of a 
catalytic amount of piperidine under MW irradiation following the procedure 
explained in chapter 1. From this reaction we obtained the corresponding 
alkylidene acetoacetate 1g in 40% and probably the not excellent yield is due to a 
polymerization of the aldehyde during the reaction. The α,β-unsatured compound 
obtained was subjected to Michael addition with TMSONHTMS and ytterbium 
triflate as catalyst to obtain the intermediate 63 that spontaneously provided 
isoxazolidine 64 (Scheme 26). 
 
Scheme 26. Synthesis of functionalized isoxazolinic ligand. 
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It has not been possible to isolate the product of this step because several 
intermediates  resulting from hemiacetalic nature of isoxazolidine are present and 
for this reason we could not calculate the yield, so we performed the subsequent 
reaction using the crude product. After treatment with  benzyl malonyl chloride and 
TEA, we obtained 65 in 44% yield after two steps. Using mesyl chloride and TEA 
in DCM isoxazoline 66 was finally obtained with good yield (82%). At this point 
the t-butylester hydrolysis, carried out with TFA in DCM, provided the 
corresponding acid 67 in 99% yield and the final coupling with p-
aminobenzylamine performed with HBTU and TEA in dichloromethane allowed us 
to obtain the desired product 68 in 80% yield (Scheme 26). 
 
Scheme 27. Conjugation of integrin ligand with fluorescent molecules by click 
reaction. 
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Having in our hand the two building block to link, we performed a click reaction 
between alkyne 68 and fluorescent molecule 41/42. The reaction was carried out 
using CuI as catalyst, DIPEA and Lutidine in MeCN at room temperature for two 
hours providing the final product 69/70 in good yield (Scheme 27). 
 
3.1.7 Experimental section 
Dehydro pyrrole derivatives: 
General procedure for the deprotection of OtBu ester 16c-d to obtain 20c-d: 
TFA (7eq) was dissolved in a 0.1M solution of proper ester in DCM and the 
reaction mixture was stirred until complete consumpyion of the starting material 
(generally 12-24h). The solvent was removed in vacuo and the crude mixture was 
used for the following step. Quantitative yield of 20c-d.. 
20c: Yellow oil ,
1
H NMR (400 MHz, CD3OD) δ = 0.90 (d, J=7.2 Hz, 3H), 0.94 (d, 
J=7.2 Hz, 3H), 0.98 (d, J=7.2 Hz, minor isomer on amide bond 0.35H), 2.22 (m, 
minor isomer on amide bond 0.35H), 2.35 (m, major isomer on amide bond 1H), 
3.73 (s, 3H), 4.10 (d, J=14, minor isomer on amide bond 0.35H), 4.35 (dd, J=20.5 
Hz, 4.4 Hz, 1H), 4.52 (dd, J =20.8 Hz, 8.8Hz, 1H), 4.93 (s, minor isomer on amide 
bond 0.35H), 5.05 (d, J= 2.8 Hz, 1H), 6.8 (s, major isomer on amide bond, 1H), 
6.90 (s, minor isomer on amide bond, 0.35H). 
13
C NMR (100 MHz, CDCl3) δ = 
17.7, 18.2, 18.9, 19.2, 33.2, 35.5, 39.4, 52.9, 55.1, 56.1, 58.3, 62.0, 69.1, 69.7, 
137.7, 138.8, 166.2, 167.5, 179.6.LC-MS ESI: r.t. 12.2 min m/z 256.1 [M+1], 
278.1 [M+Na].α(MeOH, c=1): (S)-20c: +19.5, (R)-20c: -26-1. 
20d: Yellow oil ,
1
H NMR (400 MHz, CD3OD) δ = 0.80-0.91 (m, 5H), 1.40-1.55 
(m,6H), 3.73 (s, 3H), 4.10 (d, J=14, minor isomer on amide bond 0.35H), 4.35 (dd, 
J=20.5 Hz, 4.4 Hz, 1H), 4.52 (dd, J =20.8 Hz, 8.8Hz, 1H), 4.93 (s, minor isomer on 
amide bond 0.35H), 5.05 (d, J= 2.8 Hz, 1H), 6.8 (s, major isomer on amide bond, 
1H), 6.90 (s, minor isomer on amide bond, 0.35H). α: S-20d= +33.9, R-20d= -30.3. 
LC-MS-ESI rt 8.7 min 296 (M+1). 
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General procedure for the preparation of 21c-d: 
Under nitrogen atmosphere, the acid 20c-d was dissolved in dry DCM in order to 
create a 0.2M solution, and TEA (2eq) followed by HBTU (1eq) were added. 
Finally, 4-aminobenzylamine (1,5eq) was added to reaction mixture and it was 
stirred overnight. Then other DCM was added to reaction mixture and the organic 
layer was washed once with water, dried by Na2SO4 and the DCM was evaporated 
in vacuo and the crude product was purified through flash chromatography on silica 
gel (c-Hex/EtOAc 2:8) to obtain a dark orange dense oil in yield up of 90%. 
21c: Yellow oil ,
1
H NMR (400 MHz, CD3OD) δ 0.87 (d, J=10 Hz, 3H), 0.9 (d, 
J=9.2 Hz, 3H), 2.38 (m, 1H), 3.37 (s, 2H), 3.75 (s, 3H), 4.31 (s, minor isomer on 
amide bond 0.35H), 4.4 (s, 2+1H), 4.46 (s, major isomer on amide bond 1H), 4.54 
(s, minor isomer on amide bond 0.35H), 5.05 (d, J=12 Hz, minor isomer on amide 
bond 0.35H), 5.18 (s, major isomer on amide bond 1H), 6.45 (s, major isomer on 
amide bond 1H), 6.52 (s, minor isomer on amide bond 0.35H), 7.05 (d, J=20 Hz, 
2H), 7.31 (d, J=16 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 15.3, 18.8, 19.7, 
20.1, 21.7, 33.3, 36.3, 44.3, 53.7, 55.9, 57.0, 62.3, 70.5, 70.8, 122.1, 131.0, 131.7, 
139.6, 167.3, 196.2. LC-MS rt 12.2 min, m/z 360, acid injection. α (MeOH, c=1): 
(S)-21c: +27.5, (R)-21c: -26.5. 
21d: Yellow oil ,
1
H NMR (400 MHz, CD3OD3) δ 0.8-1.2 (m, 5H), 1.45-1.80 (m, 
6H), 3.15 (d, J= 7.6 Hz, 1H), 3.19 (d, J= 7.2 Hz,1H), 4.20-4.74 (m, 4H), 4.93 (s, 
1H. minor), 5.06 (s, 1H, major), 6.33 (s, 1H, major), 6.41 (s, 1H, minor), 6.67 (d, 
J= 6.8 Hz, 2H), 7.05 (d, J= 6.8 Hz, 2H), 7.94 (s, 2H), 8.55 (bs, 1H). 
13
C NMR (100 
MHz, CD3OD) minor and major δ 11.1, 15.2, 16.6, 25.4, 25.7, 27.1, 28.1, 40.5, 
40.8, 41.6, 41.7, 46.4, 46.6, 50.8, 53.7, 54.0, 67.3, 114.6, 127.33, 127.7, 127.8, 
128.0, 137.2, 145.5, 164.5, 164.9, 167.5. LC-MS-ESI rt 4.9, 400 (M+1), 822 
(2M+Na). α (MeOH, c=1): (S)-21c: +27.0, (R)-21c: -25.2. 
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General procedure for the preparation of 22c-d: 
Compound 21c-d was dissolved in a 1:4 mixture of THF and water in order to 
create a 0.02M solution. Then K2CO3 was added and the reaction mixture was 
stirred under refluxing conditions for 4h. After that, the pH was turn acid and the 
solvent was removed in vacuo. Crude reaction mixture was dissolved in the fewer 
quantity as possible of an acidic water/MeOH solution and was then purified on ion 
exchange DOWEX resin to afford a dark green vitreous solid in typical yields of 
50-80%. 
22c: Yellow oil ,
1
H NMR (400 MHz, D2O) δ = 0.81 (d, J=6.8 Hz, 3H), 0.83 (d, 
J=7.6 Hz, 3H), 0.86 (d, J= 6.8 Hz, minor isomer on amide bond 0.35H), 2.20 (m, 
minor isomer on amide bond 0.35H), 2.38 (m major isomer on amide bond 1H), 
4.14 (dd, J= 17 Hz, 2.8 Hz, minor isomer on amide bond 0.35H) 4.37 (s, 2H), 4.43 
(m, 2H), 4.99 (s, minor isomer on amide bond 0.35H), 5.07 (s, major isomer on 
amide bond 1H), 6.48 (s, major isomer on amide bond 1H), 6.55 (s, minor isomer 
on amide bond 0.35H), 6.92 (d, J=8 Hz 2H. 
13
C NMR (100 MHz, D2O) δ = 14.9, 
15.7, 18.1, 18.3, 30.5, 33.5, 42.5, 53.7, 54.9, 68.1, 68.9, 117.7, 128.7, 128.8, 130.4, 
130.5, 130.9, 131.4, 135.5, 135.9, 141.9, 166.5, 166.6, 169.1, 174.0. LC-MS rt 4.4 
min, m/z 346, acid injection. 
22d: Vitreous yellow solid ,
1
H NMR (400 MHz, CD3OD) δ 0.9-1.2 (m, 5H), 1.5-
1.75 (m, 6H), 3.29 (s, 2H), 4.2-4.5 (m, 4H), 4.96 (s, 1H, minor), 5.08 (s, 1H, 
major), 6.32 (s, 1H, major), 6.39 (s, 1H, minor), 6.65 (d, J= 8 Hz, 2H), 6.05 (d, J= 
8.4 Hz, 1H) 
13
C NMR (100 MHz, CD3OD) minor and major δ 25.2, 25.5, 25.8, 
27.2, 28.3, 40.9, 41.7, 43.8, 54.1, 67.2, 67.8, 114.6, 127.4, 127.8, 127.9, 128.2, 
137.4, 145.7, 164.6, 167.0, 170.8. LC-MS-ESI rt 11.2 386 (M+1), 795 (2M+Na). 
 
Isoxazolines derivatives: 
General procedure for the synthesis of N-malonamido derivatives 23: 
SOCl2 (1.5 mmol, 1.5 equiv) was added dropwise to a stirred solution of benzyl 
malonic acid (1.5 mmol, 1.5 equiv) in dry DCM (5 mL) at 0°C. After removing the 
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ice bath, the solution was for 30 min at room temperature, and then pyridine (5 
mmol, 5 equiv) and proper isoxazolidine 9 (1 mmol) were added. The solution was 
left to stir overnight, and then the reaction mixture was diluted with DCM (10 mL) 
and washed with H2O (2 X 10 mL). The organic layer was dried (Na2SO4) and 
filtered, and the solvent was removed in vacuo. Purification of the crude residue by 
flash chromatography on silica gel, (eluent cyclohexane/EtOAc 9:1) afforded 
compounds 23 as racemic mixtures of trans isomers.  
23a: Yellow oil (236 mg, 60%): 
1
H NMR (200 MHz, CDCl3) δ = 1.43 (d, J=6.8 
Hz, 3H), 1.50 (s, 9H), 1.63 (s, 3H), 2.84 (d, J = 8.0 Hz, 1H), 3.54 (d, J =15.8 Hz, 
1H), 3.65 (d,  J =15.8 Hz, 1H), 4.57 (bs, 1H), 4.71 (m, 1H), 5.15 (d, J =13.2 Hz, 
1H), 5.22 (d, J =13.2 Hz, 1H), 7.37 (s, 5H). 
13
C NMR (50 MHz, CDCl3) δ = 20.4, 
23.0, 27.9, 41.1, 55.8, 62.9, 67.2, 83.0, 104.8, 128.3, 128.4, 128.7, 135.3, 160.3, 
167.4, 168.1. LC-MS ESI: r.t. 9.14 min m/z  394 [M+1], 416 [M+Na], 809 
[2M+Na]. 
23b: Yellow oil (292 mg, 66%): 
1
H NMR (200 MHz, CDCl3): =0.71 (d, J=7.0 Hz, 
3H), 0.88 (d, J=7.0 Hz, 3H), 1.40 (s, 9 H), 1.54 (s, 3H), 1.88 (m, 1 H), 2.87 (d, 
J=6.6 Hz, 1H), 3.43 (d, J=15.6 Hz, 1 H), 3.60 (d, J=15.6 Hz, 1H), 4.51 (m, 1 H), 
4.61 (bs, 1H), 5.08 (s, 2H),7.29 ppm (s, 5H); 
13
C NMR (50 MHz, CDCl3): =17.7, 
18.6, 23.0, 27.9, 32.2, 41.2, 58.8, 65.0, 67.1, 82.8, 105.7, 128.2, 128.5, 128.6, 
135.4, 168.0, 168.7, 169.2 ppm; LC–MS (ESI): tR=10.4 min, m/z: 444 [M+Na], 
865 [2M+Na]. 
23c: Yellow oil (290 mg, 63%): 
1
H NMR (200 MHz, CDCl3) δ = 0.97-1.26 (m, 
6H), 1.42-1.51 (m, 2H), 1.46 (s, 9H), 1.58-1.85 (m, 3H), 1.63 (s, 3H), 2.97 (d, J = 
6.6  Hz, 1H), 3.55 (d, J =15.4 Hz, 1H), 3.68 (d, J =15.4 Hz, 1H), 4.58 (m, 1H), 5.12 
(d, J =12.4 Hz, 1H), 5.20 (d, J =12.4 Hz, 1H), 7.34 (s,  5H). 
13
C NMR (50 MHz, 
CDCl3) δ = 23.6, 27.7, 27.9, 28.3, 29.1, 29.5, 38.0, 42.1, 66.9, 67.1, 82.0, 105.7, 
128.1, 128.3, 128.4, 136.2,  168.1, 169.2, 169.8. LC-MS ESI: r.t. 13.1 min m/z 462 
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[M+1], 484 [M+Na].  
23g: See compound 65. 
23h: Yellow oil (265 mg, 61%): 
1
H NMR (200 MHz, CDCl3) δ = 0.86-0.94 (m, 
6H), 1.44-1.55 (m, 12H), 1.64 (s, 3H), 2.98 (d, J = 7.0 Hz, 1H), 3.64 (s, 2H), 4.57 
(bs, 1H), 4.69 (m, 1H), 5.18 (s, 2H), 7.36 (m, 5H). 
13
C NMR (50 MHz, CDCl3) δ = 
11.1, 11.9, 13.1, 16.2, 23.1, 27.9, 31.9, 41.1, 66.7, 67.2, 81.0, 105.9, 128.3, 128.4, 
128.6, 135.2, 162.5, 162.7, 166.9. LC-MS ESI: 10.9 min m/z 436 [M+Na], 893 
[2M+Na].  
 
General procedure for the synthesis of dehydration of 23 to 24: 
CH3SO2Cl (116 mL, 1.5 mmol, 1.5 equiv) and Et3N (348 mL, 2.5 mmol, 2.5 equiv) 
were added in a single portion to a stirred solution of 23 (1 mmol) in dry DCM (5 
mL) at room temperature. The solution was stirred at room temperature and 
stopped upon disappearance of the starting material spot (by TLC), typically after 1 
h. The reaction mixture was then diluted with DCM (10 mL) and washed with H2O 
(2X10 mL). The organic layer was dried (Na2SO4) and filtered, and the solvent was 
removed in vacuo. Purification of the crude residue by flash chromatography on 
silica gel (eluent cyclohexane/ EtOAc 9:1) afforded compounds 24. 
24a: Yellow oil (330 mg, 88%): 
1
H NMR (200 MHz, CDCl3) δ = 1.43 (d, J=6.8 
Hz, 3H), 1.49 (s, 9H), 2.08 (s, 3H), 3.49 (d, J =15.8 Hz, 1H), 3.62 (d, J =15.8 Hz, 
1H), 5.17 (s,2H), 5.28 (q, J =6.8 Hz, 1H), 7.20-7.35 (m, 5H). 
13
C NMR (50 MHz, 
CDCl3) δ = 10.7, 19.3, 28.4, 30.6, 64.5, 66.1, 82.7, 110.3, 128.2, 128.3, 128.5, 
135.1, 150.5, 163.9, 165.3, 165.9. LC-MS ESI: r.t. 11.00 min m/z 376 [M+1], 398 
[M+Na], 773 [2M+Na].  
24b: Yellow oil (359 mg, 89%): 
1
H NMR (200 MHz, CDCl3): =0.71 (d, J=6.6 Hz, 
3 H), 0.89 (d, J=6.6 Hz, 3H), 1.41 (s, 9H), 1.55 (m, 1H), 2.01 (s, 3 H), 3.44 (d, 
J=15.8 Hz, 1 H), 3.60 (d, J=15.8 Hz, 1H), 5.08 (s, 2 H), 5.12 (bs, 1 H), 7.36 ppm 
(m, 5H); 
13
C NMR (50 MHz, CDCl3): d=10.9, 15.6, 19.7, 29.0, 31.3, 40.9, 66.9, 
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68.1, 80.7, 105.3, 128.1, 128.2, 128.4, 135.0, 161.1, 162.2, 166.3, 169.4 ppm; LC–
MS (ESI): tR= 12.4 min, m/z: 404 [M+1], 829 [2M+Na]. 
24c: Yellow oil (376 mg,  
85%): 
1
H NMR (200 MHz, CDCl3) δ = 0.94-1.85 (m, 11H), 1.47 (s, 9H), 2.27 (s, 
3H), 3.48 (d, J =15.4 Hz, 1H), 3.66 (d, J =15.4 Hz, 1H), 5.14 (s, 2H), 5.16 (bs, 1H), 
7.32 (m, 5H). 
13
C NMR (50 MHz, CDCl3) δ = 11.1, 25.3, 26.3, 26.9, 29.7, 30.5, 
41.1, 67.2, 67.8, 82.1, 105.8, 128.3, 128.5, 131.9, 136.3, 151.0, 162.5, 165.7, 169.1. 
LC-MS ESI: 12.3 min m/z 444 [M+1], 466 [M+Na].  
24g: See compound 66. 
24h: Yellow oil (354 mg, 85%): 
1
H NMR (200 MHz, CDCl3) δ = 0.76 (d, J=7.0 
Hz, 3H), 0.94 (t, J=7.2 Hz, 3H), 1.38-1.54 (m, 2H), 1.48 (s, 9H), 1.81 (m, 1H), 2.09 
(s, 3H), 3.51 (d, J =16.2 Hz, 1H), 3.60 (d, J =16.2 Hz, 1H), 5.16 (s, 2H), 5.31 (bs, 
1H), 7.28-7.42 (m, 5H). 
13
C NMR (50 MHz, CDCl3) δ = 11.0, 11.1, 13.0, 23.8, 
28.2, 38.4, 41.1, 66.7, 67.1, 81.0, 105.4, 128.3, 128.4, 128.6, 135.1, 150.9, 162.4, 
166.6, 169.7. LC-MS ESI: r.t. 14.6 min m/z 418 [M+1], 440 [M+Na].  
 
General procedure for tert-butyl ester hydrolysis (compounds 25): 
TFA (15 equiv, 15 mmol, 1.15 mL) was added to a stirred solution of 24 (1 mmol) 
in DCM (2 mL) at 0°C. After 2 h, the mixture was washed with H2O (2_5 mL), the 
organic layer was dried (Na2SO4), filtered, and the solvent was removed in vacuo. 
The acids 25 were used in the following step without further purification. 
25a: Yellow oil (305 g, 95%): 
1
H NMR (200 MHz, CDCl3) δ = 1.47 (d, J=6.8 Hz, 
3H), 2.09 (s, 3H), 3.48 (d, J =15.8 Hz, 1H), 3.66 (d, J =15.8 Hz, 1H), 5.09 (s, 2H), 
5.18 (m, 1H), 7.29 (m, 5H). 
13
C NMR (50 MHz, CDCl3) δ =11.0, 20.6, 31.6, 42.1, 
66.9, 104.8, 127.9, 128.1, 128.5, 135.0, 163.0, 167.1, 167.9, 169.1. LC-MS ESI: r.t. 
8.9 min m/z 320 [M+1], 342 [M+Na], 661 [2M+Na].  
25b:: Yellow oil (340 mg, 98%): 
1
H NMR (200 MHz, CDCl3): =0.80 (d, J=6.8 
Hz, 3 H), 0.98 (d, J= 6.8 Hz, 3 H), 2.12 (s, 3 H), 2.20 (m, 1 H), 3.53 (d, J=16.0 Hz, 
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1H), 3.74 (d, J=16.0 Hz, 1 H), 5.16 (s, 2 H), 5.26 (bs, 1H), 7.34 ppm (m, 5H); 
13
C 
NMR (50 MHz, CDCl3): d=11.4, 15.4, 19.8, 23.9, 31.2, 40.9, 67.3, 103.7, 128.3, 
128.4, 128.5, 134.9, 164.8, 166.4, 168.6, 169.9 ppm; LC–MS (ESI): tR=9.2 min, 
m/z: 348 [M+1], 370 [M+Na], 717 [2M+Na]. 
25c: Yellow oil (354 mg, 98%): 
1
H NMR (200 MHz, CDCl3) δ = 1.08-1.36 (m, 
5H), 1.49-1.78 (m, 6H), 2.39 (s, 3H), 3.45 (d, J =15.8 Hz, 1H), 3.65 (d, J =15.8 Hz, 
1H), 5.07 (s, 2H), 5.14 (bs, 1H), 7.19-7.26 (m, 5H). 
13
C NMR (50 MHz, CDCl3) δ 
= 11.6, 24.9, 25.5, 25.6, 25.8, 26.0, 26.1, 31.7, 67.3, 67.7, 103.1, 128.3, 128.5, 
128.6, 135.0, 165.6, 166.4, 166.7, 168.5. LC-MS ESI: r.t. 10.9 min m/z 362 [M+1], 
384 [M+Na], 745 [2M+Na].  
25g: See compound 67. 
25h: Yellow oil (375 mg, 97%): 
1
H NMR (200 MHz, CDCl3) δ = 0.67-0.92 (m, 
6H), 1.06-1.27 (m, 2H), 1.77 (m, 1H), 2.03 (m, 3H), 3.42 (d, J =15.6 Hz, 1H), 3.64 
(d, J =15.6 Hz, 1H), 5.07 (s, 2H), 5.24 (d, J =10.2 Hz, 1H), 7.18-7.25 (m, 5H), 
8.80-9.20 (bs, 1H). 
13
C NMR (50 MHz, CDCl3) δ = 11.4, 12.6, 16.1, 23.6, 26.9, 
31.4, 38.0, 67.2, 68.0, 103.7, 128.2, 128.4, 128.5, 134.9, 164.7, 166.4, 168.3, 170.0. 
LC-MS ESI: r.t. 11.3 min m/z 388 [M+1], 410 [M+Na], 797 [2M+Na].  
 
General procedure for coupling of 25 with p-aminobenzylamine (compounds 26): 
Under nitrogen atmosphere, the acid 25 was dissolved in dry DCM in order to 
create a 0.2M solution, and TEA (2eq) followed by HBTU (1eq) were added. 
Finally, 4-aminobenzylamine (1,5eq) was added to reaction mixture and it was 
stirred overnight. Then other DCM was added to reaction mixture and the organic 
layer was washed once with water, dried by Na2SO4 and the DCM was evaporated 
in vacuo and the crude product was purified through flash chromatography on silica 
gel (c-Hex/EtOAc 2:8) to obtain a dark orange dense oil in yield up of 90%. Data 
available for Isopropyle derivatives 2b and 2g. 
26b: Yellow oil (180 mg, 80%): 
1
H NMR (200 MHz, CDCl3) δ = 0.82 (d, J=6.6 
Hz, 3H), 0.93 (d, J=6.6 Hz, 3H), 2.04 (m, 1H), 2.13 (s, 3H), 3.48 (d, J =16.2 Hz, 
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1H), 3.68 (d, J =16.2 Hz, 1H), 4.35 (s, 2H), 5.14 (s, 2H), 5.19 (bs, 1H), 5.81 (bt, 
1H), 6.64 (d, J = 6.2 Hz, 2H), 7.06 (d, J = 6.2 Hz, 2H), 7.42 (m, 5H). 
13
C NMR (50 
MHz, CDCl3) δ =11.6, 15.9, 19.0, 28.6, 32.0, 41.7, 66.9, 67.4, 105.9, 118.7, 128.2, 
128.5, 128.6, 128.7, 129.7, 134.8, 137.6, 149.8, 163.2, 165.4, 167.9. LC-MS ESI: 
r.t. 8.35 min m/z 452 [M+1], 473 [M+Na], 925 [2M+Na].  
2g: See compound 68. 
 
General procedure for hydrogenation of 26 to 27: 
To a solution of 26 (0.5 mmol) in MeOH, Pd/C (10 mg) was added in one portion. 
The reaction mixture was stirred vigorously at room temperature under H2 
atmosphere overnight. The solution was filtered to remove catalyst, and the solvent 
was evaporated in vacuo. The crude compound was treated with Dowex 50WX2-
200 ion-exchange resin, eluting with NH4OH (0.5m). Compounds 27 were isolated 
after removal of the aqueous solvent in vacuo. 
27a: Yellow oil (126 mg, 76%): 
1
H NMR (200 MHz, CD3OD) δ = 1.68 (d, J=7.2 
Hz, 3H), 2.07 (s, 3H), 4.18 (d, J =15.8 Hz, 1H), 4.27 (d, J =15.8 Hz, 1H), 4.82 (s, 
2H), 5.33 (m, 1H), 7.04 (d, J =8.4 Hz, 2H), 7.18 (d, J =8.4 Hz, 2H), 8.07 (bt, 1H). 
13
C NMR (50 MHz, CDCl3) δ = 11.6, 21.9, 32.6, 44.9. 68.2, 115.6, 121.0, 128.7, 
129.3, 135.8, 148.1, 161.9, 164.0, 169.2. LC-MS ESI: r.t. 0.98 min m/z 334 [M+1], 
689 [2M+Na].  
27b: Yellow oil (143 mg, 79%): 
1
H NMR (200 MHz, CD3OD): =0.73 (d, J=6.6 
Hz, 3 H), 0.86 (d, J= 6.6 Hz, 3 H), 1.89 (m, 1 H), 2.10 (s, 3 H), 4.23 (d, J=15.0 Hz, 
1H), 4.35 (d, J=15.0 Hz, 1 H), 4.81 (s, 2H), 5.31 (bs, 1H), 7.00 (d, J=8.0 Hz, 2 H), 
7.20 (d, J=8.0 Hz, 2 H), 8.21 ppm (bt, 1H); 
13
C NMR (50 MHz, CDCl3): d=11.4, 
17.0, 20.1, 27.8, 30.7, 45.5, 69.8, 117.0, 120.7, 129.5, 129.7, 136.3, 146.3, 161.6, 
163.4, 167.1 ppm; LC–MS (ESI): tR= 1.46 min, m/z: 362 [M+1], 745 [2M+Na]. 
27c: Yellow oil (162 mg, 81%): 
1
H NMR (200 MHz, CD3OD) δ = 0.82-1.25 (m, 
6H), 1.44-1.70 (m, 6H), 2.10 (s, 3H), 3.24 (s, 2H), 4.21 (d, J =14.6 Hz, 1H), 4.37 
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(d, J =14.6 Hz, 1H), 5.28 (bs,1H), 6.99 (d, J =7.8 Hz, 2H), 7.20 (d, J =7.8 Hz, 2H), 
8.20 (bt, 1H). 
13
C NMR (50 MHz, CDCl3) δ = 9.8, 25.8, 25.9, 26.4, 29.6, 30.9, 
42.0, 66.6, 115.4, 118.8, 128.6, 129.8, 138.9, 146.2, 163.5, 164.1, 166.0. LC-MS 
ESI: r.t. 2.21 min m/z 402 [M+1], 803 [2M+1] 
27g: The deprotection didn’t work on this substrate. 
27h: Yellow oil (160 mg, 85%): 
1
H NMR (200 MHz, CD3OD) δ = 0.77-0.89 (m, 
6H), 1.03-1.57 (m, 3H), 2.13 (s, 3H), 3.27 (s, 2H), 4.17 (d, J =13.6 Hz, 1H), 4.37 
(d, J =13.6 Hz, 1H), 5.39 (bs,1H), 6.72 (d, J =7.6 Hz, 2H), 7.41 (d, J =7.6 Hz, 2H), 
8.12 (bt, 1H). 
13
C NMR (50 MHz, CD3OD) δ = 11.9, 12.3, 23.2, 26.8, 30.7, 45.5, 
69.8, 117.0, 120.7, 129.5, 129.7, 136.3, 146.3, 161.6, 163.4, 167.1. LC-MS ESI: r.t. 
1.54 min m/z 376 [M+1], 773 [2M+Na].  
 
Pyrimidindione derivatives 
Procedure for the preparation of the acid 28a e c: 
To a stirred solution of the carbonate 11a e c (0.2 mmol) in DCM (2 mL) at 0°C, 
trifluoroacetic acid (15 equiv, 3 mmol, 223 mL) was added. After 2 h, the mixture 
was washed twice with water (5 mL), the organic layer was dried over Na2SO4, and 
solvent was removed under reduced pressure. 
28a: Yield 95%, pale yellow solid (75:25, Z/E mixture), 
1
H NMR (CDCl3, 400 
MHz) Z isomer  1.57 (d, J = 6.8 Hz, 3H,), 2.05 (d, J = 7.2 Hz, 3H), 3.79 (s, 3H,), 
5.76 (q, J = 6.8 Hz, 1H), 7.20 (q, J = 7.2 Hz, 1H,); E isomer  1.49 (d, J = 6.8 Hz, 
3H), 1.92 (d, J = 7.2 Hz, 3H), 5.53 (q, J = 6.8 Hz, 1H), 6.67 (q, J = 7.2 Hz, 1H). IR 
(neat, cm
-1
) 1105, 1172, 1288, 1463, 1671, 1750, 2855, 2915, 2961, 3317. 
13
C 
NMR (CDCl3, 200 MHz) d Z isomer 14.3, 19.5, 50.9, 53.6, 117.1, 130.6, 139.6, 
151.3, 174.3. LC-MS-ESI rt 1.22 min, 189 (M + 1). Anal. cald. for C8H12O5 
(188.18): C 51.06, H 6.43; found C 50.95, H 6.45. 
28c: Yield 95% (>99:1, Z/E mixture), pale yellow solid, 
1
H NMR (CDCl3, 200 
MHz)  0.97 (d, J = 5.4 Hz, 6H), 1.40 (d, J = 6.6 Hz, 3H), 3.25e3.42 (m, 1H), 3.70 
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(s, 3H), 5.46 (q, J = 6.6 Hz, 1H), 6.11 (d, J = 10.0 Hz, 1H,), 10.41 (bs, 1H); 
13
C 
NMR (CDCl3, 50 MHz)  20.1, 21.9, 31.8, 54.4, 73.3, 128.9, 142.5, 154.7, 171.4; 
IR (neat, cm
-1
) 1010, 1168, 1287, 1691, 1742, 2845, 2921, 2961, 3323. LC-ESI-MS 
rt 6.65 min, m/z 216 (M), 239 (M + Na). Anal. cald. for C10H16O5 (216.23): C 
55.55, H 7.46; found C 55.57, H 7.45. 
 
Procedure for the preparation of the amide 29a e c: 
To a stirred solution of the acid 28 (0.2 mmol) in dry DCM (2 mL), under nitrogen 
atmosphere, EDCI (1.2 equiv, 0.24 mmol, 46 mg) and triethylamine (2.4 equiv, 
0.48 mmol, 67 mL) were added. After 30 min HOBT (1.2 equiv, 0.24 mmol, 33 
mg) and glycine tbutyl ester hydrochloride (1.2 equiv, 0.24 mmol, 41 mg) were 
added. The solution was stirred overnight and then the mixturewas diluted with 
DCM and washed twice with acidic water (5 mL) and twice with basic water (5 
mL). The two phases were separated, the organic layer was dried over Na2SO4, 
and solvent was removed under reduced pressure. Compound 29 was isolated by 
flash chromatography on silica gel (cyclohexane/ethyl acetate 80/20 as eluent). 
29a: Yield 60% (75:25, Z/E mixture), yellow oil, 1H NMR (CDCl3, 200 MHz) d 
1.41 (s, 9H),1.43 (d, J = 6.6 Hz, 3H),1.83 (d, J = 7.2 Hz, 3H), 3.74 (s, 3H), 3.94-
4.01 (m, 2H), 5.25 (q, J = 6.8 Hz, 1H, CHO), 5.96 (q, J = 7.2 Hz, 1H), 6.61 (bt, 
1H). 
13
C NMR (CDCl3, 50 MHz)  15.0, 20.0, 28.0 (3C), 42.0, 54.8, 76.1, 82.2, 
131.8, 137.3, 155.1, 167.3, 168.8. IR (neat, cm
-1
) 938, 1040, 1158, 1267, 1371, 
1524, 1612, 1674, 1744, 1750, 28 661, 2926, 2971, 3336. LC-MS-ESI rt 6.8 min, 
m/z 301 (M + 1). Anal. cald. for C14H23NO6 (301.34): C 55.80, H 7.69, N 4.65; 
found C 55.60, H 7.68, N 4.66. 
29c: Yield 65% (>99:1, Z/E mixture), yellow oil, 
1
H NMR (CDCl3, 200 MHz) 
1.01 (d, J = 6.6 Hz, 6H), 1.45 (d, J = 7.0 Hz, 3H), 1.49 (s, 9H), 2.70-2.88 (m, 1H), 
3.79 (s, 3H), 4.00 (d, J = 4.8 Hz, 2H), 5.27 (q, J = 6.6 Hz, 1H), 5.67 (d, J = 10.2 Hz, 
1H), 6.57 (bt, 1H); 
13
C NMR (CDCl3, 50 MHz) 19.9, 22.7 (2C), 26.8, 28.0 (3C), 
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41.9, 54.8, 76.0, 82.2, 131.8, 137.3, 155.1, 167.3, 168.8; IR (neat, cm_1) 942, 
1046, 1157, 1267, 1367, 1442, 1519, 1605, 1667, 1736, 1750, 2861, 2924, 2960, 
3348. LC-ESI-MS rt 10.82 min, m/z 329 (M), 352 (M + Na); Anal. cald. for 
C16H27NO6 (329.39): C 58.34, H 8.26, N 4.25; found C 58.20, H 8.28, N 4.26. 
 
Procedure for the preparation of the N-BOC-protected amide 30a and c: 
To a stirred solution of the amide 29 a and c  (0.2 mmol) in dry THF (1 mL), 
DMAP (0.2 equiv, 0.04 mmol, 5 mg), triethylamine (1.2 equiv, 0.24 mmol, 34 mL) 
and (BOC)2O (1.3 equiv, 0.26 mmol, 60 mL) were added. The solution was stirred 
overnight and then the solvent was removed under reduced pressure. The residue 
was diluted with ethyl acetate (10 mL) and washed twice with water (5 mL). The 
two phases were separated, the organic layer was dried over Na2SO4, and solvent 
was removed under reduced pressure. Compound 30 a and c was isolated by flash 
chromatography on silica gel (cyclohexane/ethyl acetate 95/5 as eluent). 
30a: Yield 88% (70:30, Z/E mixture), yellow oil, 
1
H NMR (CDCl3, 200 MHz)  
1.42 (s, 18H), 1.46 (d, J = 6.6 Hz, 3H), 1.72 (d, J = 7.2 Hz, 3H), 3.69 (s, 3H), 4.19-
4.41 (m, 2H), 5.41 (q, J = 6.6 Hz, 1H), 5.80 (q, J = 7.2 Hz, 1H). 
13
C NMR (CDCl3, 
50 MHz) 14.6, 19.2, 27.7 (3C), 28.0 (3C), 45.9, 54.6, 74.8, 81.8, 83.8, 126.7, 
137.6, 151.4, 155.1, 167.6, 169.8; IR (neat, cm
-1
) 790, 849, 1034, 1160, 1448, 
1592, 1657, 1679, 1746, 1762, 2866, 2928, 2979. LC-MS-ESI rt 11.0 min, m/z 424 
(M + Na), 440 (M + K). Anal. cald. for C19H31NO8 (401.45): C 56.84, H 7.78, N 
3.49; found C 57.00, H 7.76, N 3.48. 6b: Yield 90% (70:30, Z/E mixture), yellow 
oil, 
1
H NMR (CDCl3, 200 MHz)  0.99 (d, J = 6.6 Hz, 6H), 1.42 (d, J = 6.6 Hz, 
3H), 1.48 (s, 18H), 2.41-2.49 (m, 1H), 3.75 (s, 3H), 4.28 (d, J = 16.8 Hz, 1H), 4.45 
(d, J = 16.8 Hz, 1H), 5.42-5.53 (m, 2H); 
13
C NMR (CDCl3, 50 MHz) d 19.2, 22.6 
(2C), 27.2, 27.8 (3C), 28.0 (3C), 45.9, 54.5, 74.7, 81.8, 83.8, 126.7, 137.6, 151.4, 
155.1, 167.6, 169.8; IR (neat, cm
-1
) 745, 848,1030, 1159, 
1442,1588,1652,1677,1743, 1756, 2859, 2928, 2978. LC-ESI-MS rt 12.26 min, 
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m/z 429 (M), 452 (M + Na); Anal. cald. for C21H35NO8 (429.50): C 58.72, H 8.21, 
N 3.26; found C 58.78, H 8.19, N 3.25. 
 
Procedure for the preparation of the dihydropyrimidindione 31: 
To a stirred solution of 30 (0.2 mmol) in dry CH3CN (2 mL), under nitrogen 
atmosphere, 4-aminobenzylamine (1.5 equiv, 0.3 mmol, 34 mL) was added. The 
solution was refluxed for 4 days and then the solvent was removed under reduced 
pressure. Compound 31 was isolated by flash chromatography on silica gel (DCM/ 
ethyl acetate 90/10 as eluent). 
31: Yield 60% (89:11, Z/E mixture), yellow sticky oil, 
1
H NMR (CDCl3, 400 MHz) 
 0.79 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 1.42 (s, 9H), 1.48 (d, J = 7.2 
Hz, 3H), 2.13 (m, 1H), 3.77 (d, J = 7.6 Hz, 1H), 3.90 (d, J = 14.8 Hz, 1H), 4.38 (d, 
J = 16.8 Hz, 1H), 4.45 (d, J = 16.8 Hz, 1H), 5.28 (d, J = 14.8 Hz, 1H), 6.57 (d, J = 
6.8 Hz, 2H), 6.77 (q, J = 7.2 Hz, 1H), 6.94 (d, J = 6.8 Hz, 2H); 
13
C NMR (CDCl3, 
100 MHz)  14.0, 18.5, 19.7, 28.0 (3C), 33.0, 42.9, 51.0, 57.0, 81.6, 115.2 (2C), 
126.1, 129.0 (2C), 130.7, 137.2,146.0,153.1,164.9,167.6. IR (neat, cm
-1
) 
948,1196,1345,1463, 1581,1658,1705, 2853, 2922, 2950, 3366. LC-ESI-MS rt 9.5 
min, m/z 424 (M + Na), 825 (2M + Na); Anal. cald. for C22H31N3O4 (401.50): C 
65.81, H 7.78, N 10.47; found C 65.84, H 7.81, N 10.51. 
 
Procedure for the preparation of the 32: 
To a stirred solution of the N-Boc-Gly (0.2 mmol, 35 mg) in dry DMF (2 mL), 
under nitrogen atmosphere, N,N-diisopropylethylamine (2 equiv, 0.4 mmol, 69 
mL) and HBTU (1 equiv, 0.2 mmol, 76 mg) were added. After 30 min, compound 
31 (1.2 equiv, 0.24 mmol, 96 mg) was added. The solution was stirred for 3 h and 
then the mixture was diluted with ethyl acetate and washed twice with acidicwater 
(5 mL) and twice with basicwater (5 mL). The two phases were separated, the 
organic layer was dried over Na2SO4, and solvent was removed under reduced 
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pressure. Compound 32 was isolated by flash chromatography on silica gel 
(DCM/ethyl acetate 80/20 as eluent). 
32: Yield 90% (91:9, Z/E mixture), yellow oil, 1H NMR (CDCl3, 400 MHz)  0.77 
(d, J = 7.2 Hz, 3H), 0.94 (d, J = 7.2 Hz, 3H), 1.39 (s, 9H), 1.41 (s, 9H), 1.49 (d, J = 
7.2 Hz, 3H), 2.10 (m, 1H), 3.73 (d, J = 7.6 Hz, 1H), 3.84 (d, J = 6.0 Hz, 2H), 3.98 
(d, J = 15.6 Hz, 1H), 4.36 (d, J = 16.6 Hz, 1H), 4.42 (d, J = 16.6 Hz, 1H), 5.20 (bs, 
1H), 5.32 (d, J = 15.6 Hz, 1H), 6.79 (q, J = 7.2 Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 
7.40 (d, J = 8.4 Hz, 2H), 8.10 (bs, 1H); 
13
C NMR (CDCl3, 100 MHz)   
14.2,18.4,19.7, 28.0 (3C), 28.2 (3C), 33.1, 42.9, 45.4, 51.0, 57.8, 81.7, 120.1 (2C), 
127.8, 128.1 (2C), 132.5, 137.0, 137.6, 152.7, 156.5, 164.8, 167.5, 167.9. IR (neat, 
cm
-1
) 961, 1200, 1377, 1463, 1552, 1632, 1651, 1660, 1700, 2884, 2924, 2956, 
3500. LC-ESI-MS rt 9.97 min, m/z 581 (M + Na). Anal. cald. for C29H42N4O7 
(558.67): C 62.35, H 7.58, N 10.03; found C 62.53, H 7.58, N 10.01. 
 
Procedure for the preparation of the amino acid 33: 
To a stirred solution of compound 32 (0.2 mmol, 112 mg), in DCM (0.5 mL), 
H3PO4 (85% solution in water, 7.5 equiv, 1.5 mmol, 207 mL) was added. After 12 
h the organic solvent was removed under reduced pressure and the residue was 
treated with Dowex 50WX2-200 ion exchange resin, eluting with NH4OH 0.5 M. 
Compound 33 was isolated after removal of the aqueous solvent. 
33: Yield 80% (88:12, Z/E mixture), yellow solid, m.p. 130-132 °C (dec.) 
1
H NMR 
(D2O, 400 MHz)  1.68 (d, J = 6.8 Hz, 3H), 1.85 (d, J = 6.8 Hz, 3H), 2.55 (d, J = 
7.6 Hz, 3H), 3.03 (m, 1H), 4.79 (s, 2H), 5.01 (d, J = 6.8 Hz, 1H), 5.09 (d, J = 16.4 
Hz, 1H), 5.11 (d, J = 16.4 Hz, 1H), 5.23 (d, J = 15.8 Hz, 1H), 6.02 (d, J = 15.8 Hz, 
1H), 7.79 (q, J = 7.6 Hz, 1H), 8.18 (d, J = 8.4 Hz, 2H), 8.33 (d, J = 8.4 Hz, 2H); 
13
C 
NMR (D2O, 100 MHz)  13.9, 17.1, 18.3, 32.7, 41.3, 44.6, 51.2, 58.4, 121.4 (2C), 
126.6, 128.0 (2C), 133.7, 135.7, 140.6, 154.0, 166.3, 167.2, 175.3. IR (neat, cm
-1
) 
846, 1157, 1367, 1470, 1538, 1635, 1667, 1698, 2841, 2875, 2924, 2948, 3363, 
114 
 
3421. LC-ESI-MS rt 1.23 min, m/z 403 (M + 1), 425 (M + Na). Anal. cald. for 
C20H26N4O5 (402.44): C 59.69, H 6.51, N 13.92; found C 59.75, H 6.48, N 13.96. 
 
Linear derivatives: 
Procedure for the preparation of the amino derivative 34: 
To a stirred solution of 30 (0.2 mmol) in dry CH3CN (2 mL), under nitrogen 
atmosphere, 4-aminobenzylamine (1.5 equiv, 0.3 mmol, 34 mL) was added. The 
solution was refluxed for 16 h and then the solvent was removed under reduced 
pressure. Compound 34 was isolated by flash chromatography on silica gel 
(cyclohexane/ ethyl acetate 95/5 as eluent).  
34a: Yield 70% (81:19, Z/E mixture), yellow sticky oil, 
1
H NMR (CDCl3, 200 
MHz)  1.39 (s, 18H), 1.48 (d, J = 7.2 Hz, 3H), 1.73 (d, J = 7.2 Hz, 3H), 3.90 (t, J = 
6.2 Hz, 2H), 4.44 (s, 2H), 5.03 (q, J = 7.2 Hz, 1H), 6.15 (q, J = 7.2 Hz, 1H), 6.50 
(bt, 1H), 6.59 (d, J = 8.4 Hz, 2H), 7.01 (d, J = 8.4 Hz, 2H). 
13
C NMR (CDCl3, 50 
MHz)  13.6, 18.0, 28.1(3C), 28.4 (3C), 42.2, 47.3, 50.1, 79.8, 82.1, 115.0, 127.9, 
130.7, 131.3, 139.6, 144.9, 155.9, 169.1, 169.9. IR (neat, cm
-1
) 741, 848, 1163, 
1371, 1458, 1519, 1673, 1718, 1741, 2864, 2887, 2907, 2962, 3061, 3379, 3464. 
LC-MS-ESI rt 9.1 min, m/z 448 (M + 1); Anal. cald. For C24H37N3O5 (447.57): C 
64.41, H 8.33, N 9.39; found C 64.35, H 8.33, N 9.36. 
34c: Yield 65% (78:22, Z/E mixture), yellow sticky oil, 
1
H NMR (CDCl3, 200 
MHz)  0.83 (d, J = 6.6 Hz, 6H), 1.42 (d, J = 7.4 Hz, 3H), 1.47 (s, 18H), 2.60-2.81 
(m, 1H), 3.59 (bs, 2H), 3.83-3.98 (m, 3H), 4.34-4.61 (m, 2H), 6.61 (d, J = 8.0 Hz, 
2H), 6.83 (q, J = 7.4 Hz, 1H), 7.01 (d, J = 8.0 Hz, 2H); 
13
C NMR (CDCl3, 50 MHz) 
d 13.5, 20.2 (2C), 28.1 (3C), 28.5 (3C), 31.8, 42.2, 47.3, 50.1, 79.8, 82.1, 115.0, 
127.9, 130.7, 131.3, 139.6, 144.9, 156.0, 169.1, 169.9; IR (neat, cm
-1
) 737, 847, 
1157, 1367, 1463, 1519, 1674, 1715, 1738, 2863, 2902, 2962, 3047, 3373, 3467. 
LC-ESI-MS rt 9.15 min, m/z 476 (M + 1), 498 (M + Na); Anal. cald. for 
C26H41N3O5 (475.62): C 65.66, H 8.69, N 8.83; found C 65.58, H 8.70, N 8.86. 
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Procedure for the preparation of the amino acid 35: 
To a stirred solution of compound 34 (0.2 mmol), in DCM (0.5 mL), H3PO4 (85% 
solution in water, 5 equiv, 1 mmol, 69 mL) was added. After 3 h the organic 
solvent was removed under reduced pressure and the residue was treated with 
Dowex 50WX2-200 ion exchange resin, eluting with NH4OH 0.5 M. Compound 35 
was isolated after removal of the aqueous solvent.  
35a: Yield 80% (77:23, Z/E mixture), pale yellow solid, m.p. 92-94 °C (dec.) 
1
H 
NMR (CD3OD, 200 MHz)  1.38 (d, J = 7.0 Hz, 3H), 1.79 (d, J = 6.8 Hz, 3H), 
3.70-4.25 (m, 5H), 6.70-6.74 (m, 3H), 7.01-7.25 (m, 3H). 
13
C NMR (CD3OD, 50 
MHz) d 14.1, 18.7, 44.7, 49.8, 53.7, 115.1 (2C), 128.0, 130.4, 132.0 (2C), 137.8, 
144.6, 164.2,179.7; IR (neat, cm
-1
) 1109,1215,1299,1467,1578,1662,1746, 2824, 
2956, 3026, 3325, 3366. LC-MS-ESI rt 0.98 min, m/z 292 (M + 1). Anal. cald. for 
C15H21N3O3 (291.35): C 61.84, H 7.27, N 14.42; found C 62.02, H 7.25, N 14.43. 
35c: Yield 95% (80:20, Z/E mixture), pale yellow solid, m.p. 96-98 °C (dec.) 
1
H 
NMR (CD3OD, 200 MHz)  0.93 (d, J = 6.6 Hz, 6H), 1.82 (d, J = 7.2 Hz, 3H), 
2.18-2.28 (m, 1H), 3.83-4.38 (m, 5H), 6.74 (d, J = 8.4 Hz, 2H), 6.90 (q, J = 7.2 Hz, 
1H), 7.21 (d, J = 8.4 Hz, 2H); 
13
C NMR (CD3OD, 50 MHz)  14.3, 19.9 (2C), 31.9, 
46.9, 50.9, 62.4,116.3 (2C),121.1,128.8,132.0 (2C),140.7,148.5,161.6, 178.2; IR 
(neat, cm
-1
) 1107, 1206, 1289, 1455, 1574, 1662, 1750, 2821, 2842, 2926, 2981, 
3015, 3317, 3368. LC-ESI-MS rt 1.06 min, m/z 320 (M + 1), 342 (M + Na). Anal. 
cald. for C17H25N3O3 (319.40): C 63.93, H 7.89, N 13.16; found C 64.12, H 7.90, N 
13.20. 
 
General procedure for the synthesis of 36a-f: 
To a stirred solution of carbonate 11 (0.2 mmol) in dry CH3CN (2 mL), under a 
nitrogen atmosphere, was added 4-aminobenzylamine (1.5 equiv., 0.3 mmol, 34 
μL). The solution was heated at reflux for 3 d and then the solvent was removed 
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under reduced pressure. Compounds 36a-f were isolated by flash chromatography 
on silica gel (cyclohexane/ethyl acetate, 85:15). 
36a: Yield: 62–65%, 35–37 mg, isolated as a 3:1 mixture of Z/E isomers. 1H NMR 
(200 MHz, CDCl3) major isomer: δ = 1.47 (d, J = 6.8 Hz, 3 H), 1.49 (s, 9 H,) 1.73 
(d, J = 7.4Hz, 3 H), 3.52 (d, J = 12.6 Hz, 1 H), 3.68 (d, J = 12.6 Hz, 1 H), 3.81 (q, J 
= 6.8 Hz, 1 H), 6.59 (d, J = 8.4 Hz, 2 H), 6.93 (q, J = 7.4 Hz, 1 H), 7.16 (d, J = 8.4 
Hz, 2 H) ppm. 
1
H NMR (200 MHz, CDCl3) minor isomer: δ = 1.37 (d, J = 6.8 Hz, 
3 H), 1.95 (d, J = 7.0 Hz, 3 H), 4.02 (q, J = 6.8 Hz, 1 H), 6.23 (q, J = 7.0 Hz, 1 H) 
ppm. 
13
C NMR (75 MHz, CDCl3) major isomer: δ = 13.7 (CH3), 20.6 (CH3), 28.3 
(3 CH3), 49.9 (CH), 50.9 (CH2), 80.5 (C), 115.2 (2 CH), 129.4 (2 CH), 130.5 (C), 
136.3 (C), 137.7 (CH), 145.3 (C), 166.7 (C) ppm. (S)-36a [α]D = –14.0 (c = 1, 
CHCl3); (R)-36a [α]D = +14.0 (c = 1, CHCl3). HPLC (n-hexane/2-propanol, 99:1 to 
96:4 over 30 min; 1.0 mLmin–1; AD column; r.t): tR = 23.52 [(R)-36a], 26.12 min 
[(S)- 36a]. LC–ESI-MS (r.t.): tR = 8.39 min, m/z = 290 [M], 313 [M + Na]. 
C17H26N2O2 (290.2): calcd. C 70.31, H 9.02, N 9.65; found C 70.08, H 9.00, N 
9.65. 
36b: Yield: 60–65%, 38–41 mg, isolated as a 3:1 mixture of Z/E isomers. 1H NMR 
(200 MHz, CDCl3) major isomer: δ = 0.74 (d, J = 6.8Hz, 3 H), 1.10 (d, J = 6.8Hz, 
3 H), 1.49 (s, 9 H), 1.67 (d, J = 7.2 Hz, 3 H), 1.80– 2.05 (m, 1 H), 3.06 (d, J = 9.6 
Hz, 1 H), 3.38 (d, J = 12.8 Hz, 1 H), 3.70 (d, J = 12.8 Hz, 1 H), 6.63 (d, J = 8.2 Hz, 
2 H), 6.92 (q, J = 7.2 Hz, 1 H), 8.20 (d, J = 8.2 Hz, 2 H) ppm. 
1
H NMR (200 MHz, 
CDCl3) minor isomer: δ = 0.83 (d, J = 6.6Hz, 3 H), 0.97 (d, J = 6.6Hz, 3 H), 1.93 
(d, J = 7.0 Hz, 3 H), 2.77 (d, J = 8.6 Hz, 1 H), 5.77 (q, J = 7.0 Hz, 1 H) ppm. 
13
C 
NMR (50 MHz, CDCl3) major isomer: δ = 14.0 (CH3), 20.1 (2 CH3), 28.3 (3 CH3), 
32.1 (CH), 50.7 (CH2), 61.3 (CH), 80.2 (C), 114.9 (2 CH), 129.1 (2 CH), 131.1 (C), 
134.4 (C), 138.7 (CH), 144.9 (C), 167.0 (C) ppm. (S)-36b [α]D = –11.7 (c = 1, 
CHCl3); (R)-36b [α]D = +12.0 (c = 1, CHCl3). HPLC (n-hexane/ 2-propanol, 99:1 
to 90:10 over 30 min; 1.0 mLmin–1; AD column; r.t.): tR = 10.39 [(R)-36b], 10.95 
min [(S)-36b]. LC–ESI-MS (r.t.): tR = 5.87 min, m/z = 318 [M], 341 [M + Na]. 
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C19H30N2O2 (318.23): calcd. C 71.66, H 9.50, N 8.80; found C 71.52, H 9.51, N 
8.83. 
36c: Yield: 60–63%, 43–46 mg, isolated as a 3:1 mixture of Z/E isomers. 1H NMR 
(200 MHz, CDCl3) major isomer: δ = 1.07–1.27 (m, 4 H), 1.41–1.81 (m, 6 H), 1.50 
(s, 9 H), 1.65 (d, J = 7.2 Hz, 3 H), 2.36 (m, 1 H), 3.17 (d, J = 9.6 Hz, 1 H), 3.39 (d, 
J = 13.2 Hz, 1 H), 3.70 (d, J = 13.2 Hz, 1 H), 6.64 (d, J = 8.4 Hz, 2 H), 6.92 (q, J = 
7.2Hz, 1 H), 7.12 (d, J = 8.4 Hz, 2 H) ppm. 
1
H NMR (200 MHz, CDCl3) minor 
isomer: δ = 1.93 (d, J = 7.4 Hz, 3 H), 2.10 (m, 1 H), 2.80 (d, J = 8.8 Hz, 1 H), 3.41 
(d, J = 12.8 Hz, 1 H), 3.72 (d, J = 12.8 Hz, 1 H), 5.73 (q, J = 7.4 Hz, 1 H) ppm. 
13
C 
NMR (75 MHz, CDCl3) major isomer: δ = 13.9 (CH3), 26.0 (CH2), 26.2 (CH2), 
26.5 (CH2), 28.0 (3 CH3), 30.3 (CH2), 31.4 (CH2), 41.3 (CH), 50.2 (CH2), 59.6 
(CH), 80.2 (C), 114.8 (2 CH), 129.0 (2 CH), 
130.3 (C), 133.5 (C), 138.9 (CH), 144.9 (C), 166.9 (C) ppm. (S)-36c [α]D = –9.0 (c 
= 1, CHCl3); (R)-36c [α]D = +13.4 (c = 1, CHCl3). HPLC (n-hexane/2-propanol, 
99:1 to 90:10 over 30 min; 1.0 mLmin–1; AD column; r.t.): tR = 12.44 [(S)-36c], 
15.14 min [(R)- 36c]. LC–ESI-MS (r.t.): tR = 5.28 min, m/z = 358 [M], 381 [M + 
Na]. C22H34N2O2 (358.26): calcd. C 73.70, H 9.56, N 7.81; found C 73.83, H 9.54, 
N 7.83. 
36f: Yield: 63%, 45 mg, isolated as a 3:1 mixture of Z/E isomers. 
1
H NMR (200 
MHz, CDCl3) major isomer: δ = 1.35 (s, 9 H), 1.82 (d, J = 7.4 Hz, 3 H), 3.61 (d, J 
= 13.0 Hz, 1 H), 3.78 (d, J = 13.0 Hz, 1 H), 4.81 (s, 1 H), 6.66 (d, J = 8.4 Hz, 2 H), 
6.96–7.06 (m, 2 H), 7.13–7.26 (m, 4 H) ppm. 1H NMR (200 MHz, CDCl3) minor 
isomer: δ = 2.00 (d, J = 7.0Hz, 3 H), 4.51 (s, 1 H), 6.09 (q, J = 7.0 Hz, 1 H) ppm. 
13
C NMR (50 MHz, CDCl3) major isomer: δ = 14.1 (CH3), 28.1 (3 CH3), 50.6 
(CH2), 54.3 (CH), 80.7 (C), 115.2 (2 CH), 120.3 (CH), 125.0 (CH), 127.0 (CH), 
129.4 (2 CH), 130.4 (C), 134.8 (C), 138.9 (CH), 144.6 (C), 145.4 (C), 166.6 (C) 
ppm. LC–ESI-MS (r.t.): tR = 10.22 min, m/z = 358 [M], 381 [M + Na]. 
C20H26N2O2S (358.17): calcd. C 67.01, H 7.31, N 7.81, S 8.94; found C 67.19, H 
7.32, N 7.84, S 8.96. 
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General procedure for the synthesis of dehydro- -amino acids 37a-f: 
Trifluoroacetic acid (7 mmol, 7 equiv.) was added to a solution of 36a-f (1 mmol) 
in DCM (5 mL) and the reaction mixture was stirred at room temperature until 
complete consumption of the starting material. The solvent and the excess of 
reagent were removed under reduced pressure. The crude residue was treated with 
Dowex 50WX2-200 ion exchange resin, eluting with NH4OH 0.5 M. Compounds 
37a-f were isolated in 77-95% yield after removal of the aqueous solvent. 
37a: Yield 77% (75:25, Z/E mixture), pale yellow solid, m.p. 96-98 °C (dec.) 
1
H 
NMR (CD3OD, 200 MHz) Z isomer  1.53 (d, J = 6.8 Hz, 3H), 1.88 (d, J = 7.2 Hz, 
3H), 3.91 (d, J = 12.8 Hz, 1H), 4.01 (d, J = 12.8 Hz, 1H), 4.31 (q, J = 6.8 Hz, 1H), 
6.80 (d, J = 8.4 Hz, 2H), 7.02 (q, J = 7.2 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H); E 
isomer  1.53 (d, J = 6.8 Hz, 3H), 2.12 (d, J = 7.0 Hz, 3H), 3.81 (q, J = 6.6 Hz, 1H), 
3.91 (d, J = 12.8 Hz, 1H), 4.01 (d, J = 12.8 Hz, 1H), 6.05 (q, J = 7.0 Hz, 1H), 6.80 
(d, J = 8.4 Hz, 2H), 7.23 (d, J= 8.4 Hz, 2H). 
13
C NMR (CD3OD, 50 MHz) d Z 
isomer 14.3, 19.5, 50.9, 53.6, 117.1, 122.1, 130.6, 132.6, 139.6, 151.3, 174.3; IR 
(neat, cm
-1
) 1081, 1392, 1590, 1651, 1688, 2848, 2921, 2950, 3368, 3399. LC-MS-
ESI rt 1.18 min (Z isomer), 1.53 min (E isomer), 235 (M + 1), 257 (M + 23), 491 
(2M + 23). Anal. cald. for C13H18N2O2 (234.29): C 66.64, H 7.74, N 11.96; found 
C 66.40, H 7.76, N 11.99. 
37b: Yield 95% (70:30, Z/E mixture), white solid, m.p. 108-110 °C (dec.) 
1
H NMR 
(CD3OD, 200 MHz) Z isomer  0.80 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 7.0 Hz, 3H), 
1.66 (d, J = 7.2 Hz, 3H), 2.01-2.16 (m, 1H), 3.69-3.95 (m, 3H), 6.61 (d, J= 8.4 Hz, 
2H), 6.94 (q, J = 7.2 Hz, 1H), 7.04 (d, J = 8.4 Hz, 2H); E isomer  0.81 (d, J = 7.0 
Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H), 1.94 (d, J = 7.0 Hz, 3H), 2.01-2.16 (m, 1H), 
3.69-3.95 (m, 3H), 5.77 (q, J = 7.0 Hz, 1H), 6.61 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 
8.4 Hz, 2H). 
13
C NMR (CD3OD, 50 MHz)  Z isomer 14.3, 19.0, 32.6, 50.2, 62.0, 
116.3, 121.0, 131.9, 132.0, 142.0, 150.3, 176.1; E isomer 14.9, 20.0, 31.8, 50.3, 
62.0, 116.3, 121.0, 131.8, 132.0, 142.1, 151.0, 177.0. IR (neat, cm
-1
) 846, 1372, 
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1610, 1684, 2852, 2957, 3366, 3421. LC-MS-ESI rt 1.13 min (Z isomer),1.59 min 
(E isomer), 263 (M + 1), 547 (2M + 23). Anal. cald. for C15H22N2O2 (262.35): C 
68.67, H 8.45, N 10.68; found C 68.88, H 8.45, N 10.71. 
37c: Yield 88% (70:30, Z/E mixture), yellow solid, m.p. 195-197 °C (dec.) 
1
H 
NMR (DMSO, 200 MHz) Z isomer  1.74 (d, J = 7.4 Hz, 3H), 3.60 (d, J = 13.2 Hz, 
1H), 3.72 (d, J = 13.2 Hz, 1H), 5.02 (s, 1H), 6.53 (d, J = 8.6 Hz, 2H), 6.78 (q, J = 
7.4 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H), 7.10 (d, 1H), 7.47 (bs, 1H), 7.50-7.54 (m, 
1H); E isomer  1.96 (d, J = 6.8 Hz, 3H), 3.60 (d, J = 13.2 Hz, 1H), 3.72 (d, J = 
13.2 Hz, 1H), 4.60 (s, 1H), 5.89 (q, J = 6.8 Hz, 1H), 6.53 (d, J = 8.6 Hz, 2H), 7.01 
(d, J = 8.4 Hz, 2H), 7.10 (d, 1H), 7.47 (bs, 1H), 7.50-7.54 (m, 1H); 
13
C NMR 
(CD3OD, 50 MHz)  Z isomer 14.4, 51.2, 56.4, 117.1, 121.7, 126.2, 126.7, 128.7, 
130.0, 132.8, 132.9, 134.3, 138.8, 140.5, 151.3, 174.6; E isomer 16.7, 50.5, 56.4, 
117.1, 122.0, 126.3, 126.7, 128.7, 130.0, 132.6, 132.9, 134.3, 138.6, 140.5, 153.3, 
170.7; IR (neat, cm
-1
) 760, 823, 1027, 1160, 1368, 1442, 1678, 1741, 2824, 2924, 
2978, 3364, 3437. LC-MS-ESI rt 1.22 min (E isomer), 1.63 min (Z isomer), 303 
(M þ 1). Anal. cald. For C16H18N2O2S (302.39): C 63.55, H 6.00, N 9.26, S 10.60; 
found C 63.32, H 5.99, N 9.24, S 10.57. 
37f: Yield 78% (75:25, Z/E mixture), pale yellow solid, m.p. 134-136 _°C (dec.) 
1
H NMR (CD3OD, 200 MHz) Z isomer  0.80-1.36 (m, 6H), 1.64-1.88 (m, 4H), 
1.77 (d, J = 7.2 Hz, 3H), 1.99-2.01 (m, 1H), 3.89-4.11 (m, 3H), 6.83 (d, J = 7.0 Hz, 
2H), 7.22 (d, J = 7.0 Hz, 2H), 7.34 (q, J = 7.4 Hz, 1H); E isomer  0.80-1.36 (m, 
6H), 1.64-1.88 (m, 4H), 1.99-2.01 (m, 1H), 2.13 (d, J = 6.8 Hz, 3H), 3.89-4.11 (m, 
3H), 6.33 (q, J = 6.8 Hz, 1H), 6.83 (d, J = 7.0 Hz, 2H), 7.22 (d, J = 7.0 Hz, 2H). 
13
C 
NMR (CD3OD, 50 MHz) Z isomer  15.1, 27.8 (2C), 27.9 (2C), 32.0, 43.1, 51.1, 
62.3, 117.1, 121.9, 131.3, 132.7, 141.7, 151.2, 175.7; E isomer  15.6, 27.8 (2C), 
28.0 (2C), 30.7, 42.1, 51.0, 62.3, 117.1, 122.1, 131.3, 132.7, 140.8, 151.2, 175.7; 
IR (neat, cm
-1
) 1095, 1178, 1370,1455, 1614, 1651, 2841, 2922, 2939, 3307, 3409. 
LC-MS-ESI rt 1.68 min (Z isomer), 1.80 min (E isomer), 303 (M + 1), 325 (M + 
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23), 341 (M + 39), 627 (2M + 23). Anal. cald. for C18H26N2O2 (302.41): C 71.49, H 
8.67, N 9.26; found C 71.25, H 8.69, N 9.24. 
 
Procedure for the preparation of 38a: 
To a stirred solution of the 36a (0.2 mmol) in dry DCM (5 mL), triethylamine (1.2 
equiv, 0.24 mmol, 34 mL) and Fmoc-Gly-Cl (1.1 equiv, 0.22 mmol, 69 mL) were 
added. The solution was stirred for 12 h and then washed twice with water (5 mL). 
The two phases were separated, the organic layer was dried over Na2SO4, and 
solvent was removed under reduced pressure. Compound 38a was isolated by flash 
chromatography on silica gel (cyclohexane/ ethyl acetate 90/10 as eluent).  
38a: Yield 84% (75:25, Z/E mixture), pale yellow solid, m.p. 95-97 °C, 
1
H NMR 
(CDCl3, 400 MHz)  0.74 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6 Hz, 3H), 1.49 (s, 
9H),1.66 (d, J = 7.2 Hz, 3H), 1.93 (m, 1H), 3.08 (d, J = 9.2 Hz, 1H), 3.52 (d, J = 
12.8 Hz, 1H), 3.81 (d, J = 12.8 Hz, 1H) 4.00 (bs, 2H), 4.25 (t, J = 9.6 Hz, 1H), 4.42 
(d, J = 9.6 Hz, 2H), 7.14 (q, J = 7.2 Hz, 1H), 7.30-7.43 (m, 8H), 7.70 (d, J = 7.2 Hz, 
2H), 7.74 (d, J = 7.2 Hz, 2H); 
13
C NMR (CDCl3,100 MHz)  14.1, 20.1, 21.2, 28.2 
(3C), 32.0, 46.1, 50.4, 53.4, 65.0, 80.3, 114.9, 120.6, 122.2, 123.3, 124.5, 128.8, 
129.2, 130.2, 130.6, 138.0, 144.0, 149.0, 156.2,167.0,168.8. IR (neat, cm
-1
) 
1159,1276,1367,1455,1651,1682, 1698, 1738, 2823, 2861, 2923, 2982, 3018, 3450. 
LC-ESI-MS rt 5.46 min, m/z 620 (M + Na). Anal. cald. for C35H41N3O5 (597.32): 
C 72.34; H 7.25; N 7.03; found C 72.62, H 7.28, N 7.05. 
 
Procedure for the preparation of the acid 39a: 
To a stirred solution of 38a (0.2 mmol) in DCM (2 mL) at 0 °C, trifluoroacetic acid 
(15 equiv, 3 mmol, 223 mL) was added. After 2 h, the mixture was washed twice 
with water (5 mL), the organic layer was dried over Na2SO4, and solvent was 
removed under reduced pressure. The obtained acid was diluted in dry DCM (2 
mL), under nitrogen atmosphere, and EDCI (1.2 equiv, 0.24 mmol, 46 mg) and 
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triethylamine (2.4 equiv, 0.48 mmol, 67 mL) were added. After 30 min HOBT (1.2 
equiv, 0.24 mmol, 33 mg) and glycine t-butyl ester hydrochloride (1.2 equiv, 0.24 
mmol, 41 mg) were added. The solution was stirred overnight and then the mixture 
was diluted with DCM and washed twice with acidic water (5 mL) and twice with 
basic water (5 mL). The two phases were separated, the organic layer was dried 
over Na2SO4, and solvent was removed under reduced pressure. Compound 39a 
was isolated by flashchromatography on silica gel (cyclohexane/ethyl acetate 90/10 
as eluent). 
39a: Yield 55% (95:5, Z/E mixture), yellow solid, m.p.119-121 °C, 
1
H NMR 
(CDCl3, 400 MHz)  0.82 (d, J = 7.2 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H),1.49 (s, 
9H),1.71 (d, J = 7.6 Hz, 3H), 2.10 (m, 1H), 3.34-3.95 (m, 7H), 4.28 (t, J = 6.4 Hz, 
1H), 4.42 (d, J =6.4 Hz, 2H), 6.85 (q, J = 7.6 Hz, 1H), 7.31-7.44 (m, 6H), 7.55 (d, J 
=8.0 Hz, 2H), 7.71 (d, J = 7.6 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H); 
13
C NMR (CDCl3, 
100 MHz)  14.0, 20.1, 20.4, 28.3 (3C), 32.2, 38.8, 42.8, 48.3, 51.2, 62.4, 68.2, 
82.9, 120.6, 121.0, 121.3, 122.0, 126.2, 128.7, 129.8, 130.2, 130.3, 138.9, 142.5, 
145.2, 158.3, 170.5, 171.4 (2C); IR (neat, cm
-1
) 1161, 1278, 1368, 1463, 1651, 
1673, 1684, 1698, 1732, 2822, 2861, 2918, 2980, 3020, 3391. LC-ESI-MS rt 6.54 
min, m/z 655 (M + 1). Anal. cald. For C38H46N4O6 (654.80): C 69.70; H 7.08; N 
8.56; found C 69.89, H 7.05, N 8.58. 
 
Procedure for the preparation of the amino acid 40a: 
To a stirred solution of compound 39a (0.2 mmol, 112 mg), in DCM (0.5 mL), 
H3PO4 (85% solution in water, 3 equiv, 0.6 mmol, 83 mL) was added. After 16 h 
the organic solvent was removed under reduced pressure. The residue was diluted 
in methanol (2 mL), and piperidine (0.1 equiv, 0.02 mmol, 2 mL) was added. After 
8 h the organic solvent was removed under reduced pressure, the residue was 
diluted in 1 N HCl (0.5 mL) and with treated with Dowex 50WX2-200 ion 
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exchange resin, eluting with NH4OH 0.5 M. Compound 40a was isolated after 
removal of the aqueous solvent. 
40a: Yield 60% (90:10, Z/E mixture), yellow solid, m.p. 141-143 °C (dec.) 
1
H 
NMR (CD3OD, 400 MHz)  0.78 (d, J = 7.2 Hz, 3H), 0.91 (d, J = 7.2 Hz, 3H), 1.64 
(d, J = 7.2 Hz, 3H), 2.21 (m, 1H), 3.33-3.39 (m, 2H), 3.94-4.02 (m, 2H) 4.04 (s, 
2H), 4.41 (d, J = 7.8 Hz, 1H), 6.78 (q, J = 7.2 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 
7.40 (d, J = 8.4 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz)  14.7, 19.7, 19.9, 31.9, 
42.9, 43.4, 52.6, 67.1, 121.3 (2C), 128.5 (2C), 132.1, 132.4, 138.1, 154.0, 165.3, 
168.6, 171.9. IR (neat, cm
-1
) 1160, 1276, 1367, 1444, 1671, 1682, 1698, 1701, 
2824, 2855, 2921, 3368, 3410. LC-ESI-MS rt 1.04 min, m/z 377(M + 1), 399 (M + 
Na). Anal. cald. for C19H28N4O4 (376.45): C 60.62, H 7.50, N 14.88; found C 
60.43, H 7.51, N 14.91. 
 
Procedure for the synthesis of aldehyde 62: 
Under inert conditions and at -78°C, dry DMSO (5.88ml, 3eq) was added dropwise 
to a solution of oxalyl chloride (2eq) in dry DCM (317 ml) and stirred for 2 h. 
After this time hex-5-yn-1-ol (1eq) in DCM (80 ml) was added dropwise to 
reaction mixture over 30 min. The mixture was stirred for further 30 minutes and 
then TEA dry (6eq) was added dropwise. The reaction was immediately warmed to 
room temperature and stirred for 1 h. After this time the solution was diluted with 
Et2O (322 ml) and water (161 ml), extract with Et2O and washed with brine. The 
organic layer were dried with anhydrous sodium sulfate and concentrated in vacuo. 
62: Yield 99% , yellow oil, 
1
H NMR (CDCl3, 400 MHz)  1.86 (m, 2H), 1.99 (t, J= 
2.8 Hz, 1H), 2.28 (m, 2H), 2.62 (m, 2H), 9.81 (s, 1H). LC-MS-ESI rt 6.4 min, 97 
(M+1), 215 (2M+Na). 
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Synthesis of unsatured compound 1g: 
In a round-bottom flask  aldehyde 62 (1eq, 28.83mmol), tert-butyl acetoacetate 
(1eq) and piperidine (0,15 eq) were added and stirred under neat conditions for 2 
days. After this time the mixture was extracted with EtOAc and water, the organic 
layer were dried by anhydrous sodium sulfate and concentrated in vacuo. The crude 
product was purified by flash chromatography (c-Hex/EtOAc 98:2). 
1g-major isomer: Yield 35% , yellow oil, 
1
H NMR (CDCl3, 400 MHz)  1.56 (s, 
9H), 1.74 (m, 2H), 1.99 (s, 1H), 2.26 (m, 2H), 2.31 (s, 3H), 2.44 (m, 2H), 6.75 (t, 
J= 8 Hz, 1H).
 13
C NMR (CDCl3, 100 MHz)  18.13, 27.00, 27.11, 27.84, 28.69, 
69.15, 82.39, 83.31, 138.57, 145.32, 165.70, 195.07. LC-MS-ESI rt 9.2 min, 259 
(M+Na). 
1g-minor isomer: Yield 10% , yellow oil, 
1
H NMR (CDCl3, 400 MHz)  1.50 (s, 
9H), 1.67 (m, 2H), 2.02 (s, 1H), 2.25 (m, 4H), 2.36 (s, 3H), 6.79 (t, J= 7.6 Hz, 1H).
 
13
C NMR (CDCl3, 100 MHz)  17.75, 25.40, 30.45, 69.00, 81.51, 82.97, 137.68, 
145.62, 163.08, 200.74. LC-MS-ESI rt 9.1 min, 259 (M+Na). 
 
Synthesis of compound 64: 
Under inert conditions and at 0°C, Yb(OTf)3 (5% mol) was added to a stirred 
solution of compound 1g (1eq, 6.08 mmol) in dry DCM (111.2 ml). After 10 
minutes TMSONHTMS was added and the reaction mixture stirred for 30 minutes. 
After this time the reaction was quenched by water and extracted with DCM/water. 
The organic layer were dried with anhydrous sodium sulfate and concentrated in 
vacuo. The crude product was used for the next step. 
 
Synthesis of compound 65: 
Under inert conditions, SOCl2 (1,5eq) was added dropwise to a solution of mono-
benzyl-malonyl acid (1eq, 1,86 mmol) in dry DCM (35.7 ml) at 0°C and then 
stirred at room temperature for 30 min. 9,3 mmol of pyridine (5eq) and compound 
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64 in 17,7 ml of dry DCM were added. The reaction mixture was stirred overnight 
and followed by TLC. The reaction mixture was quenched with water and extracted 
with DCM. The organic layer were dried by anhydrous sodium sulfate and 
concentrated in vacuo. The crude product was purified by flash chromatography (c-
Hex/EtOAc 95:5). 
65: Yield 44% , yellow oil, 
1
H NMR (CDCl3, 400 MHz)  1.49 (s, 9H), 1.57 (m, 
2H), 1.75 (m, 2H), 1.95 (t, J= 2.8 Hz, 1H), 2.17 (s, 3H), 2.23 (m, 2H), 2.87 (d, J= 
7.2 Hz, 1H), 3.63 (d, J= 16 Hz, 1H), 3.57 (d, J=15.6 Hz, 1H), 4.67 (m, 1H), 5.14 (d, 
J=12 Hz, 1H), 5.18 (d, J=12 Hz, 1H), 7.36 (m, 5H). 
13
C NMR (CDCl3, 100 MHz)  
17.9, 22.7, 24.4, 27.6, 33.7, 40.9, 58.8, 66.7, 68.7, 82.2, 83.7, 105.3, 128.1, 135.2, 
167.1, 167.6, 168.9. LC-MS-ESI rt 10.5 min, 446 (M+1), 913 (2M+Na). 
 
Synthesis of compound 66: 
Compound 65 (1.86 mmol, 1eq) in dry DCM (9.6 ml) was stirred with TEA (2eq) 
at 0°C for 10 min. Mesyl chloride (2eq) was added and the reaction mixture was 
stirred overnight at room temperature. After this time the reaction was diluted with 
DCM and washed with water. The organic layer were dried with anhydrous sodium 
sulfate and concentrated in vacuo. The crude product was purified by flash 
chromatography (c-Hex/EtOAc 8:2). 
66: Yield 82% , yellow oil, 
1
H NMR (CDCl3, 400 MHz)  1.5 (s, 9H), 1.56 (m, 
2H), 1.75 (m, 1H), 1.93 (t, J= 2.8, 1H), 1.99 (m, 1H), 2.08 (s, 3H), 2.21 (m, 2H), 
3.65 (d, J= 16 Hz, 1H), 3.51 (d, J= 16 Hz, 1H), 5.17 (s, 1H), 5.30 (bs, 1H), 7.35 (m, 
5H). 
13
C NMR (CDCl3, 100 MHz)  11.1, 17.9, 23.7, 26.8, 28.0, 32.6, 40.9, 62.3, 
81.0, 84.0, 105.8, 128.4, 135.1, 161.2, 162.1, 166.4, 167.8. LC-MS-ESI rt 11.5 
min, 428 (M+1), 450 (M+Na). 
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Synthesis of compound 67: 
TFA (15 eq) was added to a solution of compound 66 (0.56 mmol, 1eq) in DCM 
(3ml) at 0°C and the reaction was stirred at room temperature overnight. The 
mixture was washed with water and the organic layer were dried with anhydrous 
sodium sulfate and concentrated in vacuo. The crude product was used for the next 
step. 
67: Yield 99% , yellow oil, 
1
H NMR (CDCl3, 400 MHz)  1.57 (m, 2H), 1.78 (m, 
1H), 1.94 (s, 1H), 2.02 (m, 1H), 2.13 (s, 3H), 2.21 (m, 2H), 3.55 (d, J= 16 Hz, 1H), 
3.71 (d, J= 16 Hz, 1H), 5.17 (s, 2H), 5.36 (bs, 1H), 7.37 (m, 5H), 11.56 (bs, 1H).
 
13
C NMR (CDCl3, 100 MHz)  11.5, 17.9, 23.6, 32.5, 40.7, 67.2, 68.9, 83.7, 104.1, 
128.5, 135.0, 164.3, 166.2, 168.0, 168.1. LC-MS-ESI rt 10.9 min, 372 (M+1), 394 
(M+Na). 
 
Synthesis of compound 68: 
Under inert conditions, TEA (1.5eq) and HBTU (1.5eq) were added to a solution of 
compound 67 (1 eq, 0.46 mmol) in dry DCM (5.8 ml) and stirred for 5 min. Then 
4-aminobenzylamine (2eq) was added and the reaction was stirred at room 
temperature for 4 h. After this time the reaction was extract with DCM/water, the 
organic layer were dried with anhydrous sodium sulfate and concentrated in vacuo. 
The crude product was purified by flash chromatography (c-Hex/EtOAc from 6:4 
to 5:5). 
68: Yield 80% , orange oil, 
1
H NMR (CDCl3, 400 MHz)  1.51 (m, 2H), 1.65 (m, 
1H), 1.70 (t, J= 2.8 Hz, 1H), 1.94 (m, 1H), 2.12 (s, 3H), 2.14 (m, 1H), 2.26 (m, 
1H), 3.41 (d, J= 16Hz, 1H), 3.57 (d, J= 16 Hz, 1H), 4.24 (dd, J= 14.8 Hz, J= 5.2 
Hz, 1H), 4.39 (dd, J= 14.4 Hz, J= 5.6Hz, 1H), 5.11 (s, 2H), 5.32 (bd, J= 6.8 Hz, 
1H), 5.99 (bs, 1H), 6.60 (d, J= 9.2 Hz, 2H), 7.03 (d, J= 8 Hz, 2H), 7.31 (m, 5H). 
13
C NMR (CDCl3, 100 MHz)  11.1, 17.3, 22.9, 32.6, 38.6, 43.0, 67.1, 69.1, 83.7, 
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106.4, 114.9, 128.5, 135.0, 145.9, 158.8, 161.9, 166.2, 168.3. LC-MS-ESI rt 8.5 
min, 476 (M+1), 498 (M+Na), 973 (2M+Na). 
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3.2 α4β1 Integrin Ligands 
 
3.2.1 Introduction to integrins α4β1 
As previously said regarding α5β1 and αVβ3 integrins, the α4β1 integrins are 
heterodimeric transmembrane proteins as well. Unlike the former, this class of 
integrins has a fundamental role in white blood cells migration to the inflammatory 
site and for this reason it is involved in several pathologies – including asthma, 
multiple sclerosis and rheumatoid arthritis. Different studies have shown that α4β1 
integrin bind VCAM (vascular adhesion molecule) and fibronectin, and the 
incorrect operation of this interaction causes the pathologies mentioned earlier. To 
better understand the mechanism by which an hypothetical inhibitor could block 
the activity of the integrin, a representative model of α4β1 integrin structure has 
been constructed. The design of a synthetic inhibitor is of crucial importance to 
mimick the right interactions involved between natural ligand and protein. The 
studies carried out on ligand-protein interactions have shown that both integrin 
subunits take part to ligand binding. For this kind of integrins, the complete 
interaction mechanism between the two involved parts is still unknown.  
Integrin α4β1 binds to fibronectin through recognition of three amino acids situated 
on the ligand surface: Leu-Asp-Val (LDV). This sequence can be considered 
equivalent to the RGD sequence for integrins αVβ3 and α5β1, and, in view of the 
similarities with the latter, the possibility to use RGD mimetics as α4β1 integrin 
inhibitor has been considered. Initial attemps tested with α4β1 integrin inhibitor  
mimicking RGD sequence, have not provided desired results probably because side 
chains in used ligands are too flexible. During the years, it was understood that 
LDV sequence is fundamental to obtain the interaction with integrin, and using this 
sequence a potent and selective inhibitor for α4β1 integrin has been selected: [N-(2-
methylphenyl)-ureido]phenylacethyl-Leu-Asp-Val shown in Figure 18. 
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Fig. 18. [N-(2-methylphenyl)-ureido]phenylacethyl-Leu-Asp-Val 
 
The identified interactions between protein and inhibitor show that an acidic unit 
linked to a spacer core is fundamental in order to generate hydrophilic interactions 
and an amide or an another group has to be able to establish hydrogen bond. This 
has been understood by X-ray analysis. The mentioned inhibitor is not resistant to 
enzyme hydrolysis because of the presence of a peptidic part. For this reason, it has 
been designed a non-peptidic structure to replace a LDV sequence, attempting to 
maintain the high activity on targed. Several developed antagonists contain the 
PUPA residue (Figure 19) to a structure ending with a carboxylate. 
 
 
Fig. 19. 2-methyl PUPA. 
 
Reported results suggested that the more active compounds present a PUPA residue 
along with a donor and an acceptor of hydrogen bond separated by hydrophobic 
portion. Usually, a terminal carboxylate is the acceptor and a nitrogen acts is the 
donor. After these considerations, we developed a series of compounds with 
appropriate features to be α4β1 integrin inhibitors. 
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3.2.2 Synthesis of heterocyclic and linear integrin ligands 
To obtain the α4β1 integrin ligands we decided to insert the PUPA residue on the 
intermediate of αVβ3 and α5β1 integrin ligands mentioned in the last section. 
In particular, some heterocyclic ligands from the classes of dehydro-pyrrole and 
dihydropyrimidindione and some linear ligands have been studied. A simple 
protocol was used to introduce the fundamental PUPA pharmacophore moiety, 
which employs the O-tolyl-isocyanate in DCM at room temperature for 12 hours 
(Scheme 28). 
 
Scheme 28. Insertion of PUPA moiety on integrin ligand. 
 
The compounds thus obtained, have been deprotected on the ester through defferent 
hydrolysis procedure, depending on the alkyl chain of the ester (Scheme 29). To 
hydrolyze the methyl ester present on the dehydropyrrole derivatives treatment 
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with potassium carbonate in THF/H2O for four hours under reflux allowed us to 
obtain the free acids 74c-d. 
Also for the cleavage of the same ester on the dihydropyrimidinone derivative 72a, 
several kind of methodologies have been tested but the product has never been 
observed. Finally, the acids 76a-f have been obtained by treatment with TFA in 
DCM at room temperature overnight. 
 
 
Scheme 29. Cleavage of esters. 
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3.2.3 Biological evaluations 
Jurkat cell adhesion assays were done by coating 96-well plates were coated at 4 C 
overnight with 2 mg/mL of VCAM-1 and plotting a saturation curve for the ligand 
to establish the best signal-to-noise ratio. Non-specific hydrophobic binding sites 
were blocked by incubation with a BSA (1%)/HBSS (w/v) solution for 30 min at 
37 C.  The day of the assay, the cells were counted and stained with 12.5 M 
CMFDA (30 min at 37°C).  After three rinses with BSA/HBSS to wash away the 
excess dye, aliquots of 500,000 (Jurkat) cells were divided among a number of 
tubes corresponding to the number of treatments.  For inhibition experiments, cells 
were mixed with the drug and pre-incubated at 37°C for 30 min to reach 
equilibrium before being plated.  
 
Entry Compound IC50[nM] 
α4β1
 
 
1 
 
 
No active 
 
2 
 
 
No active 
Table 11. At this stage, only the two dehyropyrroles reported in table X have been 
tested and unsatisfactory results have been observed. 
 
After 30 min incubation at 37°C in the coated wells, the non-specifically bound 
cells were washed away with BSA/HBSS solution. Adherent cells were lysed by 
the addition of 0.5% Triton-X-100 in PBS (30 min at 4°C). Released CMFDA was 
quantified by fluorescence imaging at Ex485 nm/Em535 nm (Wallac ARVO 1420 
multilabel counter) and adherent cells was counted by interpolation on a standard 
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curve. The fluorescence intensity with and without VCAM-I was taken as 
respectively 100% and 0%. Alternatively, the number of adherent cells was 
calculated by comparison with a standard curve prepared in the same plate using 
known concentrations of labeled cells. 
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3.2.4 Experimental section 
General procedure for the preparation of urea-derivatives 71-73: 
In a roun-bottom flask were added in order 249 mg (0.6 mmol, 1eq) of compound 
21, 1 ml of DCM and 75 l (0.6 mmol, 1eq) of O-tolyl isocyanate. The reaction 
was stirred at room temperature and followed by TLC. After 20h the reaction was 
complete and then has been performed an extraction with EtOAc/water. The 
organic layer were dried with anhydrous sodium sulfate and concentrated in vacuo. 
The crude product was purified by flash chromatography (c-Hex/EtOAc 8:2). 
Orange oils. Yields 80-88%. 
71c major and minor isomer on amidic bond: 
1
H NMR (acetone-d
6
, 400 MHz)  
0.87 (d, J= 5.6 Hz, 3H), 0.89 (d, J= 5.6 Hz, 3H), 2.03 (s, 3H), 2.36 (m, 1H), 4.43 (d, 
J= 6 Hz, 2H), 3.7 (s, 3H), 4.27 (dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.31 (dd, J= 16 Hz, 
J= 4,4 Hz, 1H), 5.13 (s, 1H), 6.47 (s, 1H), 6.94-7.88 (m, 8H), 7.68 (bs, 2H), 8.38 
(bs, 1H). 
71d:
 1
H NMR (acetone-d
6
, 400 MHz)  0.89-1.32 (m, 5H), 1.40-1.55 (m, 6H), 2.03 
(s, 3H), 4.43 (d, J= 6 Hz, 2H), 3.7 (s, 3H), 4.27 (dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.31 
(dd, J= 16 Hz, J= 4,4 Hz, 1H), 5.13 (s, 1H), 6.35 (s, 1H), 6.94-7.88 (m, 8H), 7.68 
(bs, 2H), 8.38 (bs, 1H). α: S-71d=+20.47, R-71d= - 17.50. LC-MS-ESI rt 7.7 min, 
533 (M+1), 555 (M+Na). 
72a: NMR (acetone-d
6
, 400 MHz)  0.86 (d, J= 4.8 Hz, 3H), 0.87 (d, J= 6.8 Hz, 
3H), 0.92-0.96 (m, 6H), 1.00 (d, J= 6.4 Hz, 3H), 1.58 (d, J= 6.4 Hz, 3H), 1.94 (m, 
1H), 2.05 (m, 1H), 2.20 (s, 3H), 3.64 (s, 3H, major), 3.66 (s, 3H, minor), 3.82 (d, 
J= 7.2 Hz, 1H), 3.84 (d, J= 7.6 Hz, 1H, minor), 3.97 (d, J= 15.6 Hz, 1H, major), 
4.01 (d, J= 15.2 Hz, 1H, minor), 5.30 (m, 1H), 5.33 (d, J= 1.2 Hz, 1H, major), 5.35 
(d, J= 4.8 Hz, 1H), 6.86 (q, J= 7.2 Hz, 2H), 6.89 (m, 1H), 6.95 (m, 1H), 7-7.2 (m, 
4H), 7.59 (d, J= 8.0 Hz, 1H, major), 7.63 (d, J= 7.4 Hz, 1H). 
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73a: Yield: 62–65%, 1H NMR (200 MHz, CDCl3) δ 1.47 (d, J = 6.8 Hz, 3 H), 1.49 
(s, 9 H,) 1.73 (d, J = 7.4Hz, 3 H), 3.52 (d, J = 12.6 Hz, 1 H),3.64 (s, 3H), 3.68 (d, J 
= 12.6 Hz, 1 H), 3.81 (q, J = 6.8 Hz, 1 H), 6.50-7.4 (m, 9H).  
 
Hydrolisis for methyl and tert-butyl ester already reported in chapter 2. 
74c: major and minor isomer on amidic bond: 
1
H NMR (acetone-d
6
, 400 MHz) 
 0.87 (d, J= 5.6 Hz, 3H), 0.89 (d, J= 5.6 Hz, 3H), 2.03 (s, 3H), 2.36 (m, 1H), 4.43 
(d, J= 6 Hz, 2H), 4.27 (dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.31 (dd, J= 16 Hz, J= 4,4 Hz, 
1H), 5.13 (s, 1H), 6.47 (s, 1H), 6.94-7.88 (m, 8H), 7.68 (bs, 2H), 8.38 (bs, 1H), 8.6 
(bs, 1H). 
74d: 
1
H NMR (acetone-d
6
, 400 MHz)  0.89-1.32 (m, 5H), 1.40-1.55 (m, 6H), 2.03 
(s, 3H), 4.43 (d, J= 6 Hz, 2H), 4.27 (dd, J= 16 Hz, J= 4,4 Hz, 1H), 4.31 (dd, J= 16 
Hz, J= 4,4 Hz, 1H), 5.13 (s, 1H), 6.35 (s, 1H), 6.94-7.88 (m, 8H), 7.68 (bs, 2H), 
8.38 (bs, 1H), 8.6 (bs, 1H). 
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3.3 Analogues of Linezolid 
 
3.3.1 Introduction to antibiotics 
 
In nature a great number of bacteria are know to be responsible of a huge number 
of diseases by combining their action. Bacteria are however divided in two big 
families, depending on the Gram’s test response: Gram positive and Gram negative 
(Figure 20). Among Gram positive bacteria appear Enterococcus, Streptococcus 
and Staphylococcus. These three classes of bacteria proved to be able to develop 
resistance to a large part of developed antibiotics and, with them, the battle against 
antibiotic resistance became an important challenge for researchers working in this 
field. 
 
            
Fig. 20. Gram positive (left) and negative (right). 
 
The first compound that was able to contrast some bacteria, Penicillin G, has been 
introduced to the drug market approximately 60 years ago, but, after some years 
later, microorganisms developed resistance to its action. During the sixties the first 
Penicillase-resistant penicillins arrived on the market The enzyme Penicillase is 
produced by the bacteria and it is able to hydrolyze penicillins on the lattamic ring 
and make them inactive. Examples of these kinds of antibiotics are Meticillin and 
Oxacillin (shown in Figure 21) and later Vancomicin, but after some years 
resistance has been registered for them too. Subsequently, several drugs have 
136 
 
provided good activities against different families of bacteria, but their exploitation 
has been often limited by resistance.  
 
 
Fig. 21. Various classes of antibiotics. 
 
In the nineties, to face this problem, a new class of compounds has been developed: 
the Oxazolidinones. The action mechanism of this class of molecules seems to be 
due to the inhibition of proteic synthesis
51
 and it appears that these compounds do 
not gave cross-resistance with other antibiotics with already known mechanisms, 
until their admission on the market. The increasing interest in these compounds is 
justified by their large action on several Gram positive bacteria, including the ones 
that demonstrate resistance to date. An important aspect of oxazolidinones is that 
they are orally active and this would allow continuing the treatment autonomously 
without resort to hospital. From the DuPont company, in the 1987, two structure 
for oxazolidinones have been introduced: Dup-105 and Dup-721(Figure 22). 
Expecially the second one demonstrated to have a good activity against a large part 
of Gram-positive bacteria, but still not comparable to Vancomicin efficacy. The 
reactivity of these compounds is closely linked to their structure and after several 
changes on molecules backbone, Eperezolid has been synthesized, which presents a 
right balance among antibacterial activity, pharmacokinetic, solubility in water and 
other proper properties. Modifications on piperazinic ring have led to Linezolid, 
which has in its structure a morpholinic ring functioning as a electron-donor group 
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and it  presents a of fluoride atom on the aromatic ring. Mentioned moieties are 
known to be fundamental in order to obtain good activity against bacteria. 
 
 
Figure 22. Isoxazolidinonic compound synthesized by DuPont company. 
 
Linezolid inhibits the protein synthesis by blocking the aggregation between 
ribosomal subunits. In particular, it binds to ribosome on subunit 50S through its 
pharmacophores: three rings and one tail highlighted in Figure 23. 
During the interaction with proteins, the morpholinic ring is orientated to the 
subunit interface, the oxazolidinic ring and the tail are orientated to ribosomal 
tunnel interacting with U2504 and A2503 residues respectively and the aromatic 
ring is between A2451 and U2506 residues (Figure 24). 
Despite the good activity registered and the demonstrated mechanism, Linezolid 
presented some cases of resistance as well. In fact, mutations related to rRNA on 
subunit 23S interfere with Linezolid action overcoming the block given by drug.  
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Fig. 23. Oxazolidinonic compounds 
 
The continuous increase of resistance cases to Linezolid by several bacterial 
families has risen the need of new molecules to counteract this propensity. Basing 
on Linezolid structure we developed compounds that retain pharmacophores, with 
some modifications though. 
            
Fig. 24. Linezolid in the binding site and its action mechanism. 
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3.3.2 Synthesis of Linezolid analogues 
Linezolid analogues were synthesized starting from 3,4-difluorobenzoic acid 77 
which has been protected as t-Butyl ester using Boc2O, tBuOH, TEA and DMAP. 
The reaction was carried out in dioxane at room temperature and, after 24 hours, 
provided the corresponding ester 78 in 66% of yield. By treating this ester with 
K2HPO4 and morpholine, via a nucleophilic aromatic substitution in DMSO at 
75°C for 30 hours, the compound 79 has been obtained in 82% of yield. The 
cleavage of t-butyl ester carried out in DCM with trifluoroacetic acid at room 
temperature for 48 hours provided the compound 80 quantitatively (Scheme 30). 
In parallel, two isoxazolidinonic ring have been synthesized, differing from each 
other only for the alkyle side chain: we selected the structure with isopropyl chain 
and cyclohexyl chain as model compounds. 
 
Scheme 30. Synthesis of 3-fluoro-4-morpholinobenzoic acid. 
 
To obtain these rings, we first prepared malonamide 2 by a simple acylation of 
ethylamine with methylmalonyl chloride using TEA as a base in dichloromethane. 
After 24 hours at room temperature, the reaction provided us the malonamide in 
79% of yield. By microwave assisted procedure, it has been possible to perform a 
very fast Knoevenagel reaction between the malonamide obtained and two different 
aldheyde (Isopropylaldehyde and cyclohexyl aldehyde) using piperidine as catalyst. 
In fact, in only 7 minutes without solvent, related alkylidenes 3a-b have been 
provided in 29% and 79% of yield respectively. From this reaction we obtained a 
mixture of isomers with an abundance of Z one (Z/E ratio 4:1). 
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Scheme 31. Synthesis of isoxazolidinonic scaffold. 
 
At this point we took advantage of the ability of alkylidene malonamides to take 
part in Michael addition as acceptor to introduce TMSONHTMS and obtain the 
adduct 6a-b. After the addition of TMSONHTMS performed at -40°C in 
dichloromethane, the reaction was left stirring at room temperature for 3 hours and 
provided the product 6a in 76% and 6b in 83% of yield. By treatment of these 
adducts with TBAF with THF as solvent, after 2 hours at room temperature, 
isoxazolidinones 7a-b have been isolated in 26% and 43% respectively (Scheme 
31). 
 
Scheme 32. Coupling between isoxazolidinonic scaffold and 3-fluoro-4-
morpholinobenzoic acid. 
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Finally, a coupling between isoxazolidinones 7ab and acid 80 using thionyl 
chloride and pyridine in dichloromethane allowed us to obtain the final compounds 
81a-b in 14% and 37% of yield respectively (Scheme 32). 
 
3.3.3. Biological evaluations 
To test the antibiotic efficiency of 7a and 7b a dilution method was used, which 
measures the minimum concentration of antibiotic able to inhibit the growth of the 
microrganism (MIC). This is an important assay because it provides informations 
about the conditions that lead to the death of the bacterium: once inhibited its 
growth it can be expelled from the body by the immune system. For the two 
molecules synthesized, the antibacterial activity in vitro by determination their 
MICs, using the method namely Broth Dilution was evaluated. The test was 
performed on Gram-positive bacteria such as S. aureus, S. epidermidis, S. hominis, 
P. aeruginosa, P. mirabilis, E. faecalis and E. mirabilis. 
The first phase of testing involved the use of commercial strains of these bacteria. 
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Family Molecule 
7a 
Molecule 
7b 
Linezolid Ciprofloxacine Cefuroxime 
ATCC S. aureus 29213 >128 >128 2 2 4 
ATCC S. aureus 25923 >128 >128 1 2 2 
BAA 977 S. aureus >128 >128 2 1 2 
MU 50 S. aureus >128 >128 2 128 4 
ATCC 43300 S. aureus >128 >128 0.5 1 >128 
BAA-1026 S. aureus  >128 2   
ATCC 35218 E. coli  >128   8 
ATCC 12453 P. mirabilis  >128   0.5 
ATCC E. faecalis 29212 >128 >128 1 4 >128 
S. hominis α 26 >128 >128 32 >128 8 
S. epidermis α 86 >128 128 16 >128 16 
S. epidermis α 99 >128 128 16 >128 128 
S. epidermis α 560 >128 128 16 >128 >128 
S. epidermis α 657 >128 128 16 >128 >128 
S. epidermis α 758 >128 128 16 >128 >128 
S. epidermis α 1453 >128 128 16 >128 128 
S. epidermis G 220 >128 128 16 >128 >128 
S. epidermis G 1027 >128 >128 16 >128 16 
S. epidermis G 1054 >128 128 16 >128 128 
S. epidermis CT 20 (2) cfr+ >128 128 16 >128 54 
Table 12. Minimum concentration of antibiotic able to inhibit the growth of the 
microrganism (MIC). Compound 7a-b. 
 
For MIC values higher than 128 mg/L, the molecule is considered devoid of 
antibacterial activity to the considered strain. So the molecule (a) can not be 
classified as an antibiotic to the strains used. Concerning the molecule (b), for nine 
strains of S. epidermidis it has a limit MIC of 128 mg/L so, it can be regarded as an 
antibiotic also if it shows a MIC considerably higher than the drugs currently used. 
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At this point, only for the molecule (b), the same analysis using bacterial strains 
isolated from patients with cystic fibrosis were performed. The results are reported 
in Table 13. 
 
Family Molecule (b) Linezolid 
S. aureus AA1 64 2 
S. aureus AA2 >128 2 
S. aureus AA3 64 2 
S. aureus FB1 64 2 
S. aureus FB2 32 2 
S. aureus FB3 32 2 
S. aureus DD1 >128 1 
S. aureus DD2 >128 1 
S. aureus DD3 >128 1 
S. aureus VV1 128 2 
S. aureus VV2 >128 2 
S. aureus VV3 64 1 
Table 13. Analysis on bacterial strains isolated from patients with cystic fibrosis. 
 
From these further tests, we observe an improvement of the MIC value against 
strains of S. aureus, in particular, the best results are observed for strains FB2 and 
FB3. However, also in this case, the values are much higher than those of Linezolid 
compared to the same strain. On the basis of these data, we can consider that our 
molecules should not be descarted but they may be considered as lead compounds, 
whose activity has to be increased by modifications of the backbone. 
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3.3.4 Experimental section 
Synthesis of compound 78: 
Under nitrogen atmosphere, 3,4-difluorobenzoic acid (1eq), tert-butanol (1.1eq), 
TEA (2eq), DMAP (0.1eq) and dioxane (1eq) were added. The reaction mixture 
was stirred at 0°C until the addition of Boc2O (1.3eq). The reaction was stirred at 
room temperature following it by TLC. The work-up was performed by quenching 
with water and extraction with EtOAc. The organic layer were collected and dried 
with sodium solfate anidrous, concentrated in vacuo. Yellow oil with 66% of yield. 
1
H-NMR (400 MHz, CDCl3): δ 1.6 (s, 9H), 7.19 (m, 1H), 7.54 (m, 2H); 
 
Synthesis of compound 79: 
In a flask for reflux were added compound 78 (1 eq), DMSO (0.3 M), K2HPO4 (4 
eq) e morpholine (2 eq). The reaction mixture was stirred at reflux for 30h at 75°C, 
following it by TLC. The work-up was performed by quenching with water and 
extraction with EtOAc. The organic layer were collected and dried with sodium 
solfate anidrous, concentrated in vacuo. Yellow oil with 82% of yield. 
1
H-NMR (200 MHz, CDCl3): δ 1.59 (s, 9H), 3.2 (t, 4H, J=2.4 Hz), 3.95 (t, 4H, 
J=2.4 Hz), 6.94 (t, J=4 Hz), 7.68 (m, 2H); 
 
Synthesis of compound 80: 
Under inert conditions 79 (1 eq) DCM (0.2 M) e K2HPO4 (4 eq) were added. The 
reaction mixture was stirred at 0°C to add TFA dropwise (25eq). The reaction was 
warmed at room temperature and stirred for 30h following it by TLC. The work-up 
was performed by acidification by HCl 1M, then an extraction with H2O/DCM. 
The organic layer were collected and dried with sodium solfate anidrous, 
concentrated in vacuo. Yellow oil with 46% of yield. 
1
H-NMR (400 MHz, CDCl3): δ 3.31 (t, 4H, J=4.8 Hz), 3.89 (t, 4H, J=4.8 Hz), 6.93 
(t, 1H, J=8 Hz), 7.76 (dd, 1H, J
1
=14.4 Hz, J
2
=2.4 Hz), 7.87 (dd, 1H, J
1
=8.4 Hz, 
J
2
=2.4 Hz); 
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General procedure for the synthesis of compounds 81a-b: 
Under inert conditions, compound 80 (1,5 eq) and DCM (0.1 M) were added. The 
reaction mixture was carried at 0°C to add SOCl2 (1.5eq) and stirred for 1h. After 
this time, pyridine (5eq) was added and the reaction mixture was stirred for further 
20 min. Finally was added isoxazolidinone 7a-b (1eq) and the reaction was stirred 
for 24h following it by TLC. The work-up was performed by quenching with basic 
water and extraction with DCM. The organic layer were collected and dried with 
sodium solfate anidrous, concentrated in vacuo. Crude orange oil . After flash 
chromatography 8:2 c-Hex/EtOAc has been obtained the 37% and 14% of yield 
respectively for 81a-b.Withe olid 
81a:
1
H-NMR (400 MHz, CDCl3):  δ 1.05 (d, 6H, J=6.4 Hz), 1.16 (t, 3H, J=7.6 Hz), 
2.17 (m, 1H), 3.22 (t, 4H, J=4.4 Hz), 3.31 (m, 2H), 3.43 (d, 1H, J=3.2 Hz), 3.88 (t, 
4H, J=4,4 Hz), 5.3 (dd, 1H, J
1
=5.6 Hz, J
2
=2.8 Hz), 6.16 (bs, 1H), 6.92 (t, 1H, J=8.8 
Hz), 7.52 (dd, 1H, J
1
=8 Hz, J
2
=1.6 Hz), 7.58 (dd, 1H, J
1
=8 Hz, J
2
=1.6 Hz); 
81b: 
1
H-NMR (400 MHz, CDCl3): δ 1,8 (m, 11H), 3.16 (m, 4H), 3.31 (m, 2H), 
3.46 (d, 1H, J=2 Hz), 3.84 (m, 4H), 5.22 (m, 1H), 6.88 (t, 1H, J=8.4 Hz), 7.48 (d, 
1H, J=9 Hz), 7.54 (d, 1H, J=8 Hz); 
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